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 ABSTRACT 
 
 Memory deficits are a devastating consequence of many neurological disorders 
including Alzheimer’s disease (AD) and epilepsy. Currently approved treatments for 
memory impairment in AD are few in number, mechanistically homogenous, and only 
marginally effective, and there are no approved treatments for memory deficits in 
epilepsy. Thus, new treatments are needed.  One path to new therapy development is to 
first obtain a mechanistic understanding of existing treatments, including those in 
development, in order to “fine-tune” their targeted effects or discover new therapeutic 
approaches. Another strategy is to investigate the underlying pathology causing memory 
dysfunction in order to identify new therapeutic targets. Research in this dissertation 
utilized both strategies. Chapter 2 used in vitro electrophysiology and 
immunohistochemistry to investigate the neurophysiology of 5-HT6 receptors, a target 
with widely reported nootropic effects. Results from these studies suggest that 5-HT6 
receptors bidirectionally modulate inhibitory synaptic transmission in the dentate gyrus 
(DG) via their direct effects on excitatory mossy cells thought to drive inhibition in the 
DG. Chapter 3 tested the procognitive and anticonvulsant effects of 5-HT6 receptor 
antagonists in J20 mice, a transgenic model with pathological hyperexcitability thought to 
contribute to disease progression. Systemic treatment with a 5-HT6 receptor antagonist 
improved spatial pattern processing in nontransgenic (NTG) mice, but not in J20 mice. 
Additionally, J20 mice had significantly a lower seizure threshold during the minimal
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clonic seizure test compared to nontransgenic mice. However, 5-HT6 receptor blockade 
had no affect on seizure threshold in either AD genotype, but did exhibit strain and 
ligand-dependent proconvulsant effects in naïve and otherwise healthy mice. Lastly, 
studies in Chapter 4 found that corneal kindled mice, which are a model of seizure 
development, exhibited DG-associated spatial pattern processing impairments. In vitro 
electrophysiology in acute hippocampal brain slices revealed DG granule cells in corneal 
kindled mice were hyperexcitable and had long-term potentiation deficits associated with 
DG-mediated cognitive dysfunction. Together, these results suggest that targeting 
disinhibition and aberrant hyperexcitability may be viable therapeutic targets for treating 
memory dysfunction in epilepsy. Ideally, new treatments for memory impairment should 
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Memory deficits are a devastating consequence of many neurological disorders, 
affecting patients with dementia, epilepsy, Down’s syndrome, autism-spectrum disorder, 
Parkinson’s disease, as well as patients with psychiatric disorders (Selkoe, 2001; 
Helmstaedter, 2002; Cirillo and Seidman, 2003; Vicari et al., 2005; Boucher et al., 2012; 
Skodzik et al., 2013; Pauls et al., 2014). Not only does memory impairment interfere with 
normal functioning, but as memory deficits worsen they become dangerous, and are thus 
among the primary causes for admission into residential nursing homes (Andel et al., 
2007). It was estimated that delaying admission into a residential care facility for 
dementia patients in the U.S. by only 1 month would cut healthcare spending by $4 
billion (Gold and Budson, 2008). Thus, treatments that attenuate memory deficits will 
improve quality of life and diminish the heavy financial and emotional burden of 
neurological disease. New treatments are needed because currently available therapies for 
memory deficits are few in number, mechanistically homogenous, only marginally 
effective, and present with side effects (Raina et al., 2008; Nygaard, 2013). Towards this 
end, the scope of this dissertation is to better understand the neurophysiology and 
behavioral pharmacology of memory enhancement and memory impairment in order to 
highlight new therapeutic targets and perhaps guide the clinical use of current treatments.  
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Memory Deficits in Disease 
Memory deficits in AD typically begin with mild cognitive impairment (MCI), 
first affecting temporal lobe-dependent episodic memories such as misplacing keys, 
forgetting an appointment, or difficulty remembering a particular conversation – events 
that are typically associated with normal aging (Frisoni et al., 2010). However, as AD 
progresses, worsening episodic memory is accompanied by semantic memory 
impairments such as difficulty with verbal recall and object recognition. At this point, 
patients are usually prompted by loved ones to seek medical attention, resulting in a 
diagnosis of MCI. Identification of the constellation of symptoms required for a diagnosis 
of MCI and probable AD can be performed during a routine visit with a clinician (a 
definitive diagnosis of AD requires postmortem examination). Cognitive tests such as the 
Mini Mental Status Exam (MMSE) or the Alzheimer’s Disease Assessment Scale with 
cognitive measures (ADAS-cog) are sensitive to subtle changes in declarative memory 
function and can be used to make an early and reliable diagnosis. MCI progresses to 
probable AD when more global cognitive deterioration occurs, indicated by deficits in 
attention, visuospatial memory, and executive function that interfere with one’s ability to 
function independently (McKhann et al., 2011).  
AD is not the only neurological disease accompanied by memory impairment. A 
survey of over 1000 epilepsy patients found that cognitive difficulty was the greatest 
concern for patients with epilepsy, and “the ability to remember things” was ranked 
highest amongst qualities affected by epilepsy (Fisher et al., 2000). Another survey 
reported that over half of all epilepsy patients regarded memory impairments as a 
moderate-to-severe “nuisance” (Thompson and Corcoran, 1992). Moreover, children with 
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temporal lobe epilepsy (TLE) also suffer from memory disturbances that contribute to 
poor performance in school and the lifelong socioeconomic difficulty patients with 
epilepsy face (Rzezak et al., 2014). Given the significant impact memory impairment in 
AD, epilepsy, and other neurological disease has on quality of life, and the 
socioeconomic ramifications endured by patients, their families, and society, new 
treatments are urgently needed. Researchers tasked with new therapy development face 
an onerous challenge and can adopt a variety of strategies to discover new treatments for 
memory impairments in disease.  
 
Top-Down and Bottom-Up Approaches to New Therapy  
Discovery for Memory Deficits in Disease 
 Perhaps the most common approach to new therapy development is to elucidate 
the underlying pathophysiological mechanisms of disease to yield effective targeted 
therapies. This strategy, which can be thought of as a bottom-up approach, has and will 
likely continue to yield beneficial therapies that dampen, prevent, or reverse disease 
symptoms, however, the complex heterogeneity of neurological disorders makes this 
approach a formidable endeavor that will likely take years, if not decades before new 
treatments are available. Nevertheless, a mechanistic understanding that targets the 
underlying pathophysiology is a cornerstone of disease research and may be necessary for 
prevention or complete remediation of symptoms. 
An alternative approach is to study existing treatments, including those in 
development, that have a more general impact on memory, and reverse-engineer their 
therapeutic effects. The rationale behind this strategy, which can be thought of as a top-
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down approach, is that a mechanistic understanding of treatments already shown to 
improve memory may provide a roadmap for their beneficial effects, and thus, lead to 
new therapies that “fine-tune” existing treatments and highlight novel therapeutic targets. 
 As it relates to the research in this dissertation, both top-down and bottom-up 
strategies were employed. The top-down approach in this study dissects the physiology 
and function of 5-HT6 receptors, a serotonin (5-HT) receptor subtype known for its 
memory enhancing effects. 5-HT6 receptor cell-type specific receptor expression patterns 
and their effects on synaptic transmission in brain areas critical for memory formation are 
poorly understood. Thus, the first goal of this study was to provide an anatomical and 
physiological blueprint for the memory enhancing effects of 5-HT6 receptor antagonists 
in the dentate gyrus (DG), a subregion of the hippocampus that is critical to new memory 
formation. The second goal was to examine the role of 5-HT6 receptors on spatial pattern 
processing and seizures in a transgenic model of AD. Results from this investigation are 
expected to direct the discovery of new therapeutic approaches for memory impairment 
in neurological disorders such as AD and epilepsy, and inform the current clinical use of 
5-HT6 receptor antagonists.  
The bottom-up approach in this study investigated brain region-specific 
pathophysiology associated with spatial pattern processing deficits in a corneal kindled 
mouse model of network hyperexcitability (Rowley and White, 2010). Although epilepsy 
patients and animal models of epilepsy exhibit memory deficits associated with neuron 
loss and hippocampal sclerosis, some epilepsy patients exhibit memory impairments in 
the absence of overt brain damage (Berg et al., 2009; Berg, 2011). Although it is ideal to 
treat all patients with memory deficits, it may be a more manageable endeavor to first 
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develop treatments for memory impairment in animal models with less neuron loss. Thus, 
we wanted to test whether corneal kindled mice, which are a readily implemented model 
of network hyperexcitability shown to lack overt hippocampal damage (Loewen et al., 
2016), exhibit cognitive dysfunction in the absence of extensive neuron loss. Further, we 
investigated the underlying pathophysiology that may contribute to these deficits. Results 
from this investigation are expected to inform the pathophysiology underlying memory 
deficits and potentially provide a model to test therapies that may reverse seizure-related 
memory impairment. 
 
An Overview of the Serotonergic System and the  
5-HT6 Receptor Subtype 
The Serotonin System 
Understanding the nootropic effects of 5-HT6 receptors is a difficult undertaking 
underscored by the complexity of the serotonin system. Serotonin, 5-hydroxytryptamine 
(5-HT), is a monoamine neurotransmitter converted from its precursor L-tryptophan by 
tryptophan hydroxylase (Millan et al., 2008; McCorvy and Roth, 2015). 5-HT is 
produced and released by neurons originating in brainstem raphe nuclei that send 
extensive long-range projections innervating almost all major brain regions (Berger et al., 
2009). Seven families of serotonin receptors comprised of 14 known receptor subtypes 
transduce serotonin’s powerful effects. Except for the 5-HT3 receptor, which is a ligand-
gated cation-permeable ion channel, all 5-HT receptors are 7 transmembrane spanning 
domain G-protein coupled receptors (GPRCs) (Millan et al., 2008). 5-HT receptors are 
primarily found in the frontal cortex, hippocampus, amygdala, striatum, and dorsal horn 
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of the spinal chord. Their activity influences numerous signaling cascades that affect 
neuronal excitability, and thus, exert powerful effects of mood, cognition, sleep, pain, 
appetite, and motor control (Millan et al., 2008). Drugs affecting the serotonin system 
have remarkable effects on brain function, perhaps best exemplified by the use of 
selective serotonin reuptake inhibitory (SSRIs) for the treatment of anxiety and 
depression (Pollack, 2005).  
Understanding the effects of serotonin or SSRIs is obscured by the myriad effects 
of its 14 receptor subtypes, although investigation into their canonical signal transduction 
pathways has revealed some order (Millan et al., 2008). For instance, 5-HT4, 5-HT6, and 
5-HT7 are positively coupled to Gs, such that activation of these receptor subtypes 
increase intracellular levels of the second messenger cyclic adenosine monophosphate 
(cAMP). In contrast, 5-HT1 and 5-HT5 receptors are negatively coupled to adenylyl 
cyclase via Gi/o, thus their activation inhibits production of cAMP. The 5-HT2 receptor is 
coupled to Gq/11, which activates phospholipase C leading to the production of inositol-
1,4,5-trisphosphate (IP3) and the release of Ca2+ from intracellular stores. In addition to 
their prototypical signaling pathways, each receptor subtype has been linked to a 
diversity of alternate signaling mechanisms. See (Millan et al., 2008) for an extensive 
review of their downstream signaling cascades.  
Attempts to untangle the complexity of the serotonergic system have been greatly 
advanced by the development of receptor subtype-selective ligands, illustrating the 
effects of each individual receptor type on brain function. For instance, agonists and / or 
antagonists of 5-HT1A, 5-HT4, and 5-HT6 receptors have cognition enhancing effects in 
rodents during a variety of learning and memory tasks (King et al., 2008). Additionally, 
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5-HT2A receptors are thought to play a critical role in executive function (Aznar and 
Hervig Mel, 2016), whereas 5-HT7 receptor antagonists are perhaps best known for their 
role as potential fast-acting antidepressants (Mnie-Filali et al., 2007; Mnie-Filali et al., 
2011). Moreover, ligands effecting 5-HT1A, 5-HT1B, 5-HT2C, 5-HT3, and 5-HT6 receptors 
have established anticonvulsant and / or proconvulsant effects, which is not surprising, 
since serotonin itself is an endogenous anticonvulsant (Hirst et al., 2006; Bagdy et al., 
2007; Panczyk et al., 2015). Although the effects of selective serotonin receptor ligands 
are intriguing and hold great promise for the treatment of neurological disease, the 
majority of serotonin’s actions do not occur in the brain. In fact,  > 90% of total body 
serotonin is found in the gastrointestinal (GI) tract (Mawe and Hoffman, 2013). Although 
5-HT receptor ligands have been successfully targeted for the treatment of GI disorders 
(Mosinska et al., 2016), their expression outside the central nervous system (CNS) 
hampers their use for treating cognitive dysfunction. Interestingly, 5-HT6 receptors, 
known for their beneficial effects on anxiety, depression, obesity, seizures, and perhaps 
most notably, learning and memory are thought to be expressed exclusively in the CNS, 
making them an ideal target for treating cognitive dysfunction (although faint 5-HT6 
mRNA expression has been detected in peripheral blood mononuclear cells and in the 
stomach (Yang and Xiao, 2015)). As a continuation of over two decades of literature 
attempting to reverse-engineer 5-HT6 receptor physiology and function, the majority of 
the work in this dissertation will focus on gaining a better understanding of the 





An Overview of 5-HT6 Receptors 
The rat 5-HT6 receptor was first identified and sequenced in 1993 by two 
independent groups (Monsma et al., 1993; Ruat et al., 1993), followed by the human and 
murine forms, which were cloned in 1996 and 2001, respectively (Kohen et al., 1996; 
Kohen et al., 2001). The human 5-HT6 receptor maps to chromosome region 1p35-p36 
and has 89% and 84% sequence homology with the rat and mouse equivalents, 
respectively. Additionally, the human and mouse form contain 440 amino acids, whereas 
the 5-HT6 receptor in rat contains 438 amino acids. In contrast to other serotonin receptor 
subtypes, the 5-HT6 receptor has no known isoforms.  
Despite being canonically linked to adenylyl cyclase, several Gs-independent 
signaling pathways are affected by 5-HT6 receptors. For instance, activation of 5-HT6 
receptors has been shown to increase activity of the extracellular signal-regulated kinase 
1/2 (ERK1/2) pathway in a Fyn tyrosine kinase-dependent manner (Yun et al., 2007).  
Although its role in mediating the effects of 5-HT6 receptor antagonists on cognitive 
function remains unclear, Fyn has been shown to play an important role in regulating 
long-term synaptic plasticity and spatial memory (Grant et al., 1992). Additionally, 5-
HT6 receptor activation was recently shown to physically recruit and directly activate 
mammalian target of rapamycin (mTOR), a pathway involved in cell proliferation, 
synaptogenesis, neurite outgrowth, as well as neural excitability via ion channel 
expression (Raab-Graham et al., 2006; Swiech et al., 2008; Meffre et al., 2012). 
Moreover, treatment with a 5-HT6 receptor antagonist attenuated aberrantly increased 
mTOR expression and reversed cognitive deficits in animal models of schizophrenia 
(Meffre et al., 2012). Lastly, 5-HT6 receptor antagonists have even been shown to 
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attenuate serotonin-induced depolarization of neurons expressing 5-HT6 receptor mRNA 
in a potassium-dependent manner (Bonsi et al., 2007). Thus, 5-HT6 receptors affect 
neurophysiology and function through a variety of complex effects. 
Few studies have investigated the role of 5-HT6 receptors in development.  
However, their expression in rat begins on embryonic day 12, remains stable throughout 
adulthood, and is implicated in developmental processes such as interneuron migration, 
neuronal differentiation, and neurite outgrowth (Riccio et al., 2009; Duhr et al., 2014). 
Gross anatomical localization of 5-HT6 receptors using radiolabeled ligands or in-situ 
hybridization suggests high levels of expression in the striatum, caudate-putamen, 
nucleus accumbens, and olfactory tubercles, with intermediate levels of expression in 
thalamus, cerebral cortex, and hippocampus in rats and humans (Gerard et al., 1996; 
Gerard et al., 1997; Roberts et al., 2002; Hirst et al., 2003). Mice exhibit a 
similar expression profile, with reduced levels of 5-HT6 receptor expression in the 
striatum (Hirst et al., 2003). Together, these studies suggest that 5-HT6 receptors are 
ideally anatomically localized to modulate cognitive function. 
Interest in 5-HT6 receptor effects on cognition was triggered by attempts to 
reverse-engineer antipsychotics and antidepressant drugs. Ligand binding studies 
revealed that tricyclic antipsychotics and antidepressants clozapine, amoxipine, and 
amitriptyline have a high affinity for 5-HT6 receptors (Monsma et al., 1993; Roth et al., 
1994). These top-down driven studies were the impetus for the discovery and 
development of a number of 5-HT6 receptor-specific ligands that have been tested for 
their behavioral effects in rodents over the last 2 decades. Although a plethora of 5-HT6 
receptor agonists and antagonists have become commercially available, many more 5-
  
10 
HT6 receptor antagonists have been developed, likely as a result of many more studies 
reporting their beneficial effects on cognitive function. Benhamú et al. (2014) and others 
have written extensive reviews covering the armamentarium of 5-HT6 receptor ligands 
and their pharmacology (Benhamu et al., 2014). However, the 5-HT6 receptor antagonists 
used in this study, SB-399885 and SB-271046, are perhaps the most widely studied 
because they exhibit over 200-fold and 50-fold selectivity, respectively, for the 5-HT6 
receptor over other serotonin receptors (Routledge et al., 2000; Hirst et al., 2006). A 
number of 5-HT6 receptor agonists have been developed as well, revealing similar effects 
as the antagonists on certain behavioral assays, particularly those assessing anxiety and 
depression (Wesolowska, 2010). To date, the most widely studied 5-HT6 receptor 
agonists are perhaps WAY-208466, which is used for in vitro studies in Chapter 2, and 
WAY-181187. Both agonists display 50-fold selectivity for 5-HT6 receptors over other 
serotonin and monoaminergic receptors, and similar efficacy to the endogenous ligand 5-
HT (Schechter et al., 2008). As a result of their development and optimization, 5-HT6 
receptor-selective agonists and antagonists have revealed a wealth of therapeutic 
potential. Most notably, 5-HT6 receptor antagonists exhibit beneficial effects in rodent 
models of anxiety, depression, obesity, and seizures (Fone, 2008; Codony et al., 2011; 
Meneses et al., 2011); however, they are perhaps best known for their effects on learning 
and memory.  
 
The Nootropic Effects of 5-HT6 Receptor Antagonists 
5-HT6 receptor antagonists fall under the moniker of “smart drugs” based on their 
remarkable cognition-enhancing effects. One the first reports of their nootropic effects 
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directed antisense oligonucleotides at 5-HT6 receptors in rats, and tested one of the first 
centrally acting 5-HT6 receptor antagonists Ro-046790, and found improved retention of 
platform location during the Morris water maze (MWM) (Woolley et al., 2001). As 5-
HT6 receptor-selective antagonists became available, studies revealed that acute, 
subchronic, and chronic administration in naïve, aged, and scopolamine-treated rats 
exhibited improved acquisition and retention in the MWM (Rogers and Hagan, 2001; 
Stean et al., 2002; Foley et al., 2004; Hirst et al., 2006). Their nootropic effects are not 
limited to spatial memory: 5-HT6 receptor antagonists have been shown to improve 
performance during associative learning and fear conditioning during passive avoidance 
and operant conditioning tasks (Foley et al., 2004; Schreiber et al., 2007; Meneses et al., 
2011), and reverse natural forgetting and scopolamine-induced deficits during novel-
object recognition and social recognition tasks (King et al., 2004; Hirst et al., 2006; 
Mitchell et al., 2006). Additionally, unpublished data from a collaboration at the 
University of Utah between Dr. Peter J. West, Dr. Julie R. Korenberg, Dr. Raymond P. 
Kesner, and Dr. Karen S. Wilcox found that acute systemic treatment with a 5-HT6 
receptor antagonist reversed memory deficits during the novel object place-recognition 
task in a mouse model of Down syndrome (Korenberg). On the strength of this 
preclinical data, 5-HT6 receptor antagonists advanced to clinical trials in patients with 
mild-to-moderate AD, and were reported to improve scores on the Clinician’s Interview-
Based Impression of Change plus Caregiver Input (CIBIC+) and ADAS-cog as a stand-
alone therapy; importantly, treatment caused minimal adverse events (Maher-Edwards et 
al., 2010; Maher-Edwards et al., 2011; Wilkinson et al., 2014). Despite their widely 
reported nootropic effects in animals, and potential to improve cognitive function in AD, 
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5-HT6 receptor localization and physiology remains poorly understood. 
 
5-HT6 Receptor Effects on Synaptic Transmission:  
What Is Known and Unknown 
Over a decade of literature attributes the memory enhancing effects of 5-HT6 
receptor antagonists to disinhibition – that is, an attenuation of inhibitory synaptic 
transmission that facilitates information flow through excitatory networks (Dawson et al., 
2001; Woolley et al., 2004; Fone, 2008; Schechter et al., 2008; Codony et al., 2011; 
Ramirez, 2013). This idea comes from studies showing that systemic administration of a 
5-HT6 receptor agonist increased extracellular levels of GABA in rat frontal cortex, 
dorsal hippocampus, striatum, and amygdala, whereas systemic administration of a 5-HT6 
receptor antagonist has been shown to increase extracellular levels of glutamate and 
acetylcholine in those brain regions (Rogers and Hagan, 2001; Woolley et al., 2001; 
Stean et al., 2002; Foley et al., 2004; Hirst et al., 2006; Marcos et al., 2006; Schechter et 
al., 2008). Additionally, West et al., (2009) reported that 5-HT6 receptor activation 
increased the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) onto 
pyramidal cells in hippocampal area CA1 without affecting their amplitude (West et al., 
2009).  Importantly, these results, obtained while fast excitatory synaptic transmission 
was pharmacologically blocked, suggest that activation of 5-HT6 receptors increased the 
excitability of inhibitory interneurons. Moreover, lesioning of serotonergic and 
cholinergic fibers originating in the brain stem failed to alter 5-HT6 mRNA levels, 
implying that 5-HT6 receptors do not function as autoreceptors or directly control 
cholinergic release (Gerard et al., 1996; Marcos et al., 2006).   
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Further support for the idea that 5-HT6 receptor antagonists dampen inhibition 
comes from studies reporting 5-HT6 receptor mRNA and protein colocalized with striatal 
GABAergic neurons (Ward and Dorsa, 1996; Marazziti et al., 2012). Additionally, 5-HT6 
receptors are GPCRs that are canonically positively coupled to adenylyl cyclase via Gs, 
such that 5-HT6 receptor activation increases intracellular levels of cAMP, an effect 
thought to increase the overall excitability of neurons (Millan et al., 2008). Consistent 
with this idea, Bonsi et al. (2007) showed that blockade of 5-HT6 receptors 
hyperpolarized the resting membrane potential of neurons expressing 5-HT6 receptor 
mRNA in the striatum (Bonsi et al., 2007).  
Controversy undermining the idea that 5-HT6 receptor antagonists directly 
attenuate the activity of inhibitory interneurons comes from studies suggesting their 
expression on excitatory neurons. For example, a recent study by Helboe et al., (2015) 
reported 5-HT6 receptor mRNA expression in the majority of pyramidal neurons and 
granule cells in the hippocampus, with much lower levels of expression in inhibitory 
interneurons (Helboe et al., 2015). Moreover, Wang et al. (2016) reported that a 5-HT6 
receptor agonist attenuated glutamate release from synaptosomes prepared from whole 
hippocampus homogenates in a Gi/o-dependent manner, suggesting the presence of 5-HT6 
receptors on presynaptic termini of excitatory neurons and unprecedented association 
with Gi/o (Wang et al., 2016). Additionally, Bonzi et al. (2007) reported that 5-HT6 
receptor antagonists hyperpolarize striatal acetylcholinergic interneurons that were 
depolarized by bath application of serotonin (Bonsi et al., 2007), results that are at odds 
with studies reporting that ablation of cholinergic fibers had no effect on 5-HT6 receptor 
mRNA expression (Gerard et al., 1996; Marcos et al., 2006). Moreover, results from the 
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study by Bonsi et al. (2007) also conflict with the disinhibition hypothesis, since 
acetylcholinergic activity is thought to promote excitability. Lastly, others have published 
examples of 5-HT6 receptor expression on pyramidal neurons and astrocytes within the 
hippocampus (Woolley et al., 2004; Marazziti et al., 2013). However, these reports lack 
quantification of 5-HT6 receptor expression patterns. Although these studies support the 
idea that 5-HT6 receptors are expressed on both excitatory and inhibitory neurons, as well 
as glial cells, confirmation of their cell-type specific expression patterns is lacking, 
largely due to the unavailability of well characterized 5-HT6 receptor-specific antibodies. 
Moreover, the effects of 5-HT6 receptor activity on synaptic transmission in the DG, the 
entranceway into the hippocampus, are lacking altogether. Thus, Chapter 2 of this 
dissertation uses in vitro electrophysiology and immunohistochemistry to dissect 5-HT6 
receptor localization and effects on inhibitory synaptic transmission in the DG. We 
hypothesize that 5-HT6 receptor activation increases inhibitory synaptic transmission 
onto DGCs and that 5-HT6 receptor blockade decreases inhibitory synaptic transmission 
onto DGCs via their direct effects on inhibitory interneurons. To circumvent a lack of 
well-characterized antibodies, we obtained commercially available transgenic mice 
expressing a modified bacterial artificial chromosome (BAC) with an enhanced green 
fluorescent protein (EGFP) reporter upstream of the 5-HT6 receptor gene (htr6-EGFP 
mice (Gong et al., 2003; GENSAT, 2016) Results from this study are expected to provide 
an anatomical and physiological blueprint for 5-HT6 receptor antagonists’ cognition 
enhancing effects, provide a platform for understanding serotonergic remodeling in 
disease, and direct future therapy discovery to treat memory deficits in neurological 
disorders such as AD and epilepsy. 
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Memory Deficits and Hyperexcitability in Disease:  
A Double-Edge Sword 
Another interesting caveat to the development of treatments for memory 
impairments is that many patients with cognitive dysfunction also exhibit seizures and 
aberrant hyperexcitability thought to contribute to cognitive dysfunction. For instance, 
depending on the study cited, 1.5-64% of AD patients have had at least 1 unprovoked 
seizure (Friedman et al., 2012).  Moreover, at least half of patients with a dual-diagnosis 
of AD and epilepsy have been shown to exhibit nonconvulsive seizures that may go 
unnoticed (Vossel et al., 2013). And recently, a longitudinal study in AD patients with no 
prior history of seizures reported that 42% of patients (compared to 10.5% of age-
matched controls) exhibited epileptiform activity, which are brief bursts of 
hypersynchronous discharges thought to impair cognitive function and facilitate disease 
progression (Palop et al., 2007; Sanchez et al., 2012; Kleen et al., 2013; Vossel et al., 
2016). Additionally, adults and children with epilepsy report that memory deficits are 
amongst their greatest concerns (Thompson and Corcoran, 1992; Fisher et al., 2000), and 
individuals with intellectual disability and autism spectrum disorder also experience 
memory deficits and an increased risk of seizures compared to the general population 
(Cirillo and Seidman, 2003; Vicari et al., 2005; Boucher et al., 2012; Pauls et al., 2014; 
Jackson et al., 2015; Buckley and Holmes, 2016). 
The occurrence of seizures and memory deficits in epilepsy, AD, and other 
neurological diseases presents a double-edged sword regarding pharmacological 
treatments: Many cognition-enhancing drugs have seizure liabilities, and many 
antiseizure drugs (ASDs) cause memory impairment. For example, 2 of the 5 currently 
  
16 
approved drug treatments for cognitive dysfunction in AD, Aricept (Donepezil) and 
Exelon (Rivastigmine), are listed on the World Health Organization’s top ten drugs 
associated with convulsive adverse drug reactions (Kumlien and Lundberg, 2010). 
Moreover, memantine, the only approved treatment for cognitive dysfunction in AD that 
is not an acetylcholinesterase inhibitor, has been shown to worsen seizures in animal 
models of epilepsy (Loscher, 1998; Mares and Mikulecka, 2009), has been associated 
with new-onset seizures in AD (Peltz et al., 2005), and comes with a package warning for 
increased risk of seizures. Not only are seizures a dangerous side effect of the only 
approved treatment options available to AD patients, but seizures and hyperexcitability 
themselves, which can manifest as subclinical epileptiform activity that is difficult to 
detect, can impair memory and worsen disease progression (Palop et al., 2007; Bakker et 
al., 2012; Sanchez et al., 2012; Kleen et al., 2013). Thus, new treatments for memory 
deficits not only need to improve cognitive function, but they must do so without 
exacerbating the risk of seizures. 
 On the other hand, treating seizures in patients with memory impairment is 
hampered by the fact that many ASDs impair cognitive function. For example, ASDs 
such as carbamazepine, phenobarbital (PHB), phenytoin, topiramate (TPM), and 
valproate have all been shown to impair cognitive function in healthy individuals and 
patients with epilepsy (Meador et al., 1993; Meador et al., 1995; Meador, 2002; Lee et 
al., 2003; Meador et al., 2005; Salinsky et al., 2005; Hamed, 2009). Moreover, many 
ASD drugs have been shown to attenuate long-term synaptic plasticity at hippocampal 
synapses critical for new memory formation (West et al., 2014). However, dampening 
hyperexcitability with ASDs does not always have deleterious effects: second-generation 
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ASDs such as Levetiracetam (LEV) and TPM have been shown to attenuate seizures and 
improve cognitive function in animal models of AD that also exhibit spontaneous 
seizures (contrary to TPM’s deleterious effects on cognition in humans) (Sanchez et al., 
2012; Shi et al., 2013). Remarkably, LEV reduced seizures and improved cognitive 
dysfunction in patients with AD (Cumbo and Ligori, 2010; Bakker et al., 2012). PHB and 
lamotrigine were also effective at reducing seizures in AD patients, but had deleterious 
effects on patients’ performance during the MMSE. Although these results are 
encouraging, and additional clinical trials testing the effects of LEV on seizures and 
cognitive function in AD are underway, new therapies that improve cognition without 
exacerbating seizures are needed. Ideally, new treatments should be both procognitive 
and anticonvulsant. 
 
5-HT6 Receptor Antagonists as a Potential Procognitive and  
Anticonvulsant Treatment 
 Interestingly, in addition to their nootropic effects, 5-HT6 receptor antagonists 
also exhibit antiseizure properties. Several studies have reported that acute systemic 
treatment with a 5-HT6 receptor antagonist increased seizure threshold in rats during the 
maximal electroshock test (Routledge et al., 2000; Stean et al., 2002; Hirst et al., 2006). 
Additionally, pretreatment with the 5-HT6 receptor antagonist SB-399885 increased 
seizure latency and reduced seizure severity in rats treated with the proconvulsant 
compound pilocarpine (Wang et al., 2015). However, the effects of 5-HT6 receptor 
antagonists in other acute seizure models remains unreported, and their effects on 
cognition and seizures in a transgenic model of AD, where seizures and hyperexcitability 
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are thought to contribute to disease progression, are also unreported. Understanding the 
effects of 5-HT6 receptor antagonists on cognition and seizures in a transgenic model of 
AD is critical, since their effects may differ from those in otherwise healthy animals due 
to remodeling of serotonergic or other neurotransmitter systems affected by 5-HT6 
receptors in the disease state (Garcia-Alloza et al., 2004; Li et al., 2016). Furthermore, if 
5-HT6 receptor antagonists do affect cognition and seizures in a transgenic model of AD, 
these results would warrant a detailed investigation into 5-HT6 receptor localization and 
physiology in transgenic models of AD, and perhaps guide their use in patients with AD. 
 Chapter 3 tests the hypothesis that 5-HT6 receptor antagonists exhibit 
procognitive and anticonvulsant effects in J20 mice. J20 mice are a transgenic model of 
AD shown to exhibit cognitive dysfunction and spontaneous nonconvulsive seizures 
thought to mimic the subpopulation of patients with AD and epilepsy (Palop et al., 2007; 
Sanchez et al., 2012; Vossel et al., 2013; Vossel et al., 2016). We evaluated the 
procognitive and anticonvulsant effects of a 5-HT6 receptor antagonist on cognition and 
seizures using a spatial pattern processing paradigm known as the metric task and the 
minimal clonic seizure threshold test, respectively. Chapter 3 also tests the hypothesis 
that 5-HT6 receptor antagonists are anticonvulsant in 2 strains of naïve and otherwise 
healthy mice. Results from these studies are expected to inform the clinical use of 5-HT6 
receptor antagonists in patients with AD, particularly with respect to their effects on 
seizures, and provide justification for dissecting 5-HT6 receptor physiology in animal 
models of AD. 
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Corneal Kindling in C57BL/6 Mice: A Bottom-Up Approach to  
Studying Memory Deficits in Epilepsy 
Patients with epilepsy not only experience spontaneous seizures but also a host of 
cognitive comorbidities including memory dysfunction. Approximately 25% of all 
patients with TLE experience memory deficits (Hermann et al., 2006), and 70-80% of the 
pharmacoresistant population, which makes up about one third of the epilepsy 
population, exhibit declarative memory impairment (Helmstaedter, 2002). Moreover, 
surveys show that the majority of epilepsy patients report that memory deficits are their 
greatest concern (Thompson and Corcoran, 1992; Fisher et al., 2000). Unfortunately, 
there are currently no approved treatments for memory impairment associated with 
epilepsy. Accordingly, the 2014 National Institute of Neurological Disorders and Stroke 
(NINDS) Benchmarks for Epilepsy Research called for studies to better understand and 
limit adverse impacts of seizures on quality of life, including intellectual abilities, thus 
prompting detailed investigations of cognitive dysfunction and its associated 
pathophysiology in animal models of epilepsy. 
The etiology of memory impairment in epilepsy is diverse and complex. Although 
there are a number of factors that contribute to cognitive dysfunction in epilepsy, cell 
death and hippocampal sclerosis (HS) are thought to play a critical role in memory 
dysfunction (Sutula et al., 1995; Kotloski et al., 2002). However, not all epilepsy patients 
demonstrating memory impairment have severe hippocampal damage (Aikia et al., 1995; 
Lah et al., 2014), and hippocampal cell loss with or without HS is not always associated 
with memory impairment (Castro et al., 2013; Schmidt et al., 2015). Moreover, 
associations between hippocampal volume loss and performance on memory tests are 
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highly variable (Aikia et al., 2001). These observations suggest, at least in some epilepsy 
patients, more subtle changes in hippocampal physiology may underlie memory 
dysfunction.  Towards this end, animal models of epilepsy that exhibit memory deficits in 
the absence of overt neuronal loss may be useful in understanding the etiology of 
memory impairment in disease.  
There are a number of animal models that produce the hallmark pathological 
features of epilepsy such as spontaneous seizures and cell death. For example, systemic 
administration of chemoconvulsants or direct electrical stimulation of limbic structures 
reliably produce spontaneous seizures and memory dysfunction in rodents but result in 
neuronal loss (Cossart et al., 2001; Hannesson et al., 2001; Sloviter et al., 2003; Harvey 
and Sloviter, 2005; Leung and Shen, 2006; Sloviter et al., 2006; Sun et al., 2007; 
Chauviere et al., 2009; Jinde et al., 2012). Although these models are useful because they 
recapitulate the pathophysiology found in many patients with epilepsy, developing 
treatments for memory impairments in epilepsy may be hampered in animal models that 
exhibit overt hippocampal damage. Support for this idea is highlighted by studies 
showing that patients with TLE or AD who exhibit severe cell loss are more likely to be 
pharmacoresistant and severely cognitively impaired (Helmstaedter, 2002; Connelly et 
al., 2005), leaving them few, if any, treatment options. While it is ideal to develop 
treatments for all patients who suffer from cognitive dysfunction, it may be a more 
manageable endeavor to first develop therapies in animal models that exhibit memory 
deficits as a result of more subtle hippocampal pathophysiology. 
Towards this end, electrical kindling models that directly stimulate limbic brain 
regions exhibit hippocampal-dependent memory impairment in the absence of overt 
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hippocampal cell loss (Hannesson and Corcoran, 2000). This suggests that more subtle 
changes in hippocampal physiology underlie memory impairment in these models. 
However, electrical kindling models are constrained by laborious implantation surgeries 
that also cause a proinflammatory response in the brain. A noninvasive model of kindling 
that employs the chemoconvulsant pentylenetetrazol (PTZ) also produces hippocampal-
dependent spatial memory impairment, but has been reported to produce hippocampal 
neuron loss (Pohle et al., 1997; Palizvan et al., 2001; Park et al., 2006; Mishra and Goel, 
2012, 2013). Taken together, these studies highlight the need for a noninvasive model of 
epilepsy that exhibits memory deficits in the absent of overt hippocampal damage. 
In a follow-up study to the report by Loewen et al. (2016) showing that corneal 
kindled CF1 mice exhibit no observable neuron loss in the hippocampus (Loewen et al., 
2016), Chapter 4 of this dissertation tested corneal kindled C57BL/6 mice for cognitive 
dysfunction in the metric task, a spatial pattern processing paradigm thought to rely on 
proper DG function (Ennaceur and Delacour, 1988; Lee et al., 2005; Goodrich-Hunsaker 
et al., 2008; Ennaceur, 2010). The corneal kindling model of network hyperexcitability in 
mice has been validated as a rapid screening model of focal seizures that secondarily 
generalize and has been validated as a useful tool in the discovery of novel ASDs, in part, 
because of its noninvasive, cost-effective methodology (Matagne and Klitgaard, 1998; 
Potschka and Loscher, 1999; Rowley and White, 2010). Upon discovery of spatial pattern 
processing deficits in corneal kindled mice, we used immunohistochemistry and in vitro 
hippocampal brain slice electrophysiology to test the hypothesis that corneal kindled 
mice exhibit altered dentate gyrus-associated synaptic transmission and plasticity in the 
absence of neuron loss. Results from this study are expected to inform the etiology of 
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memory deficits in epilepsy and perhaps provide a useful model for the development of 
treatments that ameliorate epilepsy-associated cognitive dysfunction. 
 
The Dentate Gyrus and Its Role in Learning and Memory 
 Almost all of the experiments in this dissertation are focused on the physiology 
and function of the DG. The DG is a subregion in the hippocampus, an evolutionarily 
conserved bilateral temporal lobe structure that is critical for new memory formation 
(Squire, 1992). Anatomically, the hippocampus can be divided into 3 interconnected 
subareas: the DG, CA3, and CA1. These 3 regions form the trisynaptic loop, beginning 
with perforant-path projections from the entorhinal cortex to DG granule cells (DGCs), 
which then project to pyramidal neurons in hippocampal area CA3; CA3 then projects to 
CA1. Dissecting the physiology and function of the hippocampus and its individual 
subregions in health and disease is a cornerstone of neuroscience research, in part, 
because it is expected to lay the foundation for the understanding of, and amelioration of, 
memory impairment in disease. 
Studies investigating the individual contribution of hippocampal subregions in 
rodents show that the DG and CA3 play a critical role in the rapid acquisition of new 
spatial memories, whereas hippocampal area CA1 is thought to give temporal context to 
mnemonic representations (Kesner et al., 2004; Barbosa et al., 2012). More specifically, 
the DG is thought to play a critical role in fine scale pattern separation (Lassalle et al., 
2000; Lee et al., 2005; Jerman et al., 2006; Morris et al., 2012), which is the ability to 
encode and separate spatially similar events into distinct representations. The DG 
performs this complex function, in part, by maintaining low resting membrane potentials 
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and low levels of spontaneous activity in DGCs as a result of robust afferent inhibition 
from inhibitory interneurons that gate information flow into the hippocampus (Coulter 
and Carlson, 2007; Hsu, 2007). These properties allow DGCs to orthogonalize patterns of 
information that have a high degree of overlap, and thus create metric spatial 
representations out of sensory information coming from entorhinal cortex.  
Rationale for studying 5-HT6 receptor physiology and function in the DG stems 
from preliminary data generated in our lab (presented in Chapter 2) showing that the 5-
HT6 receptor agonist WAY-208466 attenuated the amplitude of field excitatory 
postsynaptic potentials (fEPSPs) generated at perforant path-DG granule cell (DGC) 
synapses in hippocampal brain slices. Notably, this effect was not observed when tested 
on fEPSPs generated at Schafer Collateral-pyramidal neuron synapses in hippocampal 
area CA1 (West et al., 2009), intimating that 5-HT6 receptors may play a critical role in 
DG function. Moreover, other studies suggest that 5-HT6 receptor antagonists likely exert 
their memory enhancing effects, in part, by attenuating inhibition and thus increasing 
information flow through excitatory networks. Being that the DG harbors at least 5 
inhibitory interneurons subtypes that gate information flow into the hippocampus (Hosp 
et al., 2014), the DG might be an ideal anatomical location for 5-HT6 receptor antagonists 
to exert their nootropic effects through disinhibition, and perhaps via a select 
subpopulation of inhibitory interneurons. 
Despite an extensive literature delineating the nootropic effects of 5-HT6 receptor 
antagonists on cognitive function, their effects during a pattern separation task thought to 
rely on DG function have, to my knowledge, never been published. Therefore, in addition 
to testing their effects on synaptic transmission in the DG, we wanted to test 5-HT6 
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receptor antagonists in a DG-mediated spatial pattern processing task that relies on 
rodents’ natural tendency to explore changes in the distance between 2 objects – the 
“metric task” (Ennaceur and Delacour, 1988; Lee et al., 2005; Goodrich-Hunsaker et al., 
2008; Ennaceur, 2010). More specifically, we wanted to utilize the metric task to evaluate 
J20 (AD) mice for DG-associated cognitive dysfunction, as others have reported 
abnormalities in synaptic transmission and synaptic plasticity in the DG of J20 mice 
(Palop et al., 2007). Lastly, we also evaluated whether corneal kindled C57BL/6 mice 
exhibited DG-dependent memory deficits in the metric task, and dissect whether they 
exhibited DG-associated abnormalities in synaptic transmission and plasticity.  
 
Dissertation Overview 
In summary, the research in this dissertation adopted a top-down and bottom-up 
approach to studying memory enhancement and memory deficits related to DG 
physiology and function. See Table 1.1 for a summary of the hypotheses tested in this 
dissertation. Chapter 2 dissects 5-HT6 receptor localization and physiology in the DG, 
and Chapter 3 focused on the behavioral pharmacology to 5-HT6 receptors antagonists, 
investigating their effect on spatial pattern processing in transgenic model of AD.  
Moreover, studies in Chapter 3 also tested the effects of 5-HT6 receptor antagonists on 
seizure threshold in J20 mice, as well as naïve and otherwise healthy mice. Lastly, 
Chapter 4 investigated DG-associated spatial pattern processing in corneal kindled mice, 
and related pathophysiology in the DG that occurred in the absence of overt neuron loss. 
Results from these studies are expected to inform the mechanistic basis of memory 
enhancement and memory impairments, particularly as they relate to DG physiology and 
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5-HT6 RECEPTOR LOCALIZATION AND EFFECTS 
ON INHIBITORYSYNAPTIC TRANSMISION 
IN THE DENTATE GYRUS 
 
Abstract 
Current treatments for memory deficits in Alzheimer’s disease (AD) are few in 
number, mechanistically homogenous, and only marginally effective. Thus, new 
treatments are needed. One approach is to first obtain a mechanistic understanding of 
existing treatments, including those in development, in order to “fine-tune” their targeted 
effects or discover new therapeutic approaches. Towards this end, 5-HT6 receptor 
antagonists have been widely reported to produce nootropic effects and are thought to 
exert their memory enhancing effects by reducing inhibition. However, 5-HT6 receptor 
cell-type specific expression patterns remain poorly understood, and their effects on 
inhibition in the dentate gyrus (DG), a brain area critical for learning and memory, are 
unreported. Therefore, we tested the hypothesis that 5-HT6 receptor activation increases 
inhibitory synaptic transmission onto DG granule cells (DGCs), whereas 5-HT6 receptor 
blockade decreases inhibitory synaptic transmission onto DGCs, via their direct effects 
on inhibitory interneurons. This hypothesis was investigated using extracellular and 
intracellular in vitro electrophysiology recording techniques in acute hippocampal brain 
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slices prepared from rats, as well as immunohistochemistry (IHC) in transgenic mice 
expressing an enhanced green fluorescent protein (EGFP) reporter upstream of the 5-HT6 
receptor gene (htr6-EGFP mice). Bath application of the 5-HT6 receptor agonist WAY-
208466 (1µM) attenuated fEPSP amplitude during extracellular recordings from perforant 
path-dentate granule cell (DGC) synapses and increased the amplitude of evoked 
inhibitory postsynaptic currents (eIPSCs) during voltage-clamp recordings from DGCs. 
In contrast, bath application of the 5-HT6 receptor antagonist SB-399885 (1µM) 
attenuated eIPSC amplitude onto DGCs without affecting the amplitude of spontaneous 
inhibitory postsynaptic currents (sIPSCs), and also produced a late increase in sIPSC 
interevent interval (IEI) during the washout phase. Interestingly, IHC in htr6-EGFP mice 
revealed that the majority of hilar mossy cells (GluA2-immunoreactive (IR)) were also 
GFP-IR, whereas only ~1% of GABA-IR neurons and DGCs were also GFP-IR. Results 
in this study suggest that 5-HT6 receptors bidirectionally modulate inhibitory synaptic 
transmission onto DGCs via their direct effects on mossy cells and are consistent with the 




Memory deficits affect patients with a number of neurological disorders including 
dementia, epilepsy, Down’s syndrome, autism-spectrum disorder, and psychiatric 
disorders (Selkoe, 2001; Helmstaedter, 2002; Cirillo and Seidman, 2003; Vicari et al., 
2005; Boucher et al., 2012; Skodzik et al., 2013; Pauls et al., 2014). Memory impairment 
poses a significant risk of injury to patients and others and is thus among the primary 
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causes for admission into residential nursing homes (Andel et al., 2007). It was recently 
estimated that delaying admission into a residential care facility for dementia patients in 
the U.S. by only 1 month would cut healthcare spending by $4 billion (Gold and Budson, 
2008). New treatments for memory deficits are needed because currently available 
therapies are few in number, mechanistically homogenous, only marginally effective, and 
produce side effects (Raina et al., 2008; Nygaard, 2013). One approach for future therapy 
discovery is to first obtain a mechanistic understanding of existing treatments, including 
those in development, in order to “fine-tune” their targeted effects or discover new 
therapeutic approaches.  
One such promising treatment currently in development, serotonin (5-HT) 5-HT6 
receptor antagonists, have been shown to improve spatial and nonspatial memory in 
naïve, aged, and amnestic rodents during a variety of cognitive tasks including the Morris 
water maze, novel object recognition, social recognition, conditioned fear learning, and 
others (Rogers and Hagan, 2001; Woolley et al., 2001; Stean et al., 2002; Foley et al., 
2004; King et al., 2004; Hirst et al., 2006; Mitchell et al., 2006; Da Silva Costa et al., 
2009; Kendall et al., 2011) (see Fone, 2008 for a comprehensive review). On the strength 
of the preclinical data, 5-HT6 receptor antagonists advanced to clinical trails in patients 
with mild-moderate AD and were shown to improve cognitive function in dementia 
patients; importantly, there were minimal adverse events (Maher-Edwards et al., 2010; 
Maher-Edwards et al., 2011; Wilkinson et al., 2014). However, gaps in our knowledge of 
5-HT6 receptor localization and function preclude a mechanistic understanding of their 
antagonists’ therapeutic effects and the possibility of discovering new approaches to 
ameliorate cognitive dysfunction. Thus, the goal of this study was to dissect 5-HT6 
  
42 
receptor localization and physiology with unprecedented precision in the DG. 
Despite a number of studies reporting the nootropic effects of 5-HT6 receptors, 
their cellular expression patterns and effects on synaptic transmission are not well 
understood. 5-HT6 receptors are G-protein coupled receptors (GPCR) that positively 
couple to adenylyl cyclase, and their activity is linked to neuronal excitability (Millan et 
al., 2008). Accordingly, studies suggest 5-HT6 receptor antagonists produce their memory 
enhancing effects by directly reducing the activity of inhibitory interneurons to facilitate 
information flow through excitatory networks – a phenomenon known as disinhibition 
(See Figure 2.1 for a schematic) (Dawson et al., 2001; Fone, 2008; Schechter et al., 2008; 
West et al., 2009; Codony et al., 2011). Support for the disinhibition hypothesis is 
derived from in vivo microdialysis studies in rats reporting that systemic administration 
of a 5-HT6 receptor agonist increased extracellular levels of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) whereas a 5-HT6 receptor antagonist 
increased extracellular levels of glutamate and acetylcholine in limbic brain areas 
expressing 5-HT6 receptors (Dawson et al., 2001; Riemer et al., 2003; Lacroix et al., 
2004; Schechter et al., 2008). West et al. (2009) reported that 5-HT6 receptor activation 
increased the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) onto 
pyramidal CA1 neurons with excitatory synaptic transmission pharmacologically 
blocked, implying that 5-HT6 receptor activation directly increased the excitability of 
inhibitory synaptic transmission (West et al., 2009). Adding further support to the 5-HT6 
receptor antagonist-mediated disinhibition hypothesis, 5-HT6 receptor mRNA and protein 
have been colocalized with striatal GABAergic neurons (Ward and Dorsa, 1996; 
Marazziti et al., 2012), and chemical ablation of serotonergic or cholinergic fibers failed 
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to alter 5-HT6 mRNA expression, ruling out their role as autoreceptors (Gerard et al., 
1996; Marcos et al., 2006).   
Although the studies described previously are consistent with the hypothesis that 
5-HT6 receptors directly regulate the activity of inhibitory interneurons, this idea is not 
without controversy. For instance, 1 study reported 5-HT6 receptor mRNA expression in 
pyramidal neurons, granule cells, and only a small subset of interneurons within the 
hippocampus (Helboe et al., 2015), and Wang et al. (2016) reported 5-HT6 receptor 
agonist-mediated attenuation of glutamate release from hippocampal synaptosomes 
prepared from whole hippocampus homogenates (Wang et al., 2016), implying their 
expression on presynatic termini of excitatory hippocampal neurons. Moreover, 
representative examples of 5-HT6 receptor expression on pyramidal neurons, 
interneurons, and astrocytes within the hippocampus have also been published (Woolley 
et al., 2004; Marazziti et al., 2013). However, confirmation and quantification of the cell-
type specific expression patterns of 5-HT6 receptors expression in the hippocampus 
remains unpublished, and is likely due to a lack of commercially available specific 
antibodies that are suitably well characterized. Moreover, the effects of 5-HT6 receptor 
effects on synaptic transmission in the hippocampus, a brain region critical for memory 
formation (Squire, 1992), has been minimally reported, and their effects on synaptic 
transmission in the dentate gyrus (DG), the synaptic entranceway into the hippocampus, 
is lacking altogether.   
Thus, the first aim of this study was to test the effects of 5-HT6 receptor ligands 
on inhibitory synaptic transmission using in vitro electrophysiology in the DG of acute 
hippocampal brain slices. Preliminary data from these studies helped secure funding 
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generously granted from the Center on Aging at the University of Utah, which was 
allocated towards the second aim of this study: To determine cell-type specific expression 
patterns of 5-HT6 receptors in the DG we obtained commercially available transgenic 
mice expressing a modified bacterial artificial chromosome (BAC) with an enhanced 
green fluorescent protein (EGFP) reporter upstream of the 5-HT6 receptor gene (htr6-
EGFP mice) (Gong et al., 2003; GENSAT, 2016).  
We focused our investigation on the DG for several reasons. First, 5-HT6 ligands 
have been shown to improve acquisition of spatial memory in rodents (Stean et al., 2002; 
Foley et al., 2004; Hirst et al., 2006), a function thought to be mediated by DG function 
(Lee et al., 2005; Goodrich-Hunsaker et al., 2008). Second, the primary output cells of 
the DG, dentate granule cells (DGCs), are heavily inhibited by local inhibitory 
interneurons that gate information flow into the hippocampus (Hsu, 2007), and thus may 
be an ideal anatomical location for 5-HT6 receptor-mediated disinhibition. Lastly, 
preliminary data generated in our lab showed 5-HT6 receptor activation attenuated basal 
excitatory synaptic transmission at perforant path-DGC synapses, a result that is 
consistent with the idea that 5-HT6 receptor activation increased inhibitory synaptic 
transmission in the DG. Therefore, we hypothesized that 5-HT6 receptor activation 
increases inhibitory synaptic transmission onto DGCs, whereas 5-HT6 receptor blockade 
decreases inhibitory synaptic transmission onto DGCs, via their direct effects on 
inhibitory interneurons. Surprisingly, our results suggest that 5-HT6 receptors indeed 
affect inhibitory synaptic transmission onto DGCs in a manner consistent with the 
disinhibition hypothesis – albeit indirectly, via their expression on mossy cells, an 







Electrophysiology experiments were conducted in hippocampal brain slices 
prepared from either Sprague Dawley male rats (100-200 g, Charles River, Raleigh, NC, 
U.S.A.). or C57BL/6 male mice (20.0 g, Charles River, Raleigh, NC, U.S.A.). 
Electrophysiology experiments conducted in mouse are clearly indicated in the text. 
Immunofluorescence studies were conducted in commercially available male and female 
htr6-EGFP mice on an FVB/N-Swiss Webster background. Htr6-EGFP mice express a 
modified bacterial artificial chromosome (BAC) containing an EGFP reporter upstream 
of the 5-HT6 receptor gene (htr6). These mice were purchased from the Mutant Mouse 
Regional Resource Center at Jackson Laboratory (Gong et al., 2003; GENSAT, 2016). 
All animals were group housed in a light- and temperature-controlled (12 h on/12 h off) 
environment and permitted access to food and water ad libitum throughout the study. All 
experiments were conducted in accordance with the National Institute of Health Guide 
for the Care and Use of Laboratory Animals and approved by the University of Utah 
Institutional Animal Care and Use Committee. All efforts were made to minimize the 
number and suffering of animals used.  
 
Hippocampal Brain Slice Preparation 
Acute hippocampal brain slices were prepared daily from Sprague-Dawley rats 
(100-200 g) or a C57BL/6 mouse as done previously (West et al., 2014). Briefly, rats 
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were anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneal (i.p.)), and brains 
were rapidly removed and submerged in ice-cold (4°C) oxygenated sucrose-based 
artificial cerebral spinal fluid (ACSF) bubbled with 95% O2 / 5% CO2. Sucrose-based 
ACSF contained the following (in mM): Sucrose (200.0), KCl (3.0), Na2PO4 (1.4), 
MgSO4 (3.0), NaHCO3 (26.0), glucose (10.0), and CaCl2 (0.5). The pH and osmolarity of 
the sucrose-based ACSF were adjusted to 7.30-7.35 and 290–300 mOsm, respectively, 
before each experiment. Next, coronal brain slices (350µm) containing dorsal 
hippocampus were cut using a vibrating microtome (VT1000S, Leica Microsystems Inc.). 
Slices were then transferred to oxygenated standard ACSF and incubated for 2 h at room 
temperature prior to recording. Standard ACSF was made from the same recipe as 
sucrose-based ACSF, only sucrose was replaced with NaCl (126.0 mM), the MgSO4 
concentration lowered to 1.0 mM, and the CaCl2 concentration raised to 2.5 mM. 
 
Recording fEPSPs in the DG 
Extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded by 
transferring 8 coronal brain slices containing dorsal hippocampus from either hemisphere 
into the integrated brain slice chambers (IBSCs, Slicemates) of the Scientifica 
Slicemaster (Scientifica, Ukfield, East Sussex, U.K.), a high throughput semiautomatic 
brain slice recording system, which conducts separate but simultaneous extracellular 
recordings (Stopps et al., 2004). All slices were perfused with regular ACSF (2 mL / min) 
at 30°C unless noted otherwise. Homemade twisted Nichrome-Formvar stimulating 
electrodes were placed in the middle-third of the molecular layer in the upper blade of the 
DG to stimulate the medial perforant path; recording electrodes were placed in the distal 
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third approximately 400 – 600 µm away from the stimulating electrode. Input/output 
(I/O) relationships were measured by incrementally stimulating for 100 µs in 0.5 V steps 
until a population spike was observed or 20 V maximum stimulus intensity was reached. 
Data were acquired using pClamp 10 interfaced to a Digidata 1550A data acquisition 
board (Molecular Devices, Sunnyvale, CA, U.S.A.) at a sampling rate of 10 kHz, low-
pass filtered at 1 kHz, and high-pass filtered at 3 Hz. The magnitude of the fEPSP was 
determined by measuring the peak amplitude in real-time. 
After obtaining fEPSPs and conducting I/O curves, baseline stimulation strength 
was set to 50% and slices received 1 stimulation pulse every 30 s. The effects of the 5-
HT6 receptor agonist WAY-208466 on basal excitatory synaptic transmission along the 
perforant path-DGC synapse were studied in an experimental paradigm that took place in 
3 20-min phases: Baseline, drug, and washout. During the baseline phase, we obtained 
stable fEPSPs with single stimulation pulses every 30 s for 20 min (fEPSP amplitudes 
that drifted > 20% from baseline stimulation strength were excluded). Next, slices were 
bath perfused with 100 nM, 300 nM or 1 µM of the 5-HT6 receptor agonist WAY-
208466, or ACSF (control slices) from a secondary reservoir for a 20 min drug phase, 
followed by a return to ACSF for a 20 min washout phase. Following the completion of 
experiments, the amplitudes of the fEPSPs were measured using pClamp software. fEPSP 
amplitudes were normalized by dividing their amplitude by the average amplitude of the 
last 4 fEPSPs obtained during the baseline phase and multiplied by 100. Normalized 
fEPSP amplitudes were then averaged for each concentration tested and expressed as an 




Voltage-Clamp Recordings of eIPSCs, sIPSCs, and mIPSCs 
To evaluate the effects of 5-HT6 receptor activity on inhibitory synaptic 
transmission onto DGCs, the whole cell patch clamp technique was used for voltage 
clamp recordings. An individual brain slice from dorsal hippocampus was transferred to a 
perfusion chamber (RC-27L, Warner Instruments, Hamden, CT, U.S.A.), held between 2 
nylon nets, and perfused with oxygenated ACSF (2 mL / min) at room temperature. 
During experiments testing the effects of the 5-HT6 receptor agonist WAY-208466, patch 
electrodes (2.5-3.5 MΩ) were filled with the following internal solution (in mM): K-
gluconate (140), HEPES (10.0), EGTA (1.0), CaCl2 (0.5), and glucose (10.0), with the 
osmolarity set between 290–295 mOsm and the pH adjusted to 7.28 with KOH. All cells 
recorded from in the presence of a K+-based internal were held at -70 mV. During 
experiments testing the effects of the 5-HT6 receptor antagonist SB-399885, we wanted 
to optimize the signal-to-noise ratio for detecting spontaneous and miniature inhibitory 
postsynaptic events. Therefore, patch electrodes (2.5-3.5 MΩ) were filled with Cesium-
based internal solution containing the following (in mM): Cs Methanesulfonate 
(CH3CsO3S, 140.0), HEPES (10.0), EGTA (1.0), CaCl2 (0.5), Glucose (10.0), ATP (2.0), 
GTP (0.5), and QX-314 (5.0)–300 mOsm, pH=7.30 (CsOH). Cells recorded from in the 
presence of a Cs-based internal were held at 0 mV. All recordings were performed using 
a Multiclamp 700 B amplifier and the pClamp 10 (Clampex) software package interfaced 
to a Digidata 1440 A digitizer (Molecular Devices); recordings were digitized at 10 kHz 
and filtered at 1 kHz.  
DGCs were “blindly” patched by forming tight seals (4-8 GΩ) with cells located 
in the granule cell layer of the DG with regular ACSF (2 mL / min) perfused at room 
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temperature. Once a granule cell was patched, all slices were then perfused with ACSF at 
30°C. The effects of 5-HT6 receptor agonist WAY-208466 and the 5-HT6 receptor 
antagonist SB-399885 on evoked, spontaneous, and miniature inhibitory postsynaptic 
currents (eIPSCs, sIPSCs, and mIPSCs) took place in 3 separate experiments. First, we 
tested the effects of WAY-208466 on eIPSCs only. During this experiment a concentric 
bipolar stimulating electrode (MCE-100, Rhodes medical instruments, Summerland, CA, 
USA) connected to a stimulator was placed in the hilus of the DG (see Figure 2.2 panel A 
for schematic), and a paired-pulse stimulus with a 50 ms interpulse interval was given 
once every 30 s. In the second experiment, the effects of SB-399885 were tested using a 
similar paradigm, except sIPSCs were recorded during the 30-s sweeps, and stimulation 
of the hilus was performed with a Nichrome-Formvar stimulating electrode hereinafter. 
To include an ACSF control, some slices were bath perfused with regular ACSF coming 
from a secondary reservoir normally holding drug for 20 min, followed by a 10 min 
recovery to reestablish the eIPSC baseline; then slices were bath perfused with SB-
399885. In the third experiment, we tested the effects of SB-399885 on mIPSCs with 
tetrodotoxin (TTX, 1 µM) present in the bath at all times to block sodium channel-
mediated action potentials. mIPSCs were recorded continuously in 30-s sweeps.  
All voltage-clamp experiments took place in 3 phases: Baseline, drug, and 
washout. Baseline phases were always 10 min in duration and drug phases always 20 
min. The duration of the washout phase varied depending on whether recordings were 
unintentionally cut short, but was always at least 10 min in duration. Access and 
membrane resistance, holding current, and temperature were monitored in 30-s intervals 
using pClamp 10. Recordings accompanied by changes in access resistance > 25% that 
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exceeded 30 MΩ were excluded. Any cell exceeding 40 MΩ throughout the recording, 
regardless of its percentage change, was excluded.  
 
Analysis of Voltage Clamp Data 
All data analysis was completed offline following completion of each experiment. 
The amplitudes of eIPSCs were measured using pClamp 10 and were defined as the peak 
current injection between the rising and falling phase for each response to the paired-
pulse stimulation (referred to as eIPSC 1 and 2). The average holding current 0.5 s prior 
the eIPSC was subtracted from this amplitude to give the true eIPSC amplitude. Paired-
pulse ratio (PPR) was quantified as a percentage by dividing the amplitude of eIPSC2 by 
the amplitude of eIPSC1, multiplied by 100, and expressed as an average over time. The 
decay kinetics of eIPSC1 were measured by averaging the last 4 traces in the baseline, 
drug, and washout phases and fitting a single exponential decay curve to the falling 
phase. 
The amplitude, interevent interval (IEI), length, and time constants for sIPSCs and 
mIPSCs were analyzed using Mini Analysis Program v6.0.1 (Synaptosoft, Fort Lee, NJ, 
U.S.A.). To limit inclusion of false positive events, the amplitude threshold for events 
was typically set to 10 pA (or a minimum of 2x the baseline noise) and event detection 
was confirmed visually. All amplitudes, IEIs, length, and time constants of sIPSCs and 
mIPSCs were measured and averaged over the first 20 s of each 30-s sweep. All eIPSC, 
sIPSC, mIPSC measurements (except PPRs) were normalized by dividing each 
measurement by the average of the last 4 events obtained during the baseline phase, 
multiplied by 100, and expressed as a percentage of the baseline average for each cell. 
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Following normalization, each parameter was then averaged for all cells recorded during 
that experiment, and expressed as a percentage ± SEM.  
 
Immunohistochemistry 
Sectioning, staining, and imaging of htr6-EGFP mice was conducted by Mr. 
Raunauk Basu (a graduate student in Dr. Megan Williams’ lab). All cell counting and 
quantification was conducted by the author of this manuscript. Three htr6-EGFP mice 
and one nontransgenic control mouse (2 females and 2 males) between 3- and 6-months 
of age were transcardially perfused with 4% paraformaldehyde (PFA) in phosphate 
buffered saline (PBS) and the brains were carefully removed and soaked overnight in 4% 
PFA. Subsequently the brain was cut along the midline; one half was sectioned coronally, 
and the other horizontally into 100 µm sections. Sections were then incubated in blocking 
buffer (PBS with 3% BSA and 0.3% tritonX-100) for 1 h at room temperature and 
transferred to a Fab blocking solution (PBS with 3%BSA, 0.3% TritonX-100, and 2% 
Goat F(ab) anti-mouse IgG). Next, the sections were transferred to primary antibody 
solution comprising 1:3000 dilution of goat anti-green fluorescent protein (GFP) (Abcam, 
Cambridge, MA, U.S.A.), 1:2000 dilution of rabbit anti-GABA (Sigma-Aldrich, St. 
Louis, MO, USA), and 1:500 dilution of mouse anti-GluA2 (Millipore, Billerica, MA, 
U.S.A.) diluted in antibody dilution solution (PBS with 3% BSA and 0.2% Triton X-100) 
and incubated overnight at 4°C. Following incubation the sections were subjected to 3 
washes in PBS (5 min per wash) followed by 1 h incubation (at room temperature) in 
secondary antibody mix comprising 1:1000 dilution of donkey anti-goat-Alexa488, 
donkey anti-rabbit-Cy5, and donkey anti-mouse-Cy3 (all from Jackson ImmunoResearch 
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Laboratories, West Grove, PA, U.S.A.) diluted in antibody dilution solution. The sections 
were washed 3 times with PBS and incubated in 1:10000 dilution of Hoechst for 5 min, 
placed on glass slides, and mounted for imaging in Fluoromount-G (Southern Biotech, 




Quantification of cells bodies immunoreactive (IR) for GFP, GABA, or GluA2 in 
the DG were manually counted and recorded using the cell counter macro in ImageJ 
software (National Institutes of Health, Bethesda, MD). A cell was counted as GFP-IR or 
GABA-IR if its cell body was surrounded and at least partially or completely IR, whereas 
a cell was considered GluA2-IR if its soma surrounding the nucleus was IR. A cell was 
counted as a mossy cell if it was GluA2-IR (Leranth et al., 1996; Fujise and Kosaka, 
1999), non-IR for GABA, had a neuronal somata that contained a visible nucleus 
(visualized with Hoescht staining) located within the hilus that was not in contact with 
the granule cell layer, and was outside the somal and dendritic regions of area CA3c. The 
DGC layer was defined as the upper and lower blade of densely packed neuronal somata 
between the hilus and the molecular layer, which was defined by a dense band of GFP 
staining immediately adjacent to the granule cell layer. All GFP-, GABA-, and GluA2-IR 
cells and their overlap were manually counted, quantified according to DG subregion, 
and averaged in 9 coronal sections from 3 htr6-EGFP mice and 6 horizontal sections from 
2 of these 3 htr6-EGFP mice (1 ventral block was lost during sectioning). GFP-IR cells 
were expressed either as an average percent of a particular cell type expressing GFP (i.e., 
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mossy cells, inhibitory interneurons, DGCs), or as a percentage of total GFP expression.  
All mean values are expressed ± SEM. 
In order to estimate the percent of granule cells that were GFP-IR, an area of the 
upper or lower blade of the granule cell layer was randomly selected and measured (µm2) 
in 3 separate areas at least 10 µm apart along the z-axis, and all visible nuclei between the 
molecular layer and hilus that were GluA2-IR were counted. The areas were then divided 
by the number of granule cells in that region to obtain an average area per granule cell 
(µm2), so that the total number of granule cells in 1 z-plane could be estimated based on 
the entire area of the granule cell layer. The total area of the granule cell layer was then 
measured at 3 points along the z-axis separated by at least 10 µm in the z-plane. Each 
measurement was then divided by the estimated area per granule cell to yield the 
estimated number of granule cells. The number of GFP-IR cells was then counted in each 
of these z-planes, and divided by the estimated number of granule cells to yield an 
estimated percent of GFP-IR granule cells per z-plane. Estimated percentages of GFP-IR 
DGCS were quantified in 12 coronal z plans from 5 slices and 12 horizontal z-planes 
from 4 slices, averaged, and expressed as the mean ± SEM. 
 
Chemicals and Drugs 
 Unless indicated otherwise, all chemicals and drugs were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Stock solutions of WAY-208466 (Tocris Bioscience, 
Minneapolis, MN, U.S.A.), TTX and SB-399855 (Tocris Bioscience, Minneapolis, MN, 
U.S.A.) were made in ddH2O at ≥ 1000 fold their final concentrations and stored at -
20°C. On the day of the experiments, individual aliquots were defrosted and dissolved in 
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ACSF to the concentration indicated in each figure.  
 
Statistics 
For statistical comparison of all electrophysiology data, the average raw values of 
the last 4 measurements (1.5 min) during the baseline were compared to the average of 
the last 4 raw values in the drug phase using a paired Student’s t test. Normalized fEPSP, 
eIPSC, or sIPSC amplitudes, as well as IEI were compared across drug or washout 
conditions to an ACSF control or other drug concentrations (when available) using an 
unpaired Student’s t test for voltage-clamp data or one-way (nonrepeated measures) 
ANOVA with Bonferroni’s multiple comparisons for fEPSP data. The slopes of linear 
regression fits were compared by F-test. All data sets were tested for normality using 
Kolmogorov-Smirnov test. When p < 0.05, or a data set had too few values to be tested 
for normality, Mann-Whitney U test or Wilcoxon signed-rank test was employed for 
unpaired or paired data, respectively. If unequal variances were detected, comparisons 
were made using Welch’s unequal variances t-test. All statistical analysis was preformed 
using GraphPad Prism V5.0c (GraphPad Software, San Diego, CA); p < 0.05 was 
considered significant. *, **, or *** indicate a p-value of < 0.05, < 0.01, and < 0.001, 
respectively, for comparisons conducted within a particular condition. †, ††, or ††† was 
used to indicate a p-value of < 0.05, < 0.01, and < 0.001, respectively, when comparisons 






The 5-HT6 Receptor Agonist WAY-208466 Attenuated fEPSP  
Amplitude at Perforant Path-DGC Synapses 
 First, we wanted to test whether activation of 5-HT6 receptors affected basal 
synaptic transmission in the DG. We generated fEPSPs at perforant path-DGC synapses 
in acute hippocampal brain slices prepared from rats and bath perfused control ACSF, or 
ACSF containing 100 nM, 300 nM, or 1 µM WAY-208466 (Figure 2.2). Although the 
average of the last 4 raw fEPSP amplitudes during the drug phase (38.5−40 min) were 
not significantly attenuated compared to baseline for any concentration tested, raw fEPSP 
amplitudes were significantly attenuated during the washout phase for 1 µM WAY-
208466 (see Figure 2.2D for normalized data; raw values, 1 µM: baseline: -0.89 ± 0.06 
mV; washout: -0.81 ± 0.06 mV, p < 0.05, paired Student’s t test; 300 µM: baseline: -0.82 
± 0.11 mV; washout: -0.76 ± 0.11 mV, p < 0.05; paired Student’s t test). There were also 
no significant differences in the averaged normalized fEPSP amplitudes across conditions 
during the last 2 min of the drug phase (p > 0.05, one-way ANOVA). However, there was 
a significant difference during the washout (F(3, 39) = 5.50, p < 0.01, one-way ANOVA). 
Bonferroni’s multiple comparisons revealed that 1 µM WAY-208466 significantly 
attenuated the normalized fEPSP amplitude during the washout phase compared to ACSF 
(Figure 2.2E, ACSF: 99.7% ± 1.1; 1 µM: 90.0 ± 2.6, p < 0.01). A continued effect of 5-
HT6 receptor activity on synaptic transmission during the washout phase has been 
reported in other studies testing the physiological effects of 5-HT6 receptors in vitro 
(West et al., 2009) and is consistent with expectations when pharmacologically 
manipulating a GPCR. These results suggest that 5-HT6 receptor activation attenuated 
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basal excitatory synaptic transmission at perforant path-DGC synapses and has lasting 
effects on synaptic transmission beyond the “washout” phase.  
 
The 5-HT6 Receptor Agonist WAY-208466 Increased  
the Amplitude of eIPSCs onto DGCs 
Next we tested whether activation of 5-HT6 receptors affects inhibitory synaptic 
transmission onto DGCs. We used voltage-clamp electrophysiology in acute hippocampal 
brain slices prepared from rats to record eIPSCs in DGCs by applying a paired-pulse 
stimulus once every 30 s to the hilus of the DG (see Figure 2.3A for experimental 
schematic). Bath perfusion of 1 µM WAY-208466 significantly increased the amplitudes 
of eIPSCs in the drug phase compared to baseline (Figure 2.3B-D, Baseline: 91.4 pA ± 
30.3 pA; Drug: 122.7 ± 41.7 pA, n = 7, p < 0.05, Wilcoxon signed-rank test). We did not 
observe a change in the paired-pulse ratio (PPR) (Figure 2.3E, p > 0.05, Wilcoxon 
signed-rank test). Together, these results suggest that activation of 5-HT6 receptors 
increased evoked inhibitory synaptic transmission onto DGCs without affecting 
presynaptic vesicular neurotransmitter release probability. 
In a separate set of experiments performed 7 months after testing the effects of 
WAY-208466 on eIPSCs, 1 µM WAY-208466 no longer increased the amplitudes of 
eIPSCs onto DGCs (Figure 2.4, n = 5, p > 0.05, Wilcoxon signed-rank test). The 
irreproducibility of the effects of WAY-208466 on eIPSCs during this particular 
experiment could have been due to a number of experimental and / or biological 
phenomenon that are addressed in the discussion section. Importantly, the effects of 
WAY on eIPSC amplitude were reproduced at a later date in mouse. Nevertheless, it was 
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subsequently reasoned that if activation of the 5-HT6 receptor no longer increased the 
amplitude of eIPSCs, perhaps blockade of the 5-HT6 receptor with an antagonist would 
attenuate the amplitude of eIPSCs. 
 
The 5-HT6 Receptor Antagonist SB-399885 Attenuated  
the Amplitude of eIPSCs onto DGCs  
Next, we tested the effects of the 5-HT6 receptor antagonist SB-399885 on 
eIPSCs onto DGCs (Figure 2.5). Bath perfusing ACSF from a drug reservoir produced no 
significant effects on the amplitude of eIPSCs (Figure 2.5C, n = 10, p > 0.05, paired-
students t-test). However, raw eIPSC amplitude was significantly attenuated in slices 
when SB-399885 was bath perfused (Figure 2.5C, D, eIPSC amplitude, Baseline: 391.7 ± 
82.2 pA; Drug: 297.2 ± 71.7 pA, n = 13, p < 0.01, Wilcoxon signed-rank test). 
Additionally, SB-399885 significantly attenuated the normalized eIPSC amplitude during 
the drug phase compared to ACSF-treated slices (Figure 2.5C, ACSF: 112.8% ± 8.4; SB-
399885: 73.1% ± 4.7, p < 0.001, unpaired Student’s t test). We also measured eIPSC 
decay kinetics and observed no significant change in response in SB-399885 (Figure 
2.5E, tau, Baseline: 30.6 ± 3.6 ms; Drug: 31.3 ± 3.9 ms, p > 0.05, n = 12 (unable to obtain 
an accurate measurement of decay kinetics for 1 cell), paired Student’s t test). Similarly 
to WAY-208466, SB-399885 produced no significant change in the PPR (Figure 2.5F, p 
> 0.05, paired Student’s t test). These results suggest that SB-399885 did not affect the 
open-time kinetics of GABA receptors on DGCs or the probability of presynaptic vesicle 
release at inhibitory synapses.  
SB-399885 also did not significantly alter membrane resistances (data not shown, 
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n = 13, Baseline: 421.5 ± 110.6 MΩ; Drug: 554.8 ± 194.1 MΩ, p > 0.05, paired Student’s 
t test), and the normalized membrane resistance values from SB-399885-treated slices did 
not significantly differ from ACSF during the drug phase (data not shown, ACSF:  
114.1% ± 4.6; SB:  108.7% ± 11.8, p > 0.05, unpaired Student’s t test). Access resistance 
did significantly increase during the drug phase in SB-399885 treated slices (Baseline: 
18.79 ± 2.2 MΩ; Drug: 22.8 ± 2.7 MΩ, p > 0.05, paired Student’s t test). However, the 
normalized values did not significantly differ from the ACSF control (ACSF: 111.5% ± 
7.4; SB: 124.7% ± 11.4, unpaired Student’s t test). Importantly, the increase in access 
resistance was not associated with an increase eIPSC decay kinetics (tau), which suggests 
changes in access resistance did not play a role in the attenuation in eIPSC amplitude 
observed in this study. 
In summary, 5-HT6 receptor blockade significantly attenuated evoked inhibitory 
synaptic transmission onto DGCs, which is the opposite effect of 5-HT6 receptor 
activation illustrated in Figure 2.3. Moreover, we observed no significant changes in the 
PPR, tau decay kinetics of eIPSCs, or membrane resistance as a result of SB-399885. 
Thus, despite the irreproducibility of WAY-208466, results obtained insofar support the 
hypothesis that 5-HT6 receptors bidirectionally control evoked inhibitory synaptic 
transmission onto DGCs in a manner consistent with 5-HT6 receptor antagonist-mediated 
disinhibition via their presynaptic effects on interneuron excitability, as opposed to a 






SB-399885 Produced a Delayed and Transient Increase 
in the IEI of sIPSCs 
 During experiments testing the effects of the SB-399885 on eIPSCs, we also 
recorded sIPSCs. Following experimentation, their average amplitude and IEI (the 
inverse of frequency) in ACSF- and SB-399885-treated slices were quantified (Figure 
2.6, n = 10 and 13, respectively). We observed no differences in the amplitudes or IEIs of 
sIPSC when comparing the normalized values of drug and ACSF-treated slices across the 
drug phase (Figure 2.6B, C, p > 0.05, unpaired Student’s t test), and no differences in the 
raw values between the baseline and drug phases for ACSF- or SB-399885-treated slices 
(Figure 2.6D, E, p > 0.05, paired Student’s t test for amplitude, p > 0.05, Wilcoxon 
signed-rank test for IEI). However, we did observe a late effect in IEI, as the normalized 
mean sIPSC IEI was increased compared to ACSF-treated slices during the washout 
phase (Figure 2.6C, ACSF: 103.4% ± 5.2; SB-399885: 141.8% ± 11.7, p < 0.05, Welch’s 
unequal variances t test) and the raw sIPSCs IEI during the washout phase were 
significantly increased compared to baseline in SB-399885-treated slices (Figure 2.6E, 
Baseline: 1,274.0 ± 455.0 ms; Washout: 1,725.0 ± 514.3 ms, n = 13, p < 0.01, Wilcoxon 
signed-rank test). Thus, the number and amplitude of sIPSCs onto DGCs was unaffected 
by the 5-HT6 receptor antagonist until the washout phase, during which we observed a 
decrease in the average number of spontaneous inhibitory postsynaptic events in DGCs. 
Although the reason why this late effect occurs with a large delay is not presently known, 
the increase in the IEI (i.e., a decrease in the frequency) of sIPSCs is consistent with the 




Does SB-399885 Affect the Amplitudes of mIPSCs onto DGCs?  
 To determine whether 5-HT6 receptor blockade affects presynaptic inhibitory 
neurotransmitter vesicle release onto DGCs and has postsynaptic effects in DGCs, we 
tested the effects of the 5-HT6 receptor antagonist SB-399885 on mIPSCs in the presence 
of 1 µM TTX (Figure 2.7). SB-399885 significantly attenuated the average amplitude of 
mIPSCs (Figure 2.7D, Baseline: 19.8 ± 0.8 pA; Drug 17.2 ± 0.6 pA, n = 13, p < 0.01, 
paired Student’s t test), but had no significant affect on mIPSC IEI (Figure 2.7E, n = 13, 
p > 0.05; paired Student’s t test), suggesting that 5-HT6 receptors had postsynaptic effects 
on DGCs. However, linear regressions fit to the baseline, drug, and washout phases of the 
normalized mIPSC amplitudes (0−10, 10−30, 30−40 min, respectively) revealed that the 
slope of all 3 lines are significantly different from 0 (Figure 2.7B, Slope, Baseline: -0.22 
± 0.10, p < 0.05; Drug: -0.15 ± 0.03 p < 0.0001; Washout: -0.10 ± 0.01, p < 0.0001, 
linear regression) and are not significantly different from each other (p > 0.05). For 
comparison, linear regressions fit to an identical time course of eIPSC amplitudes in SB-
399885 treated slices (Figure 2.5B) revealed that the slope in the baseline and washout 
phases do not significantly differ from 0, whereas the slope for the drug phase 
significantly differs from 0 (Slope, Baseline: -0.35 ± 0.33, p > 0.05; Drug: -1.52 ± 0.12, p 
< 0.0001; Washout: -0.40 ± 0.39, p > 0.05, linear regression). Moreover, these slopes are 
significantly different from each other (p < 0.001). Thus, linear regression analysis 
suggests that mIPSC amplitudes were decreasing during the baseline phase, and the rate 
of change was not significantly altered by bath application of SB-399885, whereas eIPSC 
amplitudes were flat until SB-399885 produced a significant decrease in eIPSC 
amplitude. Together, these results suggest that SB-399885 did not attenuate the 
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amplitudes of mIPSCs via postsynaptic effects in DGCs and did not affect the probability 
of presynaptic vesicle release in inhibitory presynaptic termini synapsing onto DGCs. 
 
GFP Immunoreactivity in htr6-EGFP Mice Is Primarily  
Found in Excitatory Neurons 
 During this time, the aforementioned results were used as preliminary data to 
obtain seed funding generously granted to Dr. Peter J. West from the Center on Aging at 
the University of Utah. These funds were used to purchase BAC transgenic mice 
expressing an EGFP reporter under the 5-HT6 receptor promoter (Gong et al., 2003; 
GENSAT, 2016). Immunofluorescence staining was used to quantify GFP-
immunoreactive (IR) cell types based on colocalization with γ-aminobutyric acid 
(GABA), a marker for inhibitory interneurons, GluA2, a marker that is specific to mossy 
cells in the hilus of the DG (Leranth et al., 1996; Fujise and Kosaka, 1999), and their 
neuroanatomical localization within DG subregion: the DGC layer, the molecular layer, 
or the hilus. Representative images of staining in horizontal and coronal sections can be 
found in Figures 2.8 and 2.9, respectively. A summary of the quantification can be found 
in Table 2.1. 
Immunofluorescence experiments in tissue from htr6-EGFP mice revealed an 
interesting and unexpected staining pattern in the DG. 81.1% ± 4.1 of mossy cells in 
horizontal slices (containing primarily ventral hippocampus) were GFP-IR, whereas 
66.2% ± 4.4 of mossy cells in coronal slices (containing primarily dorsal hippocampus) 
were GFP-IR. Surprisingly, only 0.3% ± 0.1 of GABA-IR cells in horizontal slices and 
1.3% ± 0.4 of GABA-IR cells in coronal slices were also GFP-IR. This small population 
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of cells that were colabeled with GFP and GABA were always located in the hilus. 
Additionally, based on estimates of the total number of DGCs per slice, 1.2% ± 0.3 of 
DGCs in horizontal slices and 1.1% ± 0.1 of DGCs in coronal slices were GFP-IR. In 
summary, the majority of mossy cells were GFP-IR, and approximately 1% of DGCs and 
inhibitory interneurons were GFP-IR.  
As a percentage of total GFP-IR cells observed in the entire DG, GFP-IR mossy 
cells accounted for 65.6% ± 11.6 in horizontal slices but only 26.2% ± 2.9 in coronal 
slices. GFP-IR DGCs accounted for 29.2% ± 10.0 of total GFP expression in the DG in 
horizontal slices and 40.0% ± 3.4 in coronal slices, whereas cells colabeled with GFP and 
GABA accounted for 0.3% ± 0.2 of total GFP expression in horizontal slices, and 0.7 ± 
0.3% in coronal slices. Additionally, 3.0% ± 1.6 of GFP-IR cells in horizontal slices were 
located just outside the granule cell region in the molecular layer, whereas 15.1% ± 2.9 of 
EGFP-IR cells in coronal slices were located in the molecular layer. This population of 
GFP-IR cells found in the molecular layer never colocalized with GABA, and always 
colocalized with GluA2, which suggests they are excitatory neurons. Lastly, 1.9% ± 1.2 
of GFP-IR cells in horizontal slices did not colocalize with GluA2 or GABA, but had 
visible nuclei revealed via Hoescht staining. Interestingly, this population of cells 
accounted for 18.0% ± 2.3 of EGFP-IR cells in coronal slices. Although additional 
experiments are needed to identify this population of cells, we suspect that these GFP-IR 
cells lacking GABA or GluA2 labeling may be astrocytes, a finding that would parallel 
other reports of 5-HT6 receptors on astrocytes (Marazziti et al., 2013). Importantly, we 
also stained horizontal and coronal sections prepared from nontransgenic littermates of 
htr6-EGFP mice that do not express EGFP; we did not observed any GFP-IR cells in 
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these sections. See Figures 2.8A and 2.9A for representative images.   
In summary, the majority of mossy cells in both coronal and horizontal cut 
sections were GFP-IR, whereas very little GFP-immunoreactivity (~1%) was observed in 
DGCs and GABA-IR cells. The majority of total GFP-immunoreactivity in the DG of 
horizontally cut slices was found in mossy cells, followed by DGCs, molecular layer 
cells, an unknown cell type that possibly represent glia, and lastly, GABA-IR cells, 
whereas the majority of total GFP-immunoreactivity in the DG of coronally cut slices 
was observed in DGCs (but only accounted for ~1% of the total population of DGCs), 
followed by mossy cells, an unknown cell type in the hilus that may be astrocytes, 
molecular layer cells, and lastly, GABA-IR cells. See Table 2.1 for a summary of these 
quantifications.  
 
Preliminary Data: 5-HT6 Receptor Ligands Have Similar Effects  
on Inhibitory Synaptic Transmission in Mice and Rats 
Lastly, we also tested the effects of a 5-HT6 receptor antagonist and agonist on 
eIPSCs onto DGCs in hippocampal brain slices prepared from mice (Figure 2.10, n = 1). 
Although this experiment was conducted only once and needs to be repeated, we found 
that bath application of 1 µM SB-399885, followed by a washout phase and bath 
application of 1 µM WAY-208466 resulted in an attenuation of eIPSC amplitude, 
followed by an increase in eIPSC amplitude. This finding is important because the effects 
on eIPSC amplitude closely parallel the effects of 5-HT6 receptor ligands in hippocampal 




 This study investigated 5-HT6 receptor localization and physiology in the DG 
using in vitro electrophysiology and IHC. Extracellular recordings of basal excitatory 
synaptic transmission revealed that the 5-HT6 receptor agonist WAY-208466 dampened 
fEPSP amplitude at perforant path-DGC synapses. During voltage-clamp recordings from 
DGCs, WAY-208466 also increased the amplitudes of electrically evoked IPSCs onto 
DGCs, an effect that, for reasons unknown, was irreproducible 7 months later. However, 
the next experiment showed the 5-HT6 receptor antagonist SB-399885 produced the 
opposite effect by attenuating the amplitude of eIPSCs, without affecting their decay 
kinetics, and also produced a late decrease in the number of sIPSCs onto DGCs without 
affecting their amplitudes. SB-399885 may have attenuated the amplitude of mIPSCs, 
however, linear regression analysis suggests this effect may have due to nonspecific 
rundown in the amplitudes of the mIPSCs (drift). Thus, 5-HT6 receptor activity 
bidirectionally affected eIPSCs onto DGCs in a manner consistent with 5-HT6 receptor 
antagonist-mediated disinhibition. Interestingly, quantitative immunohistochemical 
analysis in the DG of htr6-EGFP mice revealed that the majority of mossy cells, an 
excitatory interneuron type in the hilus, were immunoreactive for GFP, whereas only 
~1% of DGCs and inhibitory interneurons were immunoreactive for GFP. The most 
parsimonious explanation of results obtained from electrophysiology and IHC 
experiments suggest that 5-HT6 receptors bidirectionally and indirectly modulate 
inhibitory synaptic transmission onto DGCs via their direct effects on mossy cells (see 
Figure 2.11). 
The novel hypothesis that 5-HT6 receptor ligands bidirectionally control 
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inhibitory synaptic transmission onto DGCs via their direct effects on mossy cells comes 
primarily from results obtained in htr6-EGFP mice showing the majority of mossy cells 
were GFP-IR, the lack of effect of SB-399885 on sIPSC amplitudes despite a concurrent 
decrease in eIPSC amplitude, and lastly, their lack of effect on eIPSC decay kinetics. 
This idea is also supported by other studies reporting that mossy cells are excitatory 
neurons that drive inhibition onto DGCs. For example, using dual whole-cell patch clamp 
technique, Scharfman (1998) showed that action potentials produced in mossy cells 
produced a monosynaptic depolarizing event in DGCs when inhibition was 
pharmacologically blocked, but faithfully caused a di-synaptic inhibitory postsynaptic 
potential (IPSP) in DGCs with inhibition intact (Scharfman, 1995). Moreover, Jinde et al. 
(2012) showed that near-perfect selective ablation of mossy cells attenuated the 
frequency of both sIPSCs and sEPSCs in DGCs, but rendered DGCs hyperexcitable, as 
evidence by increased synaptic responsiveness, and reduced threshold to population 
spike. Together, these studies suggest that mossy cells innervate both DGCs and 
inhibitory interneurons, but the net effect of their activity drives inhibition onto DGCs. 
Although very little is known about how 5-HT6 receptors regulate neuronal excitability, 
additional support for the idea that 5-HT6 receptors could indirectly affect inhibitory 
synaptic transmission via their direct effects on mossy cells comes from a study by Bonsi 
et al. (2007) showing that blockade of 5-HT6 receptors hyperpolarized cells expressing 5-
HT6 receptor mRNA in the striatum via K+-dependent effects, (Bonsi et al., 2007), which 
suggests that 5-HT6 receptors could regulate mossy cell excitability via their effects on 
leak potassium channels (Millan et al., 2008). Taken together, the results obtained in the 
present study, as well as those reported by others, suggests that pharmacological 
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activation of 5-HT6 receptors with WAY-208466 directly increased the excitability of 
mossy cells and their excitatory drive onto inhibitory interneurons, and thereby increased 
the excitability of inhibitory interneurons that synapse onto DGCs, such that electrically 
evoked stimulation of the hilus recruited a greater number of inhibitory interneurons in 
the presence of WAY-208466 and thereby produced an eIPSC greater in magnitude. 
Likewise, the data presented here suggest that the 5-HT6 receptor antagonist attenuated 
inhibitory synaptic transmission by directly reducing the excitability of mossy cells and 
thereby attenuating inhibition onto DGCs (see Figure 2.11 for a schematic).  
Although this hypothesis is consistent with the majority of our findings and the 
aforementioned studies published by others, not all of our findings fit with this hypothesis 
and need to be addressed. First, if SB-399885 did decrease the amplitudes of eIPSCs by 
indirectly (or even directly) altering the excitability of inhibitory interneurons synapsing 
onto DGCs, we would expect the frequency of sIPSCs to change in a manner that is 
temporally and directionally coincident with changes in eIPSC amplitudes. We did 
observe a delayed decrease in the average number of sIPSCs during the washout phase 
(Figure 2.6), but the effect on sIPSCs did not occur simultaneously with the decrease in 
the amplitudes of eIPSCs. Moreover, the increase in the IEI of sIPSCs during the washout 
phase was not observed in all recordings. This may suggest that the decrease in eIPSC 
amplitudes were mediated by mechanisms other than a change to the excitability of 
inhibitory interneurons, such as a postsynaptic effect on DGCs. However, additional 
analysis revealed that the majority of our recorded events are not likely action potential-
driven events and are comprised mostly of mIPSCs (analysis not shown). Thus, subtle 
changes in action potential-driven sIPSC frequency may have been indistinguishable in 
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the presence of events that were mostly comprised of mIPSCs. Moreover, a neuron’s 
intrinsic excitability is not linearly related to the number of spontaneous action potentials 
it fires (Jiang et al., 2015). Thus, it is more likely that the amplitudes of eIPSCs decreased 
in the presence of SB-399885 as a result of a decrease in the excitability of inhibitory 
interneurons without immediately affecting the number of sIPSCs onto DGCs. 
Another result that conflicts with the hypothesis that 5-HT6 receptors orchestrated 
changes to inhibition onto DGCs via mossy cells is that 5-HT6 receptor blockade 
attenuated the amplitudes of mIPSCs in a manner temporally coincident with the decrease 
in eIPSC amplitude (Figures 2.5 and 2.7). The canonical interpretation of this result 
suggests that 5-HT6 receptors dampened mIPSC amplitudes by reducing the number 
and/or conductance of GABAA receptors (GABAARs) directly in DGCs expressing 5-
HT6 receptors. Since DGCs were blind-patched (and thus, randomly selected) in 
hippocampal brain slices prepared from naïve rats, it is unlikely we faithfully recorded 
from the ~1% of DGCs that, according to our IHC data, express 5-HT6 receptors. Thus, 
the most parsimonious explanation for the attenuation in mIPSC amplitudes is that 5-HT6 
receptors are expressed in the majority of DGCs. This result could explain some of the 
electrophysiology results obtained in the present study, including the effects of 5-HT6 
receptor ligands on eIPSCs and fEPSPs. 5-HT6 receptor expression in DGCs would also 
fit with the results of Helboe et al. (2015) who reported 5-HT6 receptor mRNA in >70% 
of DGCs in rats, as well as findings recently reported in an online public resource 
published by Janelia Research Campus (Cembrowski et al., 2016), where whole genome 
characterization of mRNA expression in mice shows minimal expression of 5-HT6 
receptor mRNA in mossy cells and high levels of expression in DGCs. One explanation 
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for these results is that mossy cells may transcribe minute amounts of 5-HT6 mRNA into 
protein, whereas DGCs may not transcribe the high amounts of 5-HT6 receptor mRNA 
into protein. If the majority of DGCs do express 5-HT6 receptors, either endogenous 5-
HT6 receptor expression in rat differs from mouse (although preliminary data in Figure 
2.10 suggests 5-HT6 receptor ligands affect inhibitory synaptic transmission similarly in 
mouse and rat), or GFP immunoreactivity in BAC transgenic mice does not accurately 
reflect endogenous 5-HT6 receptor expression in either species. However, linear 
regression analysis suggests that the amplitudes of mIPSCs were already decreasing 
during the baseline phase and SB-399885 did not influence the continued rate of 
decrease. Thus, mIPSC amplitudes may have been unaffected by SB-399885. 
Considering the entirety of the data that is inconsistent with a direct effect of 5-HT6 
ligands on DGCs, as well as the poor baseline control and likely downward drift observed 
in this particular data set, we conclude that the decreased mIPSC amplitudes observed 
here are based on unreliable data. Accordingly, we have excluded these data from our 
overall conclusions regarding our model of where 5-HT6 receptors are expressed and 
their physiological roles on modulating inhibitory synaptic transmission in the DG. 
Another result that can be explained by 5-HT6 receptor expression in mossy cells 
or DGCs is that bath application of the 5-HT6 receptor agonist WAY-208466 attenuated 
the amplitude of fEPSPs in hippocampal brain slices. Although this result is consistent 
with a postsynaptic effect of 5-HT6 receptor on DGCs, the mechanics of this phenomena 
are complex and warrant further discussion. The fEPSP is primarily an excitatory 
postsynaptic response that is proportional to the magnitude of positive ions (i.e., Na+) 
entering DGCs via glutamate receptors following perforant-path stimulation. Thus, the 
  
69 
canonical interpretation of this result is that the attenuation of fEPSP amplitude is due to 
a reduction in the conductance and / or number of glutamate receptors inserted in the 
postsynaptic membrane, suggesting that 5-HT6 receptors located on DGCs mediated the 
WAY-208466-induced attenuation of fEPSP amplitude. However, another phenomenon 
known as shunting inhibition may have contributed to the attenuation of fEPSP 
amplitude. Shunting inhibition can be defined as the opening of extrasynaptic GABA 
receptors that produces a reduction in the local membrane resistance, and thus attenuated 
the amplitude of incoming excitatory postsynaptic potentials (Hao et al., 2009; Paulus 
and Rothwell, 2016). Support for the idea that shunting inhibition could have attenuated 
fEPSP amplitudes is derived from another study reporting that systemic administration of 
WAY-208466 increased the extracellular concentration of GABA in the hippocampus 
(Schechter et al., 2008). Although we did not observe a significant change in membrane 
resistance during patch clamp experiments, we did observe a nonsignificant increase in 
the membrane resistance of DGCs during experiments with SB-399885, an effect that 
would be expected if extracellular concentrations of GABA decreased.   
Together, these results suggest that 5-HT6 receptors bidirectionally modulate 
inhibitory synaptic transmission onto DGCs via their direct effects on mossy cells.  It is, 
however, still possible that our results are explained by 5-HT6 receptor expression on 
DGCs that alter GABA receptor responses. Moreover, these competing hypotheses need 
not be mutually exclusive; both presynaptic and postsynaptic mechanisms may have 
contributed to changes in inhibitory synaptic transmission. Additional experiments are 
needed to test their individual and perhaps combined contributions to 5-HT6 receptor-
mediated changes to inhibition in DGCs. 
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In order to begin testing whether mossy cells are physiologically responsive to 
changes in 5-HT6 receptor activity, we attempted to record from GFP+ neurons in brain 
slices prepared from htr6-EGFP mice and naïve mice. Despite clear identification of 
GFP-IR cells in fixed tissue using IHC, we observed minimal and weak fluorescence in 
acute brain slices prepared from htr6-EGFP that prevented recording from labeled 
neurons. Weak fluorescence could have been due to photobleaching during the slicing 
and incubation process, as slices were made and incubated in normal lighting. Future 
attempts to patch clamp GFP+ neurons in acute brain slices prepared from htr6-EGFP 
mice should take greater precaution to protect the slices from photobleaching.  
We also attempted to directly patch clamp mossy cells in brain slices prepared 
from naïve mice. Our efforts to patch mossy cells in our pilot study were hampered by 
the fragility of mossy cells and our inability to form a tight seal on them; unfortunately, 
we were unable to obtain any successful patch clamp recordings from mossy cells. Future 
experiments could improve our chances of recording from mossy cells by altering our 
brain slice preparation protocol to improve slice health (see 
www.brainslicemethods.com). Additionally, we could also use the “cleaning” technique, 
which employs suction via a glass capillary to remove dead tissue and debris on top of 
the brain slice that prevents visualizing cells buried deep in the slice. This could allow us 
to visually-patch mossy cells that are deep in the tissue and presumably in better health 
than those near the surface. Lastly, we could contact another lab (i.e., Dr. Helen 
Sharfman at New York University) that routinely record from mossy cells to obtain 
advice. Once we are able to record from mossy cells, a variety of current clamp protocols 
could be used to determine how 5-HT6 receptor ligands affect mossy cell excitability.  
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One experiment that could begin to test our hypothesis that 5-HT6 receptors 
modulate inhibitory synaptic transmission onto DGCs would be to retest the effects of a 
5-HT6 receptor agonist or antagonist on eIPSC amplitude in the presence of drugs that 
block excitatory synaptic transmission (i.e., CNQX and APV). If mossy cells directly 
mediate the effects of 5-HT6 receptor ligands on inhibitory synaptic transmission, we 
would expect to see no change in eIPSC amplitude with excitatory synaptic transmission 
pharmacologically blocked. Conversely, a change in the amplitude of eIPSCs onto DGCs 
would rule out the role of mossy cells and suggest that 5-HT6 receptor activity affects 
inhibitory synaptic transmission onto DGCs via their direct effects on DGCs and/or 
inhibitory interneurons expressing 5-HT6 receptors.  
Although the aforementioned experiments would begin to test our hypothesis, 
several other mechanisms could have mediated the observed effects of 5-HT6 receptor 
ligands on inhibitory synaptic transmission onto DGCs. For instance, in addition to 
mossy fiber projections onto CA3 pyramidal neurons, DGCs make axon collaterals that 
innervate hilar inhibitory interneurons and mossy cells. Although ~1% of DGCs were 
GFP-IR (according to our IHC data), GFP-IR DGCs made up the largest percentage of 
total GFP staining in the DG in coronally cut sections (Table 2.1), and all 
electrophysiology experiments in this study were conducted in coronally cut sections. 
Therefore, it is possible that 5-HT6 receptor ligands altered the intrinsic excitability of a 
subpopulation of DGCs, altering their excitatory drive onto inhibitory interneurons or 
mossy cells that innervate inhibitory interneurons and thereby affecting the amplitude of 
eIPSCs. In retrospect, we could have tested this hypothesis by conducting current clamp 
experiments in the DGCs we recorded from during these experiments. However, in most 
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of these experiments our internal solution (CsMeSO4), which fills the neuron during 
whole-cell recording, was optimized for recording spontaneous events in a manner that 
blocks potassium channels and thus prevented the study of neuronal excitability. We did 
not, however, observe any significant changes in membrane resistance associated with 
bath application of SB-399885 during these experiments, which suggests 5-HT6 receptor 
ligands did not affect the intrinsic excitability of DGCs via leak potassium channels. 
However, additional experiments are needed to comprehensively test whether 5-HT6 
receptors affect DGC intrinsic excitability.  
Another possibility is that CA3 pyramidal neurons, the majority of which were 
found to be GFP-IR (data not shown), played a role in affecting inhibitory synaptic 
transmission onto DGCs. CA3c pyramidal neurons back-project to the DG and primarily 
make synapses onto hilar inhibitory interneurons and mossy cells (Scharfman, 2007).  
Thus, CA3 pyramidal neurons may have had altered excitatory drive onto these hilar 
neurons in the presence of 5-HT6 receptor ligands and therefore contributed to the results 
observed in this study. Additionally, we also observed a population of GFP-IR cells that 
were almost exclusively found in the hilus of coronally cut sections and did not overlap 
with GluA2 or GABA-IR, but did have a nucleus. Although additional experiments are 
needed to further explore their identity, this population of GFP-IR cells may have been 
astrocytes. In support of this idea, Marazitti et al. (2013) showed a representative 
example of 5-HT6 receptor antibody staining that overlapped with glial fibrillary acidic 
protein (GFAP), a marker for astrocytes, in human hippocampal tissue. Furthermore, 
astrocytes have been shown to release GABA and play a role in modulating inhibitory 
synaptic transmission (Kozlov et al., 2006; Wu et al., 2014), and therefore may have 
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played a role in 5-HT6 receptor-mediated changes in inhibitory synaptic transmission. 
Thus, future experiments should confirm whether 5-HT6 receptors are expressed on 
astrocytes and test their potential role in mediating inhibitory synaptic transmission in the 
DG.  
In summary, the effects of 5-HT6 receptor ligands on inhibitory synaptic 
transmission could have been mediated by a variety of cell types found to express GFP 
including mossy cells, DGCs, CA3 pyramidal neurons, and/or astrocytes. However, our 
results showing that 5-HT6 receptor ligands bidirectionally control the amplitudes of 
evoked inhibitory synaptic transmission onto DGCs without affecting their decay kinetics 
or attenuating the amplitudes of sIPSCs, along with staining in tissue from htr6-EGFP 
mice illustrating that the majority of mossy cells were GFP-IR, suggest that 5-HT6 
receptors affect inhibitory synaptic transmission onto DGCs via mossy cells. Support for 
this hypothesis also comes from studies showing that mossy cells drive inhibitory 
synaptic transmission onto DGCs (Scharfman et al., 2003; Jinde et al., 2012), and that 5-
HT6 receptor activity can affect the resting membrane potential in neurons expressing 5-
HT6 receptor mRNA (Bonsi et al., 2007). Thus, we hypothesize that 5-HT6 receptor 
activity regulates inhibitory synaptic transmission onto DGCs via their direct effects on 
mossy cells.  
Although our results adequately support this hypothesis, there are a number of 
methodological limitations in the present study that need to be addressed. The first stems 
from the use of htr6-EGFP mice. Although BAC transgenic mice are a powerful tool for 
dissecting cell-type specific expression patterns, and gross anatomical staining of GFP 
expression in htr6-EGFP mice on the providers website (GENSAT, 2016) matches 
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regional expression patterns in mice shown by others using radioligand binding assays 
and in-situ hybridization (Hirst et al., 2003), validation that GFP expression in htr6-EGFP 
mice mirrors endogenous cell-type specific 5-HT6 receptor expression is lacking, in part, 
due to a dearth of well characterized commercially available 5-HT6 receptor antibodies. 
Thus, researchers need to exhibit caution when interpreting cell-type specific staining 
patterns in htr6-EGFP BAC transgenic mice.   
Another limitation in the present study is that almost all electrophysiology 
recordings performed were conducted in hippocampal brain slices prepared from rats 
(except for Figure 2.10), whereas the IHC experiments were performed in transgenic 
mice, thus creating some concern regarding species differences. We conducted the 
electrophysiology portion of this research in brain slices prepared from rats because most 
behavioral studies testing the effects of 5-HT6 receptor ligands on learning and memory 
have been conducted in rat (Fone, 2008). Additionally, other studies have reported 
species differences in 5-HT6 receptor homology that reduce the affinity of 5-HT6 receptor 
ligands in mice, and caution against conducting 5-HT6 receptor studies in mice (Hirst et 
al., 2003; Setola and Roth, 2003). Although additional experiments are needed before 
definitive conclusions can be drawn, our data in Figure 2.10 (n = 1) suggests that 5-HT6 
receptors in mice are responsive to 5-HT6 ligands and affect inhibitory synaptic 
transmission similarly in mouse and rat (data in Chapter 3 of this dissertation also suggest 
that 5-HT6 receptor ligands affect behavior in mice as well). However, we must exhibit 
caution when drawing conclusions between data obtained in mouse and rats.  
Another point worthy of discussion is the irreproducibility we observed when re-
testing the effects of the 5-HT6 receptor agonist WAY-208466 on eIPSCs. Bath 
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application of 1µM WAY-208466 consistently increased the amplitude of eIPSCs onto 
DGCs in 2013, but no longer had an effect 7 months later. Although the reason for this 
irreproducibility remains unknown, others have reported that 5-HT6 receptors can exhibit 
high levels of constitutive activity when expressed in various cell lines (Kohen et al., 
2001; Grychowska et al., 2016). Therefore, we hypothesized that 5-HT6 receptors may 
have, for reasons currently unknown, become constitutively activated, thus preventing 
further activation. This hypothesis eventually led us to test the 5-HT6 receptor antagonist 
SB-399885, which attenuated the amplitudes of eIPSCs. We also tested the effects of 
WAY-208466 in a similar experiment in a brain slice prepared from a mouse (Figure 
2.10, n = 1). Importantly, the effects 5-HT6 receptor ligands on eIPSC amplitude in 
mouse mirrored the results obtained rat. However, the observed irreproducibility of 
WAY-208466 in rat hippocampal brain slices remains a mystery. 
Despite these limitations, to date, there are no published studies testing the effects 
of 5-HT6 receptor activity on synaptic transmission in the DG, examining GFP staining in 
htr6-EGFP mice, or studies suggesting 5-HT6 receptor expression on mossy cells. A 
number of publications hypothesize that 5-HT6 receptor activity influences excitatory 
synaptic transmission via their direct effects on inhibitory interneurons (Dawson et al., 
2001; Woolley et al., 2004; Fone, 2008; Schechter et al., 2008; West et al., 2009; Codony 
et al., 2011; Ramirez, 2013). However, other studies have reported 5-HT6 receptor and 
mRNA expression on other cell types in the hippocampus such as DGCs, pyramidal 
neurons, and astrocytes (Woolley et al., 2004; Marazziti et al., 2013; Helboe et al., 2015). 
This controversy stems from, in part, a lack of 5-HT6 receptor-specific antibodies and 
thus, reliance on mRNA expression to dissect the cell-type specific expression pattern of 
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5-HT6 receptors. Although our results in htr6-EGFP need to be confirmed, they suggest 
that excitatory mossy cells are an entirely novel cellular mediator between 5-HT6 
receptors and their effects on inhibitory synaptic transmission. 
Besides prominent GFP immunoreactivity in mossy cells, IHC in htr6-GFP mice 
yielded several interesting results with respect to GFP staining patterns in coronal versus 
horizontal sections. For example, although the number of htr6-EGFP mice examined was 
low, and the precision used during the slicing process was insufficient to delineate 
differences in dorsal-ventral hippocampus in this study, the percentage of GFP-IR mossy 
cells in horizontal sections (81%), which presumably contain ventral hippocampus, was 
greater than the percentage of GFP-IR mossy cells in coronal sections (66%), which 
presumably contain dorsal hippocampus. Furthermore, mossy cells accounted for the 
largest population of all GFP-IR cells in horizontal sections (~65%), whereas DGCs 
accounted for the largest population of all GFP-IR cells in coronal sections (~40%). 
Another notable difference between coronal and horizontal slices is the occurrence of 
GFP-IR cells that were not GluA2- or GABA-IR but contained a nucleus. This 
population, which may have been astrocytes, made up almost 20% of total GFP-IR cells 
in coronal sections, but only ~2% in horizontal sections. Lastly, we also observed a 
population of GFP-IR cells in the molecular layer that accounted for ~15% of the all 
EGFP-IR cells in coronal slices. Their cell bodies were often found on the border of the 
DGC layer and molecular layer, were never GABA-IR, and were always GluA2-IR. 
Interestingly, there is a population of excitatory neurons known as semilunar granule 
cells (SGCs) that reside on the DGC-molecular layer border. Very little is known about 
this recently discovered population of neurons, however, SGCs receive perforant-path 
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inputs and send axons to hilar and CA3 neurons, but differ from DGCs in that they have 
high intrinsic excitability and exhibit a sustained unaccommodating firing pattern upon 
depolarization (Williams et al., 2007). It is suspected that this population of GFP-IR 
neurons could be SGCs, however, additional studies are needed to confirm their identity. 
Future studies should confirm the interesting 5-HT6 receptor expression patterns observed 
in the present study, perhaps using 5-HT6 receptor antibodies that may be developed in 
the future, and determine how their expression patterns affect DG physiology and 
function.   
In summary, our results are consistent with other studies suggesting that 5-HT6 
receptor antagonist may exert their nootropic effects via disinhibition. Augmenting neural 
circuits via disinhibition is a fundamental theme in nervous system function and may be 
targetable for memory enhancement and remediation of memory deficits in disease 
(Froemke, 2015; Letzkus et al., 2015). Additionally, several studies suggest that mossy 
cells play a role in mediating spatial pattern separation and contextual fear memory and 
thus, 5-HT6 receptors may be ideally anatomically situated on mossy cells to mediate 5-
HT6 receptor antagonists’ procognitive effects by disinhibiting DGCs (Myers and 
Scharfman, 2009; Jinde et al., 2012). Thus, studies reverse-engineering 5-HT6 receptors 
are expected to highlight new therapeutic targets to co-opt disinhibition for the treatment 
memory deficits in disease, and inform novel therapy development for treatments of 





Figure 2.1.  A working model of 5-HT6 receptor-mediated disinhibition. Serotonergic 
fibers originating in the brainstem innervate inhibitory interneurons (GABA, red) 
throughout the brain thought to express 5-HT6 receptors. Previous studies suggest 5-HT6 
receptor agonists increase the activity of GABAergic interneurons and thus, dampen the 
activity of glutamatergic or acetylcholinergic neurons. Conversely, 5-HT6 receptor 
antagonists are thought to disinhibit glutamatergic (GLU, green) or acetylcholinergic 
(ACh, green) neurons by decreasing the activity of GABAergic neurons.  
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Figure 2.2.  WAY-208466 attenuated the amplitudes of fEPSPs in the DG. A) 
Experimental schematic for recording fEPSPs in the DG. B) Representative fEPSPs taken 
at 60 min. The black and red traces are from ACSF- and WAY-208466-exposed slices, 
respectively. Scale bar: 0.2 mV, 5 ms. C) The amplitudes of the fEPSPs are normalized to 
the average amplitude of the last 4 fEPSPs during the baseline phase (18.5−20 min) and 
expressed as an average percentage ± SEM by condition. The black bar on top indicates 
when drug or ACSF was perfused onto the slices, and the numbers in parentheses 
indicate the number of slices tested from the number of animals. D) Time-course 
concentration-response of the effects of WAY-208466 on the amplitudes of fEPSPs in the 
DG. The average of the last 4 raw fEPSP amplitudes at the end of the drug phase 
(38.5−40 min) were not significantly attenuated compared to baseline for any 
concentration of WAY-208466 (p > 0.05, paired Student’s t test). However, raw fEPSP 
amplitudes during the washout (58.5−60 min) were significantly attenuated compared to 
baseline for both 300 nM (green) and 1 µM (red) WAY-208466 (raw data not shown, * p 
< 0.05, paired Student’s t test) E) Concentration-response for the washout phase. Each 
bar represents the mean amplitude during the washout (58.5−60 min) as a percent of 
baseline ± SEM in slices exposed to ACSF, 100 nM, 300 nM, or 1 µM WAY-208466. 1 
µM WAY-208466 significantly attenuated the amplitudes of the fEPSPs compared to 
ACSF during the washout (** p < 0.01; one-way ANOVA with repeated measures and 







Figure 2.3.  WAY-208466 attenuated the amplitudes of eIPSCs onto DGCs. A) 
Experimental schematic for recording eIPSCs in DGCs. B) Representative traces of 
paired-pulse eIPSCs during voltage-clamp recordings from DGCs before (black) and 
during (red) exposure to the 5-HT6 receptor agonist WAY-208466 (1µM). Scale bars: 25 
pA, 20 ms. C) Time course amplitudes of the first pulse (IPSC1) obtained during eIPSCs 
normalized to the average amplitude of the last 4 eIPSCs during the baseline phase 
(8.5−10 min) expressed as a percentage ± SEM. n = number of DGCs recorded from. D) 
WAY-208466 significantly increased the average raw amplitude of eIPSCs (* p < 0.05, 
Wilcoxon signed-rank test). E) There was no change in the PPR of eIPSCs over time (p > 









Figure 2.4.  WAY-208466 no longer attenuated the amplitudes of eIPSCs onto DGCs. 
The amplitudes of the first pulse obtained during paired-pulse eIPSCs was normalized to 
the average amplitude of the last 4 eIPSCs during the baseline phase (8.5-10 min) and 
expressed as a percentage ± SEM. WAY-208466 no longer affected the amplitude of 




Figure 2.5.  SB-399885 attenuated the amplitudes of eIPSCs onto DGCs. A) 
Experimental schematic for recording eIPSCs from DGCs. B) Representative traces of 
paired-pulse eIPSCs during voltage-clamp recordings before (black) and during (red) 
exposure to the 5-HT6 receptor antagonist SB-399885 (1µM). Scale bars: 50 pA, 25 ms. 
C) Time-course amplitudes of the first pulse obtained during eIPSCs (IPSC1) normalized 
to the average amplitude of the last 4 eIPSCs during the baseline phase (8.5−10 min) and 
expressed as a percentage ± SEM. The average normalized amplitude of eIPSC 1 at the 
end of the drug phase was significantly attenuated in SB-treated slices compared to 
ACSF-treated slices (††† p < 0.001, unpaired Student’s t test). D) SB-399885 
significantly attenuated the average raw amplitude of the eIPSC during the drug phase 
compared to the baseline phase (** p < 0.01, Wilcoxon signed-rank test), whereas ACSF 
had no significant effect on eIPSC amplitude (raw data for ACSF not shown, p > 0.05, 
paired Student’s t test). E) Additionally SB-399885 did not affect the decay kinetics of 
eIPSC 1 (n = 12 (unable to obtain an accurate measurement of the decay kinetics for 1 









Figure 2.6.  SB-399855 had no effect on the amplitude or IEI of sIPSCs during the drug 
phase, but increased IEI during the washout. A) Representative images of sIPSCs 
recorded from DGCs. Scale bars: 25 pA, 1 s. B) The amplitudes and (C) IEIs of sIPSCs 
are normalized to the average of the last 4 amplitudes and IEIs during the baseline phase 
(8.5−10 min) and expressed as a percentage ± SEM. IEI in SB-399885 treated slices was 
significantly increased compared to ACSF-treated slices during the washout phase only 
(† p < 0.05, Welch’s unequal variances t test). SB-399885 (1µM) had no affect on the 
average raw amplitudes (D) or IEIs (E) of SB-399885-treated slices during the drug 
phase. However, SB-399885-treated slices exhibited a delayed increase in the IEI during 









Figure 2.7.  SB-399885 significantly attenuated the amplitudes of mIPSCs but did not 
affect their IEIs. A) Representative images of mIPSCs recorded from DGCs in the 
presence of 1 µM TTX. Scale bars: 25 pA, 1 s. B) The amplitudes and (C) IEIs of 
mIPSCs are normalized to the average of the last 4 amplitudes and IEIs during the 
baseline phase and expressed as a percentage ± SEM. D) The average raw mIPSC 
amplitudes and IEIs (E) are illustrated across by phase. SB-399885 significantly 
decreased the mean raw amplitudes of mIPSCs during the drug and washout phases but 
did not affect IEIs (** p < 0.01, paired Student’s t test). Additionally, linear regression 
analysis of the normalized mIPSC amplitudes in panel B suggest that the slope of the line 
was significantly decreasing during all 3 phases including the baseline phase, and that 








Figure 2.8.  The majority of mossy cells in horizontally cut slices are GFP-IR. A) 
Absence of GFP staining in a horizontally cut section from a nontransgenic wild-type 
littermate. Note the lack of GFP filled cells in the hilus and granule cell layer. Scale bar, 
100 µm. B) GFP staining in a horizontal section from an htr6-EGFP mouse. Note GFP 
filled cells in the hilus, and the occasional GFP staining in the granule cell layer indicated 
by arrows. Scale bar, 100 µm. C) Zoom in of the area indicated by the white box in panel 
B. Scale bar, 50 µm. Arrowheads indicate cells that are IR for GFP and, D) the mossy cell 
marker GluA2. Arrows indicate cells that are GluA2-IR but not GFP-IR. E) Arrows now 
indicate the presence of GABA filled cells, presumably inhibitory interneurons. F) 
Hoescht stain illustrating cellular nuclei. G1) Zoom-in from panels C and D illustrating 
GFP and GluA2 merge. Arrowheads indicate cells co-labeled with GFP and GluA2 as 
illustrated by a yellow surround, presumably GFP filled mossy cells. Arrows indicate 
cells that are GluA2-IR but not GFP filled. Scale bar, 20 µm. G2) Zoom-in from panels D 
and E. The arrow indicates a GABA-IR cell that does not express the mossy cell marker 
GluA2. H1) Zoom-in from panels C and D illustrating another representative example of 
a GFP- and GluA2-IR cell (arrow head) and GluA2-IR cell that does not express GFP 







Figure 2.9.  The majority of mossy cells in coronally cut slices are GFP-IR. A) Absence 
of GFP staining in a coronally cut section from a nontransgenic wild-type littermate. Note 
the lack of GFP filled cells in the hilus and granule cell layer. Scale bar, 100 µm. B) GFP 
staining in a coronally cut section from an htr6-EGFP mouse. Note GFP filled cells in the 
hilus, and the occasional GFP staining in the granule cell layer indicated by arrows. C) 
Zoom in of the area indicated by the white box in panel B. Scale bar, 50 µm. Arrowhead 
indicates a cell that is IR for GFP and, D) the mossy cell marker GluA2. Arrows indicate 
cell that are GluA2-IR but not GFP-IR, presumably a mossy cell that does not express 
GFP. Carats indicate GFP-IR cells that are not GluA2-IR, E) but do have nuclei labeled 
with a Hoescht stain; possibly GFP-IR glial cells. Lastly, the asterisk indicates the rare 
occurrence of a GFP- and GluA2-IR cell, that is also, F) GABA-IR, presumably an 
inhibitory interneuron. G1) Zoom-in from panels C and D illustrating GFP and GluA2 
merge. Scale bar, 20 µm. Arrowhead indicates a GFP-IR cell that is co-labeled with 
GluA2 as illustrated by a yellow surround, presumably a GFP filled mossy cell. The 
arrow indicates a cell that is GluA2-IR but not GFP filled. The caret indicates a GFP-IR 
cell that is not, G2) GluA2- or GABA-IR, G3) but does have a nucleus. The asterisk 
indicates the rare occurrence of a cell that is IR for GFP, GluA2, and GABA, and has a 
nucleus. G4) GFP, GluA2 and GABA merge illustrating all 3 markers in the cell above 











Figure 2.10.  5-HT6 receptor ligands have similar effects in mouse and rat. The 5-HT6 
receptor antagonist SB-399885 attenuated the amplitudes of eIPSCs onto DGCs, and the 
5-HT6 receptor agonist enhanced the amplitudes of eIPSCs onto DGCs in a manner 
similar to that observed in hippocampal brains slices prepared from rat (n = 1) (see Figure 






Figure 2.11.  5-HT6 receptors indirectly modulate inhibitory synaptic transmission in the 
DG via mossy cells. Depicted on the right is a simplified schematic for synaptic 
connections in the DG. Together, our electrophysiology and IHC data suggests that 5-
HT6 receptor activation increases the activity of mossy cells (bottom, green) and their 
excitatory drive onto GABAergic inhibitory interneurons (red). This increases the activity 
of inhibitory interneurons that dampen the activity of granule cells (top, green). In 
contrast, our data also suggests that 5-HT6 receptor antagonists directly attenuate the 
activity of mossy cells and thereby decrease the activity of inhibitory interneurons, thus 




Table 2.1  
GFP quantification in the DG of htr6-EGFP mice.  
The number of mossy cells, granule cells, GABA+ cells, molecular layer (ML) cells, and 
other unknown cell types were either hand-counted or estimated (granule cells), and the 
percentage of each cell type IR for GFP is reported. We also quantified the mean 
percentage of each cell type that makes up total GFP expression in the DG. All averages 
are expressed ± SEM by the orientation of the slice. Horizontal, n = 6 slices from 2 
animals. Coronal, n = 9 / 3.   
 
 % of DG cell type that  
was GFP-IR 
% of total GFP in the DG 
by cell type 
Cell type Horizontal Coronal Horizontal Coronal 
Mossy Cells 81.1 ± 4.1 66.2 ± 4.4 65.6 ± 11.6 26.2 ± 2.9 
Granule cells 1.2 ± 0.3 1.1 ± 0.1 29.2 ± 10.0 40.0 ± 3.4 
GABA+ cells 0.3 ± 0.1 1.3 ± 0.4 0.3 ± 0.2 0.7 ± 0.3 
ML cells − − 3.0 ± 1.6 15.1 ± 2.9 
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5-HT6 RECEPTOR ANTAGONISTS AND THEIR EFFECTS 
ON SPATIAL PATTERN PROCESSING AND SEIZURES  




Progressive loss of cognitive function in Alzheimer’s disease (AD) may be partly 
driven by hyperexcitability in the form of seizures and subclinical epileptiform activity. 
However, current treatments for AD have seizure liabilities and are only marginally 
effective at improving cognitive function. Thus, procognitive and antiseizure treatments 
are needed. 5-HT6 receptor antagonists have procognitive and anticonvulsant effects in 
rodents, and have been shown to improve cognitive function in patients with AD. 
However, their effects on seizures and cognition in a transgenic mouse model of AD are 
unreported, and may differ from those in otherwise healthy animals. We tested the 
hypothesis that 5-HT6 receptor antagonists will exhibit procognitive and anticonvulsant 
effects in J20 mice, a transgenic model of familial AD that exhibits cognitive dysfunction 
and aberrant hyperexcitability. J20 mice were first evaluated in a spatial pattern 
processing task reliant on proper DG-function – the metric task. Treatment with a 5-HT6 
receptor antagonist SB-399885 (10 mg / kg, intraperitoneal (i.p.)) 30 min prior to testing 
  
104 
improved performance in nontransgenic (NTG) but not J20 mice, and also attenuated 
distance traveled in both genotypes. Additionally, vehicle-treated J20 mice exhibited a 
significantly lower seizure threshold than vehicle-treated NTG mice, and SB-399885 (30 
mg / kg, i.p.) had no effect on either genotype’s seizure threshold. We also tested the 
hypothesis that SB-399885 and another 5-HT6 receptor antagonist, SB-271046, (both 10 
mg / kg, i.p.) would exhibit anticonvulsant effects in naïve C57BL/6 and CF1 male mice 
in the minimal clonic seizure threshold test. Surprisingly, SB-399885 reduced seizure 
threshold in C57BL/6 mice but had no effect on seizure threshold in CF1 mice. SB-
271046 had no effect on seizure threshold in either strain. These results suggest 5-HT6 
receptor antagonists significantly improved DG-associated spatial pattern processing in 
NTG mice but not J20 mice, and that 5-HT6 receptor antagonists have strain- and ligand 
dependent proconvulsant effects in naïve and otherwise healthy mice. Thus, 5-HT6 
receptor antagonists exhibited varying effects on cognition and seizures and should be 
more thoroughly evaluated, particularly with respect to their effects on seizures, to inform 
their current clinical use in humans with AD that have an increased tendency for seizures.  
 
Introduction 
Alzheimer’s disease (AD) is a progressive neurological disorder beginning with 
memory deficits that slowly advances to a complete loss of cognitive function. As of 
2015, 5.4 million Americans suffer from AD, and it is estimated that number will triple 
by 2050 (Alzheimer's Association, 2015). Annual healthcare costs of AD, primarily 
arising from round-the-clock nursing care, exceeds $600 billion and places an enormous 
financial burden on patients, their families, and society (Wimo et al., 2013). Memory 
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impairment is among the primary causes for admission into residential nursing care 
(Gaugler et al., 2009), and it is estimated that delaying nursing home admission for all 
dementia patients in the U.S. by only 1 month would cut spending by $4 billion (Gold 
and Budson, 2008). However, current treatments for memory impairment in AD are few 
in number, mechanistically homogenous, and only marginally effective (Raina et al., 
2008; Nygaard, 2013). Thus, new treatments that attenuate memory deficits will improve 
quality of life and diminish the heavy financial and emotional burden of AD. 
Recent studies have highlighted that in addition to cognitive dysfunction, 
anywhere from 1.5–64% of AD patients have had at least 1 unprovoked seizure, with 
particularly high rates in patients with familial AD (FAD) (Friedman et al., 2012). 
Patients with AD and epilepsy exhibit greater cognitive impairments and their symptoms 
typically progress faster than AD patients without epilepsy (McAreavey et al., 1992; 
Volicer et al., 1995). Moreover, it is suspected that up to half of all AD patients with 
epilepsy have nonconvulsive seizures, and 43% exhibit subclinical epileptiform activity 
(Vossel et al., 2013; Vossel et al., 2016).  These studies suggests that a large portion of 
AD patients may be having “silent seizures” and bursts of hypersynchronous discharges 
that disrupt their excitation-inhibition balance and cognition (Kleen et al., 2013). 
Moreover, transgenic animal models of AD, patients with mild cognitive impairment, and 
even patients with probable AD have been shown to exhibit hyperexcitability and 
cognitive impairments that are attenuated by the anticonvulsant drug levetiracetam (LEV) 
(Cumbo and Ligori, 2010; Bakker et al., 2012; Sanchez et al., 2012). Thus, 
hyperexcitability is now considered an early pathological mechanism in AD, and new 
treatment approaches for AD need to address both cognitive dysfunction and seizures. 
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Treating cognitive dysfunction in the presence of pathological hyperexcitability 
presents a double-edged sword: many cognition-enhancing drugs have seizure liabilities, 
and seizures and subclinical epileptiform activity disturb memory, whereas many 
anticonvulsant drugs dampen seizures, but also worsen cognitive function. For example, 
2 of the 5 currently approved drug treatments for cognitive dysfunction in AD, Aricept® 
(Donepezil) and Exelon® (Rivastigmine), are listed on the World Health Organization’s 
top ten drugs associated with convulsive adverse drug reactions (Kumlien and Lundberg, 
2010). Memantine, the only approved treatment for cognitive dysfunction in AD that is 
not an acetylcholinesterase inhibitor, comes with a package insert warning for seizures, is 
associated with new-onset seizures in AD (Peltz et al., 2005), and worsens seizures in 
animal models of epilepsy (Loscher, 1998; Mares and Mikulecka, 2009). On the other 
hand, several first and second generation antiseizure drugs (ASDs) that are effective for 
reducing seizures have been shown to worsen cognitive function in healthy volunteers, 
patients with epilepsy, as well as AD patients (Meador et al., 1993; Meador et al., 1995; 
Meador, 2002; Lee et al., 2003; Meador et al., 2005; Salinsky et al., 2005; Hamed, 2009; 
Cumbo and Ligori, 2010). Thus, most currently prescribed ASDs are not well suited to 
treat seizures in AD. Although LEV reduced seizures and cognitive dysfunction in 
animals models and patients with AD (Cumbo and Ligori, 2010; Bakker et al., 2012; 
Sanchez et al., 2012), and Phase II clinical trials evaluating the cognitive effects of LEV 
in AD are currently underway are still needed, particularly those that may exhibit 
improved efficacy and lack side effects associated with LEV, such as aggression and 
irritability (Helmstaedter et al., 2013). 
One class of drugs that may improve cognitive function without worsening 
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seizures is serotonin (5-HT) 5-HT6 receptor antagonists. Drugs that block the activity of 
5-HT6 receptors have been shown to improve memory in naïve, aged, and amnestic 
rodents (Rogers and Hagan, 2001; Woolley et al., 2001; Stean et al., 2002; Foley et al., 
2004; King et al., 2004; Hirst et al., 2006; Mitchell et al., 2006; Da Silva Costa et al., 
2009; Kendall et al., 2011), and have even been shown to improve cognitive function in 
randomized, double-blind, placebo controlled clinical trials in patients with mild-to-
moderate probable AD as an adjunctive therapy to Donepezil (Maher-Edwards et al., 
2011; Wilkinson et al., 2014). In addition to their procognitive effects, 5-HT6 receptor 
antagonists also exhibit anticonvulsant effects. For instance, several 5-HT6 receptor 
antagonists have been shown to increase seizure threshold in rats during the maximal 
electroshock test, (Routledge et al., 2000; Hirst et al., 2006), and 5-HT6 receptor blockade 
produced a reduction in seizure severity and latency when administered prior to 
pilocarpine treatment in rats (Wang et al., 2015). Despite their advancement to clinical 
trials in humans, their effects on cognition and seizures have never been reported in an 
animal model of FAD that exhibits spontaneous seizures. Understanding their effects in a 
relevant disease model of AD is necessary because their effects on cognition and seizures 
may differ from those in otherwise healthy animals due to serotonergic remodeling 
(Garcia-Alloza et al., 2004; Ramirez et al., 2014). More specifically, the effects of 5-HT6 
receptor antagonists on seizures have only been minimally evaluated and could have 
beneficial effects on 1 type of seizure and deleterious effects on another – effects that 
could easily go unnoticed in patient populations. Thus, additional studies are needed to 




Therefore, we tested the effects of a 5-HT6 receptor antagonist on cognitive 
function and seizures in J20 mice – a transgenic model of FAD that expresses human 
amyloid precursor protein (hAPP) harboring Swedish and Indiana mutations (Mucke et 
al., 2000). At 3- to 5-months-of-age, J20 mice accumulate amyloid-beta plaques and 
develop spontaneous nonconvulsive seizures, hippocampal-dependent memory deficits, 
and impaired synaptic plasticity, as well as increased GABAergic synaptic transmission 
in the dentate gyrus (DG) (Palop et al., 2007) thought to be a compensatory response to 
hyperexcitability. Thus, treatments that dampen excess inhibition in the DG of J20 mice 
without exacerbating seizures may restore normative DG physiology and function in J20 
mice. Towards this end, 5-HT6 receptor antagonists are thought to produce their 
nootropic effects, in part, by dampening inhibitory synaptic transmission to facilitate 
information flow through excitatory networks – a phenomenon known as disinhibition 
(Dawson et al., 2001; Fone, 2008; Schechter et al., 2008; West et al., 2009; Codony et al., 
2011).  Moreover, work in Chapter 2 of this dissertation revealed that 5-HT6 receptors 
bidirectionally control inhibitory synaptic transmission in the DG in a manner consistent 
with 5-HT6 receptor antagonist-mediated disinhibition. Thus, 5-HT6 receptor antagonists’ 
established procognitive and anticonvulsant effects may be subtle enough to attenuate 
aberrantly increased inhibition in the DG of J20 mice and improve DG-mediated 
cognitive function without exacerbating seizures. 
We hypothesized that the 5-HT6 receptor antagonist SB-399885 exhibits 
procognitive and anticonvulsant effects in J20 mice. We also tested the hypothesis that 5-
HT6 receptor antagonists would exhibit anticonvulsant effects in 2 strains of naïve and 
otherwise healthy mice. First, J20 mice were evaluated for spatial pattern processing 
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deficits in the metric task, a behavioral paradigm that relies on proper DG function 
(Ennaceur and Delacour, 1988; Lee et al., 2005; Goodrich-Hunsaker et al., 2008; 
Ennaceur, 2010). Preliminary data suggested J20 mice may be impaired in the metric 
task. Therefore, we tested the effects of acute treatment with SB-399885 in J20 mice and 
their NTG littermates. Following cognitive testing, we also evaluated the effects of 5-HT6 
receptor blockade on seizure threshold in the minimal clonic seizure threshold test in J20 




Four- to six-month-old (20–25 g) male heterozygous transgenic J20 mice 
expressing human amyloid precursor protein (hAPP) containing the Swedish and Indiana 
FAD mutations, as well as their nontransgenic (NTG) wild-type littermates, were 
obtained from Jackson Laboratory, Mutant Mouse Regional Research Center (Mucke et 
al., 2000). Three cohorts of J20 and NTG mice were purchased. J20: n = 22, NTG: n = 
24. The first cohort was used for minimal clonic seizure threshold testing (n = 8 per 
group) and the second and third cohorts were used for cognitive testing in the metric task 
(J20: n = 14; NTG: n = 16). 
Seven- to eight-week-old male C57BL/6 mice (20–25 g, Charles River 
Laboratories, Raleigh, NC, U.S.A.) and 5- to 6-week-old male CF-1 mice (18–25g; 
Charles River Laboratories, Wilmington, MA) were used to test the effects of 5-HT6 
receptor antagonists on minimal clonic seizure threshold in naïve mice. The number of 
mice used in each experiment is indicated in each figure. All mice were group housed in 
  
110 
a light- and temperature-controlled (12 h on/12 h off) environment and permitted access 
to food and water ad libitum throughout the study. All experiments were conducted 
during the light cycle, in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals, and approved by the University of Utah 
Institutional Animal Care and Use Committee. All efforts were made to minimize the 
number and suffering of animals used. 
 
Metric Task 
Beginning at 4- to 6-months of age (20–25 g), J20 mice and their NTG littermates 
were tested in the metric task. Mice were acclimated to the testing room for 1 h prior to 
behavioral testing. Mice were then individually habituated to a square plexiglass arena 
(40 L x 40 W x 60 H cm; illumination: ~50 lux) for 2 consecutive days by freely 
exploring the testing arena for 10 min. Animals were then placed into an empty holding 
cage for 5 min, and returned to the arena for an additional 5 min of exploration. During 
habituation, the arena contained 2 objects in separate locations that were not used during 
testing and were not moved during habituation. Distinct visual spatial cues were always 
located 15 cm from each side of the arena.  
On day 3, each mouse was weighed and administered the 5-HT6 receptor 
antagonist SB-399885 (10 mg/kg, i.p.) or vehicle (0.5% methyl cellulose with 0.2% 
Tween, i.p.) 30 min prior to testing, which was conducted in 5 phases (see Figure 3.1A 
for an experimental schematic of the metric task). During phase 1 (acquisition 1), mice 
were individually allowed to explore the arena containing 2 dissimilar objects placed 30 
cm apart for 5 min. Mice were then moved to a holding cage for 5 min (phase 2, delay 1) 
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while the arena underwent a minimal cleaning protocol to wipe up any feces, and were 
then placed back into the arena for 15 min (phase 3, acquisition 2). In phase 4 (delay 2), 
the animal was removed from the arena and placed in a holding cage for 5 min while the 
arena underwent minimal cleaning. During this time, the objects were replaced with a 
duplicate, precleaned pair of objects now placed 8 cm apart. During phase 5 (test), the 
mouse was placed back in the arena for an additional 5 min. Before each trial, the arena 
and 4 objects (a duplicate pair of dissimilar objects) were precleaned with a 0.4% HDQ 
solution. 
During testing, animals were tracked using EthoVision software (Noldus, 
Leesburg, VA, U.S.A.). An observer who was “blinded” to the experimental group 
manually scored object exploration. Exploration was defined as investigative behavior, 
where the mouse was orienting its head towards the object when within 2 cm of the 
object, or touching or smelling the object with its nose, whiskers or forepaws. A mouse 
that was climbing on the objects, or in close proximity without actively attending to it, 
was not counted as exploration. Throughout the acquisition and test phases, total object 
exploration time, regardless of which object was being explored, was recorded in 5-min 
epochs. Performance was then expressed as a recognition index (RID): object  exploration !"#! − object  exploration !"#$%&%'%()  !"!!"  !"#object  exploration !"#! + object  exploration !"#$%&%'%()  !"!!"  !"# 
RIDs were calculated for each mouse and averaged by experimental group. Total 
distance traveled (cm), time spent in the center, and number of center crossings 
normalized to individual distance traveled were measured using EthoVision and averaged 
by treatment group. Data are expressed as the mean ± standard error of the mean (SEM) 
with scatter plots. Data from crossover studies are presented as paired scatter plots.  
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First, J20 and NTG mice (n = 6 per genotype) were tested in a pilot study in 
which they were injected with vehicle only 30 min prior to the beginning of phase 1. One 
week following this preliminary study, we tested the effects of the 5-HT6 receptor 
antagonist SB-399885 (10 mg / kg, i.p.) in J20 and NTG mice using a “crossover” design, 
such that animals treated with SB-399885 during the first week of testing were retested 
the following week after treatment with vehicle, and animals treated with vehicle during 
the first week of testing were retested the following week after drug treatment. We tested 
a second cohort of J20 (n = 14) and NTG (n = 16) mice in the metric task using a similar 
crossover experimental paradigm. New objects were used for the second half of each 
crossover so that mice never encountered the same objects when re-tested in the metric 
task. 
 
Minimal Clonic Seizure Threshold Test 
Dr. Peter J. West conducted minimal clonic seizure experiments in J20 mice. The 
author of this manuscript, Dr. Gregory J. Remigio, conducted minimal clonic seizure 
experiments in naïve C57BL/6 and CF1 mice. 
Electrical stimulation during seizure testing was done using transcorneal 
stimulation with a custom constant current (60 Hz) electroconvulsometer (60 Hz, 0.2 ms 
sinusoidal current pulse, varying intensities). Prior to stimulation, 0.5% tetracaine was 
applied to the cornea for anesthesia and electrical conductivity. J20 mice and their NTG 
littermates (n = 8 per genotype) were individually administered the 5-HT6 receptor 
antagonist SB-399855 (30 mg / kg, i.p.) or vehicle (0.5% methyl cellulose with 0.2% 
Tween, i.p.). Thirty minutes after drug treatment, convulsive current (CC) curves were 
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generated in J20 and NTG mice using a staircase procedure, such that stimulation 
intensity increased or decreased depending whether the previous stimulus produced a 
seizure. Minimal clonic seizures are characterized by rhythmic face and forelimb clonus 
and ventral neck flexion that may progress to rearing and falling. Behavioral seizures 
were visually confirmed by an observer who was “blinded” to the experimental groups. 
Due to a limited number of animals, minimal clonic seizure testing in J20 mice was 
completed across 4 experimental days each separated by 1 week using a “double 
crossover” design, such that each animal was treated with drug or vehicle twice. CC 
curves are illustrated with the percentage of mice that had a seizure at each stimulation 
strength tested. Data are also expressed as the CC50 by experimental group 
In a separate group of experiments, naïve C57BL/6 and CF1 mice were 
administered SB-399885 (10 mg / kg, i.p.), SB-271046 (10 mg / kg i.p.), or vehicle (0.5% 
methyl cellulose with 0.2% Tween, i.p.). Thirty minutes later, mice were stimulated at 
their known CC50 (5.5 mA for C57BL/6 and 6.8 mA for CF1 mice), which were 
previously determined using the staircase method. Behavioral seizures were visually 
confirmed by an observer who was “blinded” to the treatment groups. Data are 
represented as the total number of mice to exhibit a seizure compared to the number of 
mice that did not have a seizure. Naïve mice were also tested using a “crossover” 
experimental design, with experimental days separated by at least 4 days. Minimal clonic 
seizure threshold data in naïve mice is expressed as the number of mice to exhibit a 




Drug Preparation and Treatment 
The 5-HT6 receptor antagonists SB-399885 and SB-271046 were purchased from 
Tocris Bioscience (Minneapolis, MN, U.S.A.). All drugs were dissolved in 0.5% methyl 
cellulose with 0.2% tween (vehicle) to a stock concentration of 3 mg / mL or 1 mg / mL 
and were administered at either 30 mg / kg or 10 mg / kg, respectively, via i.p. injection 
30 min prior to testing. Drugs for cognitive testing were made fresh at the beginning of 
the test week. Drugs for seizure testing were made fresh before each experiment.  
 
Statistics 
Metric task data obtained in the presence of vehicle injections alone were 
compared using an unpaired Student’s t test. All metric task data obtained in the presence 
of drug or vehicle injection was compared using two-way repeated measures ANOVA 
with Bonferroni’s post hoc test. For minimal clonic seizures threshold testing, CC curves 
generated in J20 and NTG mice were tested for statistical significance using Probit 
analysis (Minitab, Minitab Inc., State College, PA, U.S.A.). The mean CC50 in vehicle- 
and drug-treated J20 and NTG mice was compared using two-way repeated measures 
ANOVA with Bonferroni’s post hoc test. Minimal clonic seizure threshold data obtained 
in naïve C57BL/6 or CF1 mice was compared using Fisher’s exact test. All statistical 
analysis besides Probit was performed using GraphPad Prism V5.0c (GraphPad Software, 
San Diego, CA); p < 0.05 was considered significant. *, **, or *** indicate a p-value of < 





Performance of J20 Mice in the Metric Task 
To determine whether J20 mice exhibit deficits during spatial pattern processing, 
we conducted a pilot study in which J20 mice and their NTG littermates were injected 
with vehicle only 30 min prior to testing in the metric task (Figure 3.1A, n = 6 per 
genotype); no drug was tested during this preliminary study. Results showed that the 
mean RIDs for J20 and NTG mice were not significantly different (Figure 3.1B, RID in 
NTG: 0.30 ± 0.11, J20: -0.01 ± 0.12, p = 0.08, unpaired Student’s t test). A power 
analysis using variances generated in this experiment suggested the experiment was 
underpowered and that 8 animals per treatment group would have sufficiently powered 
the experiment. We also measured object exploration time in 5-min epochs, and showed 
that NTG mice spent more time exploring the objects during the test phase compared to 
the last 5 min of acquisition (Figure 3.1C, object exploration time, NTG test phase: 14.2 
± 1.1 s; last 5 min of acquisition: 8.5 ± 1.9 s, p < 0.05, paired Student’s t test), whereas 
J20 mice did not spend significantly more time exploring the objects (p > 0.05, paired 
Student’s t test). We also observed no significant difference in total object exploration 
time or total distance traveled between J20 and NTG mice (Figure 3.1D, E, p > 0.05, 
unpaired Student’s t test). Together, these results suggest that J20 mice did not exhibit 
spatial pattern processing deficits during our preliminary experiment but may have 






The Effects of SB-399885 on Performance of NTG  
and J20 Mice in the Metric Task 
Next, we tested the effects of the 5-HT6 receptor antagonist SB-399885 (10 mg / 
kg, i.p.) on spatial pattern processing in J20 and NTG mice in the metric task using a 
“crossover” experimental design (n = 6 per treatment group). Two-way repeated 
measures ANOVA revealed no significant effect of treatment group, genotype, or 
interaction (Figure 3.2A, Treatment group: F(1, 10) = 2.79; p = 0.13). Despite poor 
performances by vehicle-treated NTG and J20 mice (an average RID of 0.30 is common 
for healthy animals in novelty recognition tasks (Smith et al., 2014)), the data suggested 
that SB-399885 improved performance in both NTG and J20 mice. Therefore, we tested a 
second cohort of J20 and NTG mice (n = 8 and 10, respectively) in the metric task 
following treatment with SB-399885 (10 mg / kg, i.p.). Two-way repeated measures 
ANOVA revealed a significant effect of treatment but not genotype or interaction (Figure 
3.2B, F(1, 16) = 7.43; p < 0.05). Bonferroni’s post hoc test revealed this effect was 
significant in NTG mice only (RID Vehicle: -0.04 ± 0.07; SB-399885: 0.33 ± 0.12; p < 
0.05). We also combined data from the first and second cohorts that were treated with 
vehicle or SB-399885 (Combined, J20: n = 14; NTG: n = 16). Similarly, two-way 
repeated measures ANOVA revealed a significant effect of treatment but not for 
genotype or interaction (Figure 3.2C, F(1, 28) = 10.18; p < 0.01). Bonferroni’s post hoc test 
revealed this effect was significant in NTG mice only (RID Vehicle: 0.01 ± 0.07; SB-
399885: 0.32 ± 0.09; p < 0.05). In summary, testing in 2 cohorts of J20 mice and their 
NTG littermates suggests that the 5-HT6 receptor antagonist SB-399885 improved 
performance during the metric task in NTG mice only.  
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To better understand these results, we also quantified total distance traveled, time 
spent in the center, number of center crossing normalized to distance traveled, and total 
object exploration time for the combined cohorts of J20 mice and their NTG littermates 
during the metric task (Figure 3.3). Two-way repeated measures ANOVA showed a 
significant effect of treatment on total distance traveled, but no effect of genotype or 
interaction (Figure 3.3A; F(1,28) = 47.67; p < 0.001). Bonferroni’s post hoc test revealed 
SB-399885-treated NTG mice traveled significantly shorter distances than vehicle-treated 
NTG mice (NTG VEH: 6175 ± 440 cm; SB: 4339 ± 191 cm, p < 0.001). The same trend 
was observed in J20 mice (J20 VEH: 6202 ± 483 cm; VEH: 4228 ± 536 cm p < 0.001). 
Additionally, SB-399885 significantly attenuated total time spent in the center (Figure 
3.3B; F(1,28) = 6.76; p < 0.05, two-way repeated measures ANOVA). However, 
Bonferroni’s multiple comparisons revealed no significant differences between vehicle- 
or SB-399885-treated mice in either genotype. There were no significant effects observed 
on total number of center entries normalized to 1000 cm of distance traveled (Figure 
3.3C, p > 0.05, two-way repeated measures ANOVA). Together, these results suggest 
that SB-399885 may have had sedative and / or anxiogenic effects in NTG and J20 mice. 
However, the reduction in distance traveled was not due to increased time spent exploring 
the objects since we observed a significant decrease, rather than an increase, in total 
object exploration time in SB-treated animals (Figure 3.3D; F(1,28) = 8.37; p < 0.01, two-
way repeated measures ANOVA). Bonferroni’s multiple comparisons revealed no 
significant differences in total object exploration time between vehicle- or SB-399885-
treated mice in either genotype. Together, these results suggest that SB-399885 
significantly improved performance of NTG mice during the metric task and this 
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improved performance was unlikely due a reduction in anxiety or increased time spent 
exploring the objects. 
 
SB-399885 Has No Effect on Seizure Threshold  
in J20 or NTG Mice 
Next, we tested the effects of 5-HT6 receptor antagonists on seizure threshold in 
both J20 and NTG mice (n = 8 per treatment group). First, we generated CC curves in J20 
and NTG mice in the minimal clonic seizure threshold test using the staircase method. 
Results revealed that J20 mice had a significantly lower seizure threshold than NTG mice 
(Figure 3.4A, p < 0.05, Probit analysis). However, SB-399885 (30 mg / kg i.p.,) had no 
significant effect on seizure threshold in J20 or NTG mice when administered 30 min 
before testing. Additionally, two-way ANOVA of the average CC50 revealed a significant 
effect of genotype but no significant effect of drug or interaction (Figure 3.4B, F(1, 28) = 
65.28; p < 0.001). These results suggest that J20 mice have a lower seizure threshold 
compared to their NTG littermates, and that acute treatment with the 5-HT6 receptor 
antagonist SB-399885 (30 mg / kg, i.p.) 30 min prior to seizure testing did not 
significantly affect seizure threshold in either genotype. 
 
5-HT6 Receptor Antagonists Have Drug- and Strain-Dependent 
Effects on Seizures in Mice 
In addition to investigating the effects of 5-HT6 receptor blockade on cognition 
and seizures in a transgenic model of AD, we also wanted to test the effects of 2 5-HT6 
receptor antagonists in 2 stains of naïve and otherwise healthy mice. Male C57BL/6 and 
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CF1 mice were administered SB-399885 (10 mg / kg, i.p.), SB-271046 (10 mg / kg, i.p.), 
or vehicle and 30 min later were stimulated at their CC50. Surprisingly, all 16 C57BL/6 
mice that received SB-399885 had seizures (Figure 3.5A, number of mice seized / 
number of mice tested: Vehicle: 11/18; SB-399885: 16/16, p < 0.01, Fisher’s exact test). 
However, SB-399885 had no significant effect on seizure threshold in CF1 mice (Figure 
3.5B, p > 0.05, Fisher’s exact test). Additionally, the 5-HT6 receptor antagonist SB-
271046 had no significant effect on seizure threshold in C57BL/6 or CF1 mice (Figure 
3.5C, D, p > 0.05, Fisher’s exact test). Together, these results suggest that 5-HT6 receptor 
antagonists have strain- and ligand-dependent effects on seizure threshold in mice. See 
Table 3.1 for a summary of the effects of 5-HT6 receptor antagonists on seizure threshold 
obtained in this study. 
 
Discussion 
The present study tested the effects of 5-HT6 receptor antagonists on cognition 
and seizures in a transgenic model of AD, and also explored their effects on seizures in 
naïve C57BL/6 and CF1 mice. Initial results in the metric task suggested that vehicle-
treated NTG mice can successfully perform during the metric task, whereas vehicle-
treated J20 mice may be impaired. However, in the following experiments involving 2 
cohorts, both vehicle-treated NTG and J20 mice exhibited poor performances, and the 5-
HT6 receptor antagonist SB-399885 significantly improved performance in NTG mice 
but not in J20 mice. Additionally, SB-399885 also attenuated total distance traveled and 
time spent in the center in both genotypes, but had no effect on number of center 
crossings. Results from minimal clonic seizure threshold testing revealed that J20 mice 
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had a significantly lower seizure threshold compared to their NTG littermates, and SB-
399885 had no effect on seizure threshold in either group. Additionally, SB-399885 
lowered minimal clonic seizure threshold in C57BL/6 mice but had no effect in CF1 
mice, whereas another 5-HT6 receptor antagonist SB-271046 had no effect on seizure 
threshold in either strain. In summary, 5-HT6 receptor blockade improved spatial pattern 
processing in NTG mice during the metric task but not in AD mice, and also had strain- 
and ligand-dependent proconvulsant effects in C57BL/6 and CF1 mice. 
The significance of this study stems from the idea that anywhere from 1.5–64% of 
AD patients experience seizure (Friedman et al., 2012). Thus, new treatments for AD 
need to be both procognitive and anticonvulsant. Prior studies report procognitive and 
anticonvulsant properties of 5-HT6 receptor antagonists, but their effects on cognition and 
seizures in a transgenic animal model of AD are unreported. Despite their advancement 
to clinical trials, understanding the effects of 5-HT6 receptor antagonists on cognition in 
animal models of AD would justify laborious attempts to reverse engineer 5-HT6 receptor 
physiology in transgenic animal models of AD, where remodeling of the serotonergic 
system and other neurotransmitter systems may alter their effects from those in otherwise 
healthy animals. Moreover, understanding the effects of 5-HT6 receptor antagonists on 
seizures in AD models is critical because they may produce various dose-, time-, strain-
dependent effects on seizures, which may also vary depending on seizure type. Thus, 
results from such investigations may inform their effects on seizures in humans and thus 
guide their clinical use.   
The primary limitation in the present cognition study is NTG mice in the first 
cohort successfully performed during the metric task (Figure 3.1), but neither cohort 
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successfully performed during subsequent testing (Figure 3.2). It is unlikely that this 
irreproducibility is due to natural aging-related impairment in NTG mice, since the first 
test in Figure 3.1 was conducted between 1 and 2 weeks before the second test in Figure 
3.2A, and the second cohort was tested at a similar age. Although NTG mice did initially 
exhibit a successful performance, the metric task was initially designed for rats 
(Goodrich-Hunsaker et al., 2008) and may be a difficult task for mice to consistently 
perform. Moreover, object exploration times could have potentially been increased by 
using a smaller arena (i.e., 20 X 20 cm) and objects that are incapable of being mounted 
by mice, which may have improved learning and produced more consistent performances 
by NTG mice in the metric task (Dr. Marco Bortolotto, personal communication).  
Nevertheless, treatment with a 5-HT6 receptor antagonist did significantly 
improve the average RID of NTG mice. This improvement is not surprising, since several 
studies have reported that acute systemic treatment with a 5-HT6 receptor antagonist 
improved cognitive function in naïve and otherwise healthy rodents (Fone, 2008). 
Interestingly, both genotypes of 5-HT6 receptor antagonist-treated mice traveled 
significantly less distances and spent less time in the center of the arena. Distance 
traveled and time spent in the center during open field and natural exploratory tasks in 
rodents can be used as surrogate measures of anxiety (Prut and Belzung, 2003), such that 
reductions in these measures are thought to be indicative of increased anxiety. 
Anxiogenic effects of SB-399885 is surprising since several other studies have reported 
anxiolytic effects of 5-HT6 receptor antagonists. For example, acute treatment with the 5-
HT6 receptor antagonists SB-399885 or SB-258585 increased the number of open arm 
entries and time spent in the open arms in the elevated plus maze (EPM), and also dose-
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dependently increased the number of shocks mice would withstand in the Vogel conflict 
drinking test, which mirrored the anxiolytic-like effects of diazepam (DZP) (Wesolowska 
and Nikiforuk, 2007; Wesolowska, 2008). Similarly to other anxiolytic drugs (Prut and 
Belzung, 2003), 5-HT6 receptor blockade was shown to attenuate locomotion and 
exploratory behavior in the open field test. However, in contrast to the aforementioned 
anxiolytic effects of 5-HT6 receptor blockade, others have reported anxiogenic effects 
following chronic treatment with a 5-HT6 receptor-directed antisense oligonucleotide in 
the EPM as well as a social interaction test (Hamon et al., 1999; Otano et al., 1999). 
Further adding to this controversy, studies have reported anxiolytic effects of 5-HT6 
receptor agonists in rats during EPM testing (Carr et al., 2011). Thus, the effects of 5-
HT6 receptor activity on anxiety are complex and remain unclear. Results in our study – 
which show a reduction in distance traveled and time spent in the center – support the 
idea that SB-399885 treatment may have had anxiogenic effects. Although increased 
anxiety is generally thought to impair cognitive function, it is possible that SB-39985 
simultaneously produced anxiogenic effects that did not interfere with its procognitive 
effects, and are thus mutually exclusive phenomena. It is also possible that the reduction 
in distance traveled and center crossings were due to sedative effects of 5-HT6 receptor 
antagonists, which may have attenuated distance traveled and time spent in the center, as 
well as anxiety, and thus contributed to improve spatial pattern processing. Lastly, it is 
unlikely that the reduction in distance traveled in SB-399885-treated animals is due to 
increased immobility time dedicated towards object exploration (and hence, learning), 
since total object exploration time was reduced in SB-399885-treated animals (Figure 
3.3D). Thus, results obtained in this study suggest that improved performance in SB-
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399885-treated NTG mice during the metric task are possibly attributable to sedative 
effects of SB-399885, but not increased time spent exploring the objects, and thus may 
have actually improved spatial pattern processing as indicated by increased RID’s in 
NTG mice. Nevertheless, additional studies are needed to assess the effects of 5-HT6 
receptor antagonists on spatial pattern processing, anxiety, and sedation in NTG and J20 
mice. 
Testing the effects of 5-HT6 receptor antagonists on minimal clonic seizure 
threshold in AD and naïve mice also revealed several interesting results. For example, 
seizure threshold in vehicle-treated J20 mice was significantly reduced compared to 
vehicle-treated NTG mice (Figure 3.4). This result is not surprising since others have 
reported spontaneous nonconvulsive seizures as well as increased susceptibility to 
pentylenetetrazol- (PTZ) induced seizures in J20 mice and other transgenic models of AD 
(Del Vecchio et al., 2004; Palop et al., 2007). Although 5-HT6 receptor antagonists are 
thought to attenuate inhibitory synaptic transmission, an effect that is generally 
considered proconvulsant, others studies have reported their, albeit paradoxical, 
anticonvulsant effects (Routledge et al., 2000; Hirst et al., 2006; Wang et al., 2015). 
However, we did not observe any effect of SB-399885 on seizure threshold in J20 mice.  
Several factors may have contributed to a lack of effect on seizure threshold in 
J20 mice. For example, 5-HT6 receptor antagonists have shown anticonvulsant effects in 
the MES test at 10 mg / kg in rats (Routledge et al., 2000; Hirst et al., 2006), whereas all 
seizure threshold testing in the present study was conducted in mice. Therefore, species 
differences may have contributed a lack of effect observed on seizures in J20 and NTG 
mice in the present study. Another possibility is the dose tested: Others have reported 
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inverted U-shaped concentration-response curves for a 5-HT6 receptor ligand in vitro 
(West et al., 2009). Thus, it is possible that we did not observe an effect of SB-399885 on 
seizure threshold in J20 or NTG mice because 30 mg / kg was too high on the dose-
response curve to impact seizure thresholds. A lack of effect on seizure threshold in J20 
and NTG mice is particularly interesting considering that SB-399885 was proconvulsant 
at 10 mg / kg in naïve C57BL/6 mice, but had no effect in CF1 mice. Although J20 and 
NTG mice were backcrossed to a C57BL/6 background at least 12 times, they were 
originated on a partial DBA/2 mouse background (Mucke et al., 2000). Thus, it is 
possible that slight differences in genotype or dosing contributed to the discrepancy 
between the proconvulsant effects observed in C57BL/6 mice, as well as the lack of 
effect on seizures threshold in J20, NTG, and CF1 mice. 
In addition to dose- and strain-dependent effects, we also observed ligand-
dependent effects of 5-HT6 receptor antagonists. SB-399885 had proconvulsant effects in 
C57BL/6 mice, whereas SB-271046 had no effect on seizure threshold in C57BL/6 or 
CF1 mice. This discrepancy may be due to pharmacokinetic differences between the 2 
ligands. For instance, SB-399885 has been shown to exhibit a superior pharmacokinetic 
profile over SB-271046, with a 3-fold increase in brain penetrance, and a superior 
pharmacokinetic-pharmacodynamic relationship (Routledge et al., 2000; Hirst et al., 
2003). The ligand-dependent effects are unlikely to be due to differences in binding 
affinity, since both SB-399885 and SB-271046 are high-affinity ligands with 200-fold 
and 50-fold selectivity, respectively, for 5-HT6 receptors over other neurotransmitter 
receptor, ion channels, and enzymes. Thus, the lack of effect we observed when testing 




It is also possible that the strain- and ligand-dependent effects we observed are a 
false-positive. SB-399885’s proconvulsant effects on seizure threshold was only tested in 
1 cohort of C57BL/6 mice and thus need to be repeated and confirmed in a second cohort 
of animals. Furthermore, all the data obtained in this study were minimally varied with 
respect to dose and time-point and deserve more comprehensive testing. Future studies 
should test 5-HT6 receptor antagonists for their dose-, time-, strain-, and species-
dependent effects on seizures, and ultimately, their effects in multiple seizure models. 
The latter point is of critical importance since different seizure tests recruit different brain 
regions (Barton et al., 2001; Eells et al., 2004). Thus, 5-HT6 receptor antagonists may 
exhibit various effects on seizures, or lack thereof, depending on seizure type. Moreover, 
testing each of these parameters in J20 mice and other transgenic animal models of AD is 
critical because 5-HT6 receptor antagonists are currently being evaluated for their 
procognitive effects in humans with AD; thus, their effects on seizures, beneficial or 
deleterious, are unknown, and may go unnoticed in patients. Thorough evaluation of the 
convulsant properties of 5-HT6 receptor antagonists in rodents would inform and perhaps 
advise future clinical use in patients. Lastly, 5-HT6 receptor agonists have been shown to 
promote inhibitory synaptic transmission, and reports of their effects on seizures, to date, 
are lacking. Thus, future studies should consider testing the effects of 5-HT6 receptor 
agonists on seizures in rodents. 
In conclusion, the present study began to explore the effects of 5-HT6 receptor 
antagonists on cognitive function and seizures in a transgenic mouse model of AD, as 
well as their effects on seizures in 2 stains of WT mice. SB-399885 did not improve 
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cognitive function or affect seizures in J20 mice, and did exhibit a proconvulsant profile 
in C57BL/6 mice. Nevertheless, these results are informative because they highlight the 
critical need to further evaluate the effects of 5-HT6 receptor antagonists on seizures, and 
raise clinical awareness that may inform their use in humans.   
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Figure 3.1.  Pilot study indicates J20 mice may exhibit spatial pattern processing deficits 
in the metric task. A) Schematic illustrating the metric task. NTG and J20 mice were 
treated with methyl cellulose (vehicle) 30 min prior to testing. No drug was tested in this 
preliminary study. B) Mean recognition index (RID) ± SEM with scatter plots for NTG 
and J20 mice (n = 6 per genotype). RIDs in J20 mice were not significantly different than 
RIDs in NTG mice, however, the results were trending towards an impaired performance 
in J20 mice (p = 0.08, unpaired Student’s t test). C) Mean object exploration time ± SEM 
by epoch. NTG mice spent significantly more time exploring the objects in the test phase 
compared to the last 5 min of acquisition (p < 0.05, paired Student’s t test), where J20 
mice did not (p > 0.05). D) Mean total object exploration times ± SEM with scatter plots. 
NTG and J20 mice exhibited no significant differences in total object exploration times 
(p > 0.05, unpaired Student’s t test). E) Mean total distance traveled ± SEM with scatter 
plots. No differences between J20 or NTG mice were detected (p > 0.05, unpaired 









Figure 3.2.  SB-399885 improved the performance of NTG but not J20 mice in the metric 
task. A) Paired scatterplot of recognition index (RID) for vehicle (blue) and SB-399885-
treated (red) NTG and J20 mice (n = 6 per genotype and treatment group). The same 
cohort tested in Figure 3.1 was retested 1 week later in the metric task; only this time, 
mice were treated with methyl cellulose (VEH, 0.5% methyl cellulose, i.p.) or SB-
399885 (SB, red, 10 mg / kg, i.p.) 30 min prior to first 5 min epoch using a crossover 
experimental design, so that each mouse was tested following treatment with VEH or SB. 
Acute treatment with SB-399885 did not significantly improve the average RID 
compared to VEH-treated NTG or J20 mice (p = 0.13, two-way repeated measures 
ANOVA with Bonferroni’s post hoc test). B) Paired scatterplots of RIDs for a second 
cohort of NTG and J20 mice were also tested in a crossover experimental design (n = 10 
and 8, respectively). SB significantly increased the RID of NTG mice only (* p < 0.05, 
two-way repeated measures ANOVA with Bonferroni’s post hoc test). C) Paired 
scatterplots of RIDs for both cohorts combined. SB-treated NTG mice performed 
significantly better than vehicle treated NTG mice (* p < 0.05, two-way repeated 
measures ANOVA with Bonferroni’s post hoc test). No significant improvement was 





Figure 3.3.  SB-399885 attenuated total distance traveled, total time spent in center, and 
total object exploration time in NTG and J20 mice during the metric task. A) Paired 
scatterplot of total distance traveled in vehicle-treated (VEH, blue) and SB-399885-
treated (SB, red, 10 mg / kg, i.p., 30 min) in NTG and J20 mice (n = 16 and 14, 
respectively). SB-treatment significantly attenuated distance traveled in both NTG and 
J20 drug-treated mice compared to vehicle-treated and uninjected NTG and J20 mice, 
respectively (*** p < 0.001, two-way repeated measures ANOVA with Bonferroni’s post 
hoc test). B) Paired scatterplot of total time spent in the center zone for VEH- and SB-
treated NTG and J20 mice. A significant effect of drug on total time spent in the center 
was observed (* p < 0.05, two-way repeated measures ANOVA). However, Bonferroni’s 
multiple comparisons revealed no significant reduction in total times spent in the center 
in either genotype C) Paired scatterplot of total number of center entries normalized to 
distance traveled. No significant effects were detected (p > 0.05, two-way repeated 
measures ANOVA). D) Paired scatterplot of total object exploration time. A significant 
effect of drug was observed (** p < 0.01, two-way repeated measures ANOVA). 





Figure 3.4.  J20 mice have a lower seizure threshold in the minimal clonic seizure test 
that is unaffected by SB-399885.  A) Convulsive current (CC) curves for J20 (red) and 
NTG mice (black) treated with vehicle (VEH, solid lines) or SB-399885 (SB, dashed 
lines, 30 mg / kg, i.p., 30 min) in the minimal clonic seizure threshold test (n = 8 per 
treatment group). Middle line is the CC; flanked lines represent the 95% CI. J20 mice 
have significantly a lower seizure threshold compared to NTG mice (Probit analysis, p < 
0.05). B) CC50 for VEH-treated (blue) and SB-treated (red) NTG and J20 mice. J20 mice 
had significantly lower CC50 compared to NTG mice, but SB had no effect on seizure 
threshold in either group (*** p < 0.001, two-way ANOVA with Bonferroni’s post hoc 





Figure 3.5. 5-HT6 receptor antagonists have strain- and ligand-dependent effects on 
seizure threshold in mice. A) Number of C57BL/6 mice to exhibit seizures (black) versus 
the number of mice that did not have seizures (white) during the minimal clonic seizure 
test when treated with vehicle (VEH) or SB-399885 (10 mg / kg, i.p., 30 min). SB-
399885 caused a greater number of C57BL/6 mice to have seizures compared to VEH-
treated mice (n = # of mice seized or not seized and the total # of mice tested, ** p < 
0.01, Fisher’s exact test). B) SB-39985 had no effect on seizure threshold in CF1 mice (p 
> 0.05, Fisher’s exact test). C) The 5-HT6 receptor antagonist SB-271046 (10 mg / kg, 
i.p., 30 min) did not alter seizure threshold in C57BL/6 mice or, D) CF1 mice (p > 0.05 




Summary of 5-HT6 receptor antagonist effects on  





J20 No effect Not tested 
NTG No effect Not tested 
C57BL/6 Proconvulsant No effect 
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CORNEAL KINDLED C57BL/6 MICE EXHIBIT  
DG-ASSOCIATED MEMORY DEFICITS  
AND HYPEREXCITABILITY IN THE  






Memory deficits have a significant impact on quality of life of the patient with 
epilepsy and currently no effective treatments exist to mitigate this comorbidity. 
Although epilepsy patients exhibit varying degrees of hippocampal cell death and 
hippocampal sclerosis (HS), not all patients with memory impairments exhibit severe cell 
loss, and HS is not always associated with memory deficits. Thus, more subtle changes in 
hippocampal physiology may underlie memory dysfunction in some epilepsy patients. 
Animal models of epilepsy or epileptic processes exhibiting memory deficits in the 
absence of cell loss could facilitate novel therapy discovery. Following corneal kindling, 




associated spatial memory test – the metric task. Quantitative immunohistochemical 
analysis revealed hippocampal astrogliosis in the absence of overt neuron loss. 
Additionally, using in vitro brain slice electrophysiology, several changes in synaptic 
transmission were detected suggestive of hyperexcitability in dentate granule cells 
(DGCs): Input-output I/O curves revealed DGCs have an increased postsynaptic response 
and reduced threshold to population spikes during perforant path (pp) stimulation, and 
voltage-clamp recordings from DGCs revealed increased membrane resistance and 
amplitude of spontaneous excitatory events. We also observed attenuated long-term 
potentiation (LTP) at the pp-DGC synapse. These changes, observed in the absence of 
alterations to paired-pulse ratios (PPRs) and inhibitory synaptic transmission, suggest that 
DGCs from corneal kindled mice are hyperexcitable and have long-term synaptic 
plasticity deficits. These changes may contribute to impaired spatial pattern processing in 




Epilepsy is a neurological disorder that affects 1 in 26 individuals worldwide 
(Hesdorffer et al., 2011). Besides spontaneous recurrent seizures, patients with epilepsy 
frequently experience cognitive comorbidities. For example, approximately 1 in 4 
individuals with temporal lobe epilepsy exhibit cognitive impairment during 
neuropsychological evaluation, most notably on memory tests (Hermann et al., 2006). 
Despite the need, there are currently no treatments for memory deficits experienced by 
patients with epilepsy that can exert a significant impact on the epilepsy patient’s quality 
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of life (Giovagnoli and Avanzini, 2000; Hrabok et al., 2013). The discovery of treatments 
for this constellation of debilitating cognitive symptoms would be greatly facilitated by 
an improved understanding of the underlying pathophysiology contributing to these 
symptoms. 
Patients with epilepsy exhibit varying degrees of cell death and hippocampal 
sclerosis (HS) (de Lanerolle et al., 2012), and similar neuronal damage can be 
recapitulated in a number of animal models (Friedman et al., 1994; Covolan and Mello, 
2000; Rao et al., 2006; Groticke et al., 2008; Chauviere et al., 2009). However, not all 
epilepsy patients demonstrating memory impairment have severe hippocampal damage 
(Aikia et al., 1995; Lah et al., 2014), and hippocampal cell loss with or without HS is not 
always associated with memory impairment (Castro et al., 2013; Schmidt et al., 2015). 
Moreover, associations between hippocampal volume loss and performance on memory 
tests are highly variable (Aikia et al., 2001). These observations suggest, at least in some 
epilepsy patients, more subtle changes in hippocampal physiology may underlie memory 
dysfunction. Thus, a better understanding of these physiological changes is needed, and 
animal models of epileptic processes that exhibit memory dysfunction without cell loss or 
HS would be particularly useful.  
Rodent kindling models of epilepsy that employ direct electrical stimulation of 
limbic structures exhibit minimal neuronal loss (Tooyama et al., 2002; Brandt et al., 
2004) and spatial memory impairment (Hannesson and Corcoran, 2000) but suffer from 
the labor intensive nature of invasive electrode implantation surgeries. However, the 
corneal kindling model of seizures in mice, which has been validated as a rapid screening 
model of focal seizures that secondarily generalize in humans, has become a useful tool 
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in the discovery of novel antiseizure drugs, in part, because of its noninvasive, cost-
effective facile methodology (Matagne and Klitgaard, 1998; Potschka and Loscher, 1999; 
Rowley and White, 2010). Moreover, Loewen et al. (2016) recently reported that corneal 
kindled CF1 mice do not exhibit significant neuronal loss within hippocampal area CA1, 
but do exhibit astrogliosis and microglia activation. Although these data suggest that 
corneal kindled mice may provide a noninvasive model of focal seizures that secondarily 
generalize that lacks overt hippocampal neuron loss, it is unknown whether corneal 
kindling in other strains, particularly C57BL/6 mice, similarly spare hippocampal 
neurons. Importantly, alteration of hippocampal physiology, particularly in mice that 
demonstrate learning and memory impairment without hippocampal cell loss, may 
provide insight into the relationships between pathophysiological remodeling of the 
hippocampus in epilepsy and cognitive comorbidities.  
Therefore, we tested the hypothesis that corneal kindled mice exhibit spatial 
pattern processing deficits in a task reliant on dentate gyrus (DG) function in the absence 
of cell loss. To accomplish this, we evaluated neurodegeneration in the hippocampus of 
corneal kindled C57BL/6 mice as well as their performance in a DG-mediated spatial 
pattern processing test that relies on the rodents’ natural tendencies to explore changes in 
the distance between 2 objects – the “metric task” (Ennaceur and Delacour, 1988; Lee et 
al., 2005; Goodrich-Hunsaker et al., 2008; Ennaceur, 2010). Next, we examined 
physiological changes in the DG of corneal kindled mice that may contribute to 
hyperexcitability and/or memory impairment. We used in vitro extracellular and whole-
cell patch clamp electrophysiology to evaluate changes in synaptic transmission, granule 
cell excitability, and short- and long-term synaptic plasticity in the DG. Our results 
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demonstrate that corneal kindled C57BL/6 mice exhibit DG-associated cognitive deficits 
associated with pathophysiological remodeling of excitatory synaptic transmission and 




Forty, 5- to 6-week-old male C57BL/6 mice (15–20 g, Charles River, Raleigh, 
NC, U.S.A.) were used in this study. The first cohort (n = 20) of mice was used for the 
metric task, immunofluorescence, and synaptic plasticity experiments. The second cohort 
(n = 20) was used for basal synaptic transmission and patch clamp electrophysiology 
experiments. All experiments were conducted between 3 days and 2 weeks after kindling. 
All mice were group housed in a light- and temperature-controlled (12 h on / 12 h off) 
environment and permitted access to food and water ad libitum throughout the study. All 
experiments were conducted in accordance with the National Institute of Health Guide 
for the Care and Use of Laboratory Animals and approved by the University of Utah 
Institutional Animal Care and Use Committee. All efforts were made to minimize the 
number and suffering of animals used.  
 
Corneal Kindling 
C57Bl/6 mice were corneal kindled using a protocol adapted from CF1 mice 
(Rowley and White, 2010). Briefly, a 0.9% saline solution containing 0.5% tetracaine 
hydrochloride was applied to each eye to provide local anesthesia and electrical 
conductivity. Two cohorts of 10 mice were stimulated twice daily (4 h apart) with corneal 
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stimulation of 1.5 mA (60 Hz) for 3 s. Mice were considered fully kindled when 5 
consecutive stage 5 seizures were achieved according to a slightly modified Racine scale 
(Racine, 1972): 0 = no reaction or immobility; 1 = jaw clonus; 2 = myoclonic twitches in 
the forelimbs and head nodding; 3 = clonic convulsions in the forelimbs; 4 = clonic 
convulsions in the forelimbs with rearing and falling; and 5 = generalized clonic 
convulsions associated with loss of balance. Mice were stimulated daily until 5 days 
before being evaluated for memory deficits and stimulated once 3 days before beginning 
electrophysiology experiments to confirm persistence of the fully-kindled state. 
Additionally, 2 cohorts of control mice (n = 10 per cohort) were also brought into the 
kindling facility and handled but not stimulated.   
 
Metric Task 
Habituation for the metric task began 3 days after ceasing daily kindling 
stimulation. At the start of each day, 1 cohort of mice (n = 10 kindled, n = 10 control, 20–
25 g) was acclimated to the testing room for 1 h prior to behavioral testing. Mice were 
then individually habituated to a square plexiglass arena (40 L x 40 W x 60 H cm) for 2 
consecutive days by freely exploring the testing arena for 10 min. Animals were then 
placed into an empty holding cage for 5 min, and returned to the arena for an additional 5 
min of exploration. During habituation, the arena contained 2 objects in separate 
locations that were not used during testing and were not moved during habituation. 
Distinct visual spatial cues were always located 15 cm from each side of the arena. On 
day 3, testing was conducted in 3 phases: during phase 1 (acquisition), mice were 
individually allowed to explore the arena that contained 2 dissimilar objects placed 30 cm 
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apart for 15 min. In phase 2 (delay), the animal was removed from the arena and placed 
in a holding cage for 5 min, while the arena underwent a minimal cleaning protocol to 
wipe up any feces and exchange the objects for a duplicate precleaned pair, with the 
objects now placed 8 cm apart. During phase 3 (testing), the mouse was placed back in 
the arena for an additional 5 min. Before each trial, the arena and 4 objects (a duplicate 
pair of dissimilar objects) were precleaned with a 4% HDQ solution.  
During testing, animals were tracked using EthoVision software (Noldus, 
Leesburg, VA, U.S.A.). An observer who was “blinded” to the experimental group 
manually scored object exploration. Exploration was defined as investigative behavior, 
where the mouse was orienting its head towards the object when within 2 cm of the 
object, or touching or smelling the object with its nose, whiskers, or forepaws. A mouse 
that was climbing on the objects, or in close proximity without actively attending to the 
objects, was not counted as exploration. Throughout phases 1 and 3, total object 
exploration time, regardless of which object was being explored, was recorded in 5 min 
epochs, expressed in seconds by epoch, and averaged by experimental group. 
Performance was also expressed as a recognition index (RID):   
RID =    object  exploration !"#! − object  exploration !"#$%&%'%()  !"!!"  !"#object  exploration !"#! + object  exploration !"#$%&%'%()  !"!!"  !"# 
RIDs were calculated for each mouse and averaged by treatment group.  
 
Immunofluorescence 
All immunohistochemistry was performed as reported by Loewen et al. (2016). 
Briefly, 4 mice (20–25g) per treatment group were anesthetized and transcardially 
perfused with 0.1M phosphate-buffer solution (PBS) followed by 4% paraformaldehyde 
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(PFA). Brains were removed, postfixed in 4% PFA at 4°C for 7 hours, transferred to a 
15/30% sucrose gradient for cryoprotection, and frozen on dry ice. Next, brains were 
coronally cut on a freezing stage microtome (Leica Microsystems, Buffalo Grove, IL, 
U.S.A) into 25 µm-thick sections through dorsal hippocampus and stored in 0.1M PBS at 
4°C. Sections immediately caudal to the septum (3 sections/animal for each stain; 4 
animals/treatment group) from corneal kindled and control animals were slide mounted 
and batch processed. First, sections were washed 3 times with 0.1 M PBS and blocked 
with 0.25% bovine serum albumin and 0.2% Triton X-100 in PBS for 1 h. Sections were 
then incubated with NeuN 555 MAB377A5 (1:500, EMD Millipore LLC, Billerica, MD, 
U.S.A.) and GFAP C9205 (1:1000, Sigma-Aldrich, St. Louis, MO, U.S.A.) for 2 h. All 
slides were then counterstained with DAPI D9542 (1:100, Sigma-Aldrich), rinsed in 
0.1M PBS and coversliped with ProLong® Gold antifade reagent (Thermo Fisher 
Scientific, Grand Island, NY, U.S.A.). 
 
Imaging and Analysis 
Images were captured with a Nikon A1 confocal microscope (Nikon Instruments, 
Melville, NY, U.S.A.) using 20x/NA 1.0 air and 60x/NA 1.0 oil immersion objectives 
and analyzed utilizing NIS Software. Briefly, the left dorsal DG, hilus, and CA1 were 
identified using a 100 W halogen lamp and a filter set for DAPI to avoid selection bias. 
Once the region was selected, laser-scanning mode was used to collect images in the z-
axis. A minimum of 12 z-stack optical images (1 µm thick) were imaged for each stain 
from triplicate sections.  
Raw grey scale 16-bit images from the channel of each cell marker (NeuN and 
  
148 
GFAP) were utilized to perform quantification analysis. To remove bias in the analysis, 
an automated macro created using ImageJ software (National Institutes of Health) was 
utilized (Loewen et al., 2016). The total field area stained by each cell marker was 
measured for each optical section through the stained tissue section. These values were 
then averaged for each tissue section and averaged by treatment group and brain region.   
 
Hippocampal Brain Slice Preparation 
Acute hippocampal brain slices were prepared daily as described previously 
(West et al., 2014) from either a kindled or control mouse beginning 3 days-post 
kindling. Briefly, mice (20–25 g) were anesthetized with sodium pentobarbital (60 mg / 
kg, i.p.), and brains were rapidly removed and submerged in ice-cold (4°C) oxygenated 
sucrose-based artificial cerebral spinal fluid (ACSF) bubbled with 95% O2/5% CO2. 
Sucrose-based ACSF contained the following (in mM): Sucrose (200.0), KCl (3.0), 
Na2PO4 (1.4), MgSO4 (3.0), NaHCO3 (26.0), glucose (10.0), and CaCl2 (0.5). The pH and 
osmolarity of the sucrose-based ACSF were adjusted to 7.30–7.35 and 290–300 mOsm, 
respectively, before each experiment. Next, coronal brain slices (350 µm) containing 
dorsal hippocampus were cut using a vibrating microtome (VT1000S, Leica 
Microsystems Inc.). Slices were then transferred to oxygenated standard ACSF and 
incubated for 2 h at room temperature prior to recording. Standard ACSF was made from 
the same recipe as sucrose-based ACSF, only sucrose was replaced with NaCl (126.0 
mM), the MgSO4 concentration lowered to 1.0 mM, and the CaCl2 concentration raised to 




Long-Term Potentiation of Excitatory Synaptic Transmission 
Extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded by 
transferring 8 coronal brain slices containing dorsal hippocampus from either hemisphere 
into the integrated brain slice chambers (IBSCs) of the Scientifica Slicemaster 
(Scientifica, Ukfield, East Sussex, U.K.), a high throughput semiautomatic brain slice 
recording system, which conducts separate but simultaneous recordings (Stopps et al., 
2004). All slices were perfused with regular ACSF (2 mL/min) containing 10 µM 
picrotoxin (PTX) at 30°C unless noted otherwise. Twisted Nichrome-Formvar 
stimulating electrodes were placed in the middle-third of the molecular layer in the upper 
blade of the DG to stimulate the medial perforant path; recording electrodes were placed 
in the middle-third of the molecular layer approximately 400 – 600 µm away from the 
stimulating electrode. Input/output (I/O) relationships were measured by incrementally 
stimulating for 100 µs in 0.5 V steps until a population spike was observed or 20 V 
maximum stimulus intensity was reached. Data were acquired using pClamp 10 
interfaced to a Digidata 1550A data acquisition board (Molecular Devices, Sunnyvale, 
CA, U.S.A.) at a sampling rate of 10 kHz, low-pass filtered at 1 kHz, and high-pass 
filtered at 3 Hz.  The magnitude of the fEPSP was determined by measuring the 20–80% 
slope of the rising phase and expressed as an average for each stimulation strength by 
treatment group. 
After obtaining fEPSPs and conducting I/O curves, baseline stimulation strength 
was set to 50% and slices received 1 stimulation pulse every 30 s. Once stable baselines 
were obtained for 30 min (maximum allowable fEPSP amplitudes drift ± 20%), LTP was 
induced via theta-burst stimulation (TBS) (pulse duration = 200 µs; intra-train frequency 
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= 100 Hz; intertrain frequency = 5 Hz; 4 trains of 4 pulses = 1 burst; 4 bursts with an 
interburst interval of 20 s). LTP induction was then followed by 60 min of single 
stimulation pulses every 30 s.  All fEPSPs were normalized to the average slope of the 
last 5 fEPSPs prior to TBS.  
 
Basal Excitatory Synaptic Transmission and Short-Term Plasticity 
Eight coronal brain slices containing dorsal hippocampus from either hemisphere 
were moved into the IBSCs of the Scientifica Slicemaster. Twisted Nichrome-Formvar 
wire stimulating electrodes were placed in the middle third of the molecular layer of the 
upper blade of the DG to stimulate the medial perforant path; recording electrodes were 
placed in the middle third approximately 400 – 600 µm away from the stimulating 
electrode. I/O curves were conducted as described above, except stimulus intensity went 
to 20V regardless of the appearance of a population spike, and responses for each 
stimulation strength were averaged by treatment group.   
To explore changes in presynaptic short-term plasticity, the baseline stimulation 
strength was set to 50% of the range between the minimum and maximum detectable 
fEPSP (as indicated by the appearance of a population spike during I/O curves) and a 
paired-pulse protocol was conducted where an initial stimulus was given, followed by a 
second pulse with an interpulse interval ranging from 25–300 ms, in sequentially 
increasing 25 ms intervals; each paired-pulse was separated by a 30-s interval. Paired-
pulse ratio (PPR) was quantified as a percentage by dividing the slope of the second pulse 





To evaluate the effects of kindling on excitatory and inhibitory synaptic 
transmission onto DG granule cells (GCs), the whole cell patch clamp technique was 
used for voltage clamp recordings. An individual brain slice from dorsal hippocampus 
was transferred to a perfusion chamber (RC-27L, Warner Instruments, Hamden, CT, 
U.S.A.), held between 2 nylon nets, and perfused with oxygenated ACSF (2 mL/min) at 
room temperature. Patch electrodes (2.5–3.5 MΩ) were filled with the following internal 
solution (in mM): Cs Methanesulfonate (CH3CsO3S, 140.0), HEPES (10.0), EGTA (1.0), 
CaCl2 (0.5), Glucose (10.0), ATP (2.0), GTP (0.5), and QX-314 (5.0)–300 mOsm, 
pH=7.30 (CsOH). Cells were “blindly” patched by forming tight seals (4–8 GΩ) with 
cells located in the GC layer of the DG. All recordings were performed using a 
Multiclamp 700 B amplifier and the pClamp 10 (Clampex) software package interfaced 
to a Digidata 1440 A digitizer (Molecular Devices); recordings were digitized at 10 kHz 
and filtered at 1 kHz. For recording spontaneous excitatory and inhibitory postsynaptic 
currents (sEPSCs and sIPSCs), cells were held at -70 mV and 0 mV, respectively. Access 
and membrane resistance, temperature, and holding current were monitored in 30-s 
increments; changes in these parameters >20% rendered a cell excluded from analysis. 
The amplitude, interevent interval (IEI), length, and time constants for sEPSCs and 
sIPSCs were analyzed using Mini Analysis Program v6.0.1 (Synaptosoft, Decatur, GA, 
U.S.A.) with the amplitude threshold for events set to 10 pA. All measurements were 
obtained by averaging amplitude, IEI, length or time constant from a 30-s recording 
epoch for each cell after recording for 15 min at either -70 mV or 0 mV. Measurements 




All numerical values were expressed as the mean ±	  SEM, and all error bars on 
graphs represent SEM, except for the immunofluorescence data represented by box and 
whisker plots. Metric task, immunofluorescence, and patch clamp data were compared 
using a two-tailed Student’s t test. LTP and PPR data were compared using a repeated 
measure two-way ANOVA, and I/O curves were compared using repeated measure two-
way ANOVA or linear regression. All data sets were tested for normality using 
Kolmogorov-Smirnov test. When p < 0.05, the appropriate nonparametric statistical test 
was employed. All statistical analyses were preformed using GraphPad Prism V5.0c 
(GraphPad Software, San Diego, CA); *, **, or *** indicate a p-value of < 0.05, < 0.01, 
and < 0.001, respectively.  
	  
Results 
Corneal Kindling in C57BL/6 Mice 
 To model the development of seizures in C57BL/6 mice, we corneal kindled 2 
cohorts of 20 mice each (10 kindled and 10 nonstimulated controls) by stimulating twice 
daily until each mouse had achieved at least 5 consecutive stage 5 seizures (Racine, 1972; 
Rowley and White, 2010). Our kindling paradigm illustrates that C57BL/6 male mice 
were fully kindled by stimulation #13 on day 7 (Figure 4.1). We also stimulated the mice 
on day 30 to ensure they were still kindled 3 days prior to beginning electrophysiology 
experiments. Despite using a weaker stimulus strength than what has been reported in 
corneal kindled CF1 mice, C57BL/6 mice kindled almost twice as quickly compared to 
CF1 mice (Rowley and White, 2010).  
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Corneal Kindled Mice Exhibit DG-Dependent  
Spatial Memory Deficits 
 Three days following cessation of kindling stimuli, corneal kindled and control 
mice (n = 10 per group) were habituated and tested for spatial memory impairments in 
the metric task (Lee et al., 2005; Goodrich-Hunsaker et al., 2008) (Figure 4.2A). Corneal 
kindled mice spent significantly less time exploring the objects in the spatially-novel test 
configuration compared to nonstimulated control mice (Figure 4.2B; control: 39.7 ± 5.4 s, 
kindled: 21.6 ± 4.4 s, p < 0.05, unpaired Student’s t test). Additionally, corneal kindled 
mice had a significantly lower average RID compared to nonkindled mice (Figure 4.2C; 
control RID: 0.40 ±	  0.06, kindled RID: -0.02 ±	  0.11,	  p	  <	  0.01,	  unpaired Student’s t test).	  
We also quantified distance traveled and found no significant differences between 
corneal kindled and control mice (p > 0.05, unpaired Student’s t test). These results 
indicate that corneal kindled mice exhibited impaired spatial pattern processing when 
performing a behavioral test thought to rely on proper DG function. 
 
Corneal Kindled Mice Exhibit Astrogliosis in the Absence  
of Overt Hippocampal Cell Loss 
 To determine whether corneal kindled mice exhibit cell loss or astrogliosis in the 
DG and CA1, we performed immunofluorescence staining for both neuronal nuclear 
antigen (NeuN), a neuron specific protein (Kim et al., 2009), and glial fibrillary acidic 
protein (GFAP), a marker for astrocyte activation (Anderson et al., 2014), on sections 
from both corneal kindled and nonkindled control mice (n = 12 sections from 4 mice / 
group). Quantification of NeuN reactivity in the DG granule cell (DGC) layer revealed 
there was no significant difference between kindled and control animals (Figure 4.3A–C), 
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whereas GFAP immunoreactivity was significantly increased (Figure 4.3D, GFAP area, 
control:  8050 ±	  485.7 μm2; kindled: 12271 ±	  515.8 μm2, p < 0.001, unpaired Student’s t 
test). Additional quantification of NeuN reactivity in the hilus revealed no difference 
between kindled and control animals (Figure 4.3E, F). 
We also quantified NeuN and GFAP expression in hippocampal area CA1. 
Quantification of NeuN reactivity revealed there was no significant difference between 
kindled and control animals (Figure 4.4A–C), whereas GFAP immunoreactivity was 
significantly increased (Figure 4.4D, GFAP area, control: 8945 ±	   497.7 μm2; kindled: 
11296 ±	  387.8 μm2, p < 0.01, Mann-Whitney U test). Together, these results suggest that 
corneal-kindled C57BL/6 mice exhibit increased astrocyte activation in the DG and CA1 
in the absence of overt neuron loss, consistent with results found in corneal kindled CF1 
mice (Loewen et al., 2016). 
 
Long-Term Potentiation is Attenuated in the Dentate  
Gyrus of Corneal Kindled Mice 
 To evaluate long-term synaptic plasticity in the DG of corneal kindled mice, we 
examined TBS-induced LTP at the medial perforant path to DGC synapse in acute 
hippocampal brain slices from kindled and control mice. Kindled mice exhibited 
significantly reduced LTP compared to control mice 30–60 min following TBS (Figure 
4.5A, B; Control: 156% ±	  8.9,	  n	  =	  11	  slices	  from	  2	  animals;	  kindled:	  119.4% ± 4.7, n = 
13 slices from 2 animals; F(1,22) = 16.98, p < 0.001, two-way repeated-measures 
ANOVA). These results suggest that corneal kindled mice have impaired synaptic 
plasticity at excitatory synaptic inputs onto DGCs.  
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Dentate Gyrus Granule Cells Are Hyperexcitable  
in Corneal Kindled Mice 
To further explore potential alterations in synaptic transmission in this model of 
partial epilepsy, we examined basal synaptic transmission at the medial perforant path to 
DGC synapse in acute hippocampal brain slices prepared from kindled and control 
animals (n = 14 slices from 2 animals / group). fEPSPs obtained during acquisition of I/O 
relationship curves revealed an increased postsynaptic response at equivalent stimulation 
strengths in kindled mice (Figure 4.6A, B; F(1, 475) = 475, p < 0.05, two-way repeated 
measures ANOVA). To further explore this relationship and rule out potential confounds 
associated with stimulation, we plotted fEPSP response as a function of presynaptic input 
determined by fiber volley amplitudes. DGCs from kindled mice had a greater 
postsynaptic response for an equivalent presynaptic input over a range of increasing 
stimulation strengths (Figure 4.6C; F(1, 1050) = 130.521, p < 0.001, linear regression). 
Moreover, DGCs from kindled mice required a lower stimulation strength (Figure 4.6D; 
average stimulation strength at first population spike, control: 6.63 ± 0.70 V, kindled: 
4.46 ± 0.05 V, p < 0.05, Student’s t test) and a smaller postsynaptic depolarization (Figure 4.6E; average slope of fEPSP at first population spike, control: -0.25 ±	  0.05 mV / 
ms, kindled: -0.09 ±	   0.01 mV / ms, p	   <	   0.01,	   unpaired Student’s t test)	   to achieve a 
population spike. Additionally, quantification of PPRs showed no differences in short-
term synaptic plasticity at the medial perforant path to DGC synapse (Figure 4.6F, G). These	  results	  demonstrate	  that while the presynaptic perforant path input to the DG is 
unaltered, DGCs from kindled animals exhibit a larger postsynaptic depolarization in 
response to equivalent presynaptic input and require less presynaptic input and less 
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postsynaptic excitation to achieve a population spike. Taken together, these results 
suggest that DGCs from kindled mice are hyperexcitable.  
 
Dentate Gyrus Granule Cells Exhibited Increased Membrane  
Resistances and Amplitudes of sEPSCs 
 Lastly, we wanted to determine the underlying mechanisms of increased 
excitability in DGCs using voltage-clamp electrophysiology. To record sEPSCs in acute 
hippocampal brain slices and minimize the contributions of GABAergic IPSCs, we held 
the membrane potential of DGCs at -70 mV. DGCs from kindled mice (n = 12 cells from 
5 animals) had significantly increased membrane resistances compared to nonkindled 
control animals (n = 14 cells from 5 animals) (Figure 4.7A, B, representative traces; 
Table 4.1, control: 312.8 ± 21.5 MΩ, kindled: 431.2 ± 39.4 MΩ, p < 0.05, unpaired 
Student’s t test). Although there were no differences in IEI, the amplitudes of sEPSCs in 
kindled mice were significantly increased compared to control mice (Table 4.1; control: 
15.7 ± 0.6 pA, kindled: 17.9 ± 0.7 pA, p < 0.05 unpaired Student’s t test). We also 
observed no difference in the decay rate or half-width of sEPSCs (Table 4.1).  
After recording sEPSCs from DGCs at -70mV, we held the cells at 0 mV to 
minimize the contributions of glutamatergic EPSCs and recorded sIPSCs. We found no 
difference in IEI, amplitude, decay rate, or half-width of sIPSCs (Table 4.1). Together, 
these findings illustrate that corneal kindled mice have enhanced excitatory synaptic 
transmission in DGCs along with increased membrane resistances, again suggesting that 




This study demonstrates that corneal kindled mice exhibit spatial pattern 
processing deficits in the absence of overt hippocampal cell loss. We also observed 
several changes in synaptic transmission, including attenuated LTP at the medial 
perforant path to DGC synapse, as well as an increased postsynaptic response and 
reduced threshold to population spike in DGCs during perforant path-DGC I/O 
relationships. Moreover, DGCs in kindled mice had greater membrane resistances and 
received sEPSCs that were greater in amplitude compared to nonkindled controls. We did 
not observe any differences in the frequency of excitatory or inhibitory spontaneous 
events in kindled animals, or the amplitudes of inhibitory synaptic events, and PPRs of 
fEPSPs were also unchanged. Together, these results suggest that DGCs in corneal 
kindled mice are hyperexcitable and have altered synaptic plasticity. Moreover, these 
alterations, observed in the absence of overt hippocampal neuron loss, may contribute to 
the observed DG-associated spatial memory impairments. Thus, corneal kindled mice 
may represent a novel model for the discovery of new treatments to ameliorate memory 
deficits in the patient with epilepsy or to determine whether a new therapeutic 
exacerbates cognitive dysfunction seen in the absence of treatment. 
The significance of these findings stem from the idea that developing treatments 
for memory impairments in epilepsy may be hampered in animal models that exhibit 
overt hippocampal damage. It may be a more manageable endeavor to first develop 
therapies in animal models that exhibit memory deficits as a result of more subtle 
hippocampal pathophysiology.  Moreover, not all patients with epilepsy who experience 
memory deficits have overt cell loss (Aikia et al., 1995; Lah et al., 2014), and cell loss 
  
158 
with HS are not always associated with memory impairment (Castro et al., 2013; Schmidt 
et al., 2015). Additionally, a growing body of literature suggests cognitive dysfunction in 
epilepsy may result from pathophysiology independent of cell death or the seizures 
themselves (Bender et al., 2013; Holmes, 2016). In a follow-up study to the report by 
Loewen et al. (2016) showing that corneal kindled CF1 mice exhibit no observable 
neuron loss in the hippocampus, we found that corneal kindled C57BL/6 mice exhibit 
DG-dependent spatial processing deficits and altered synaptic transmission and plasticity 
in the absence of overt hippocampal cell loss. Our results parallel findings in other 
kindling models also reporting neuronal hyperexcitability, impaired long-term synaptic 
plasticity, and hippocampal-dependent spatial memory deficits in the absence of overt 
hippocampal damage (Hannesson and Corcoran, 2000; Hannesson et al., 2001; Leung 
and Shen, 2006); however, these models are constrained by laborious implantation 
surgeries that cause a proinflammatory response in the brain. A noninvasive model of 
kindling that employs the chemoconvulsant pentylenetetrazol (PTZ) also produces 
hippocampal-dependent spatial memory impairment, increased neuronal excitability, and 
altered synaptic plasticity, but does produce hippocampal neuron loss (Pohle et al., 1997; 
Palizvan et al., 2001; Park et al., 2006; Mishra and Goel, 2012, 2013). Our results were 
found in a noninvasive cost-effective corneal kindling model of partial seizures that is not 
constrained by severe hippocampal damage and laborious implantation surgeries and is 
thus suitable to the development of new therapies for epilepsy-related memory deficits. 
Considering the anatomy and physiology of proper DG function, DGC 
hyperexcitability in corneal kindled mice could have contributed to impaired performance 
during the metric task, which requires animals to discriminate spatial pattern differences 
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between 2 objects. The DG is the anatomical entranceway into the hippocampus that is 
critical for pattern separation, defined as the ability to discriminate similar synaptic inputs 
and transform them into dissimilar outputs (Amaral et al., 2007; Schmidt et al., 2012). 
DGCs accomplish this function, in part, by maintaining a hyperpolarized resting 
membrane potential and low firing probability – and thus, gate information flow into the 
hippocampus (Coulter and Carlson, 2007; Hsu, 2007). Moreover, pathological increases 
in DG excitability have been associated with impaired performance during pattern 
separation tasks in rodents (Jinde et al., 2012; Park et al., 2015) and humans alike 
(Bakker et al., 2012); remarkably, attenuating aberrantly increased DG excitability 
restored pattern separation ability in these studies. These findings support the idea that 
DGC hyperexcitability in corneal kindled mice could impair spatial pattern processing 
during the metric task and may represent a valid therapeutic target for the treatment of 
memory impairment in epilepsy. 
The underlying causes of neuronal hyperexcitability in models of epilepsy are 
numerous and frequently investigated. Studies that employ direct electrical stimulation or 
chemoconvulsants to produce status epilepticus and subsequent spontaneous seizures in 
rodents report increased excitability in the hippocampus that is thought to facilitate 
seizure activity and contribute to memory dysfunction, but is often attributed to gross 
anatomical changes such as neuronal loss – primarily the loss of inhibitory interneurons 
that synapse onto DGCs, or the loss of excitatory mossy cells within the hilus of the DG 
that drive inhibition, as well as aberrant neuronal sprouting and reorganization (Cossart et 
al., 2001; Hannesson et al., 2001; Sloviter et al., 2003; Harvey and Sloviter, 2005; Leung 
and Shen, 2006; Sloviter et al., 2006; Sun et al., 2007; Chauviere et al., 2009; Jinde et al., 
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2012). In contrast, electrical kindling models also exhibit hippocampal-dependent 
memory impairment and neuronal hyperexcitability, but usually in the absence of overt 
hippocampal cell loss (Hannesson and Corcoran, 2000), which suggests more subtle 
changes in hippocampal physiology underlie these deficits. Although the underlying 
causes of DG-mediated memory impairment in the present study are likely multifactorial, 
we observed DGC hyperexcitability in the absence of overt hippocampal cell loss, 
alterations to PPR of fEPSPs at the perforant path-DGC synapse, and the frequency of 
spontaneous excitatory or inhibitory synaptic transmission – which suggests that DGC 
hyperexcitability is likely due to changes within DGCs as opposed to the gain or loss of 
presynaptic drive. Besides increased membrane resistances, the increased expression, 
insertion, and/or phosphorylation of glutamate receptors on DGCs may have contributed 
to the increased postsynaptic response observed in DGCs, as similar changes in glutamate 
receptor activity and function has been reported in other epilepsy models (Mathern et al., 
1997; Lopes et al., 2013). We also cannot rule out the possibility that increased activation 
of astrocytes in the DG, observed in the form of increased GFAP immunoreactivity, may 
have also contributed to DGC hyperexcitability, since activation of astrocytes has been 
shown to be sufficient to alter glutamate uptake by astrocytes and cause seizures in mice 
(Takahashi et al., 2010; Robel et al., 2015). Future experiments are needed to better 
understand the causes of DGC hyperexcitability in corneal kindled mice.   
Besides DGC hyperexcitability, many other alterations may have contributed to 
DG-associated memory dysfunction observed in corneal kindled mice. For example, LTP 
in the DG has been shown to be critical for the performance of pattern separation tasks in 
mice (McHugh et al., 2007). Thus, our observation of impaired LTP at the perforant path-
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DGC synapse, which parallels findings in tissue from humans with epilepsy (Beck et al., 
2000), may have also contributed to DG-mediated memory impairments in corneal 
kindled mice. Although beyond the scope of this study, myriad pathological changes may 
have contributed to attenuated LTP in the DG of corneal kindled mice. For instance, the 
development of seizures in response to initially subconvulsive stimulations during 
kindling occurs via synaptic and cellular mechanisms similar to those of LTP (Albensi et 
al., 2007)`. Therefore, corneal kindling may have saturated the capability for further 
synaptic potentiation at the perforant-DGC synapse via metaplastic changes, as suggested 
by others (Huang et al., 1992; McIntyre et al., 2002; Meador, 2007). However, limited 
conclusions regarding the cause and effect relationships of attenuated LTP and DGC 
hyperexcitability can be drawn from the present study. We also cannot rule out the 
possibility that changes in adult hippocampal neurogenesis may have contributed to DG-
mediated memory deficits observed in corneal kindled mice as attenuating aberrantly 
increased hippocampal neurogenesis has been shown to prevent cognitive impairment in 
animal models of epilepsy (Jessberger et al., 2007a; Jessberger et al., 2007b; Fournier et 
al., 2013; Botterill et al., 2015). Future experiments are needed to further explore the 
relationships between DGC hyperexcitability, synaptic plasticity, and hippocampal 
neurogenesis in cognitive deficits in corneal kindled mice. 
Regardless of the underlying cause for DG-mediated memory impairment in 
corneal kindled mice, a growing body of work suggests that the DG supports 
performance during pattern separation tasks by “fine-tuning” the balance of excitatory 
and inhibitory networks and disrupting this balance impairs DG-mediated task 
performance (Piatti et al., 2013; Park et al., 2015). Although excitatory-inhibitory 
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imbalance is a key feature in models of epilepsy, and studying the underlying causes in 
models of epilepsy can provide insight into the pathological mechanisms that give rise to 
seizures and associated cognitive comorbidities, it may be more manageable to study 
memory impairment in seizure models without severe hippocampal damage, where more 
subtle changes in hippocampal physiology underlie memory deficits. Towards this end, 
corneal kindled mice represent a noninvasive, cost-effective rapid screening model of 
local seizures that secondarily generalize. Targeting DGC hyperexcitability and impaired 
synaptic plasticity may be useful in the discovery of novel treatments for epilepsy-related 





Figure 4.1.  Corneal kindling curve in mice. Male C57BL/6 mice (n = 20, 15–20 g) were 
stimulated twice daily and their average seizures scores determined according to the 
Racine scale. Mice took approximately 13 stimulations (7 days) to become fully kindled. 





Figure 4.2.  Corneal kindled mice exhibit DG-dependent memory impairment during the 
metric task. A) Schematic illustrating the metric task. B) Total object exploration time 
averaged by phase. There were no significant differences between the control and kindled 
mice until the test phase, when kindled mice spent significantly less time exploring the 
objects compared to control mice (p < 0.05, Student’s t test, n = 10 per treatment group). 
C) Average recognition index (RID) in kindled mice was significantly less than the 





Figure 4.3.  Corneal kindled mice exhibit increased activation of astrocytes in the DG in 
the absence of overt neuronal cell loss. A) Representative images of NeuN and GFAP 
staining from the DG. B) The region of interest that was quantified. Scale bar: 50 μm. C) 
Quantification of NeuN staining in the DG revealed no significant differences (n = 12 
sections from 4 mice per group), however, D) quantification of GFAP staining revealed 
increased expression in kindled mice (p < 0.001, Student’s t test). E) Representative 
images of NeuN staining used to quantify staining in the hilar region of the DG. Scale 
bar: 100 μm. F) Quantification of NeuN staining in the hilus revealed no significant 





Figure 4.4.  Corneal kindled mice exhibit increased astrocyte activation in hippocampal 
area CA1 in the absence of overt neuronal cell loss. A) Representative images of NeuN 
and GFAP staining in CA1 and, B) the region of interest that was quantified. Scale bar: 
50 μm. C) Quantification of NeuN staining in CA1 revealed no significant differences (n 
= 12 sections from 4 mice per group), however, D) quantification of GFAP staining 





Figure 4.5.  Brain slices from corneal kindled mice exhibit attenuated LTP along the 
perforant path.  A) Representative fEPSPs from 30 s prior to (1, gray) and 60 min post-
TBS (2, black) in control and kindled mice. Scale bars 0.25 mV, 2 ms. are applicable to 
both control and kindled traces. B) fEPSP slope as a function of time from control (open 
circles, n = 11 slices from 2 animals) and kindled animals (closed circles, n = 13 from 2 
animals) conducted in the presence of 10 μM PTX. fEPSP amplitudes are normalized to 
the average of the last 4 fEPSPs before TBS.  TBS occurred at time = 0 min. Kindled 
mice exhibited significantly attenuated LTP between 30 and 60 min post-TBS (*** p < 
0.001, two-way ANOVA).  
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Figure 4.6.  Input / output curves along the perforant path indicate that DGCs are 
hyperexcitable. A) Representative fEPSPs from Input / output (I/O) relationships in both 
control and kindled animals.  From left to right, each fEPSP is a response from a 5, 10, 
15, or 20 V stimulus. B) I/O curves by experimental group. fEPSP slopes are shown as a 
function of stimulus strength. Kindled mice exhibited an increased postsynaptic response 
compared to control animals (* p < 0.05, two-way repeated measures ANOVA, n = 14 
slices from 2 animals per treatment group). C) I/O curves as a function of fiber volley 
amplitudes. Kindled mice exhibited an increased postsynaptic response compared to 
control animals (*** p < 0.001, linear regression; n = 14 slices from 2 animals, per 
group). D) DGCs of kindled mice develop a population spike in response to lower 
stimulus strengths. D1) Representative images from a 5.5 V stimulus. Note the population 
spike is only present in the representative trace from the kindled animal. D2) Average 
stimulus voltage when a population spike was first detected during I/O relationships was 
lower in kindled animals (p < 0.05, Student’s t test). E) Action potentials in DGCs of 
kindled mice are triggered by comparatively smaller postsynaptic depolarizations as 
indicated by the slope of the fEPSP when the first population spike was identified. E1) 
Representative fEPSPs. The dashed lines illustrate two fEPSPs with the same slope. Note 
that the population spike is only present in the representative trace from the kindled 
animal. E2) Average slope of the fEPSP when a population spike was first detected 
during I/O relationships was lower in kindled animals (p < 0.05, Student’s t test). F) 
Representative traces of fEPSPs evoked by paired-pulse stimulations of varying 
interstimulus intervals, and G) paired-pulse ratios (PPRs) plotted as a function of the 
(ISI). PPRs did not differ between kindled and control animals. Scale bars for fEPSPs: 










Figure 4.7.  DGCs from kindled mice receive sEPSCs with increased amplitudes but did 
not exhibit any changes in spontaneous inhibitory synaptic transmission. A) 
Representative sEPSCs, and B) sIPSCs from control and kindled mice when DGCs are 
held at -70 mV or 0 mV, respectively. Scale bars: 10 pA, 1 s.  
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Table 4.1  
 
Results from voltage-clamp experiments showing the effects of corneal kindling on 
excitatory and inhibitory postsynaptic currents in dentate granule cells.  
 
Measurements are shown as mean ± SEM. Rm = membrane resistance; IEI = interevent 
interval; Amp = amplitude (* p < 0.05, unpaired Student’s t test, n = 12 cells from 5 














15.7 ± 0.6 6.5 ± 0.7 6.4 ± 0.7 












22.0 ± 1.4 11.8 ± 0.5 10.1 ± 0.5 
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 The work in this dissertation investigated the neurophysiology and behavioral 
pharmacology of memory enhancement and memory deficits. Chapter 2 examined 5-HT6 
receptor localization and physiology in the dentate gyrus (DG) to better understand how 
5-HT6 receptor antagonists produce their widely reported nootropic effects, and Chapter 3 
tested whether 5-HT6 receptor antagonists exhibit procognitive and anticonvulsant 
properties in a transgenic model of Alzheimer’s disease (AD). Lastly, Chapter 4 found 
spatial pattern processing deficits and associated hyperexcitability that may contribute to 
cognitive dysfunction in corneal kindled mice. For a broader perspective on these results, 
I will evaluate the global implications of the results obtained in these studies, which 
suggest that targeting disinhibition and hyperexcitability may represent worthwhile 
approaches for the treatment of memory deficits in epilepsy and AD. Both of these 
phenomena and their roles in memory enhancement and memory impairment have been 
studied extensively. Therefore, this discussion will begin by evaluating the top-down and 
bottom-up approaches that guided the research in this dissertation and highlight the pros 
and cons of targeting disinhibition and hyperexcitability for the treatment of memory 
deficits in disease. I will then discuss how targeting disinhibition and hyperexcitability 
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for the treatment of memory deficits in disease are inextricably linked, highlighting the 
idea that treatments for cognitive dysfunction in disease should be both procognitive and 
anticonvulsant. Lastly, I will discuss how these themes instruct future therapy 
development and fit into the armamentarium of treatments that may be needed to combat 
cognitive dysfunction in disease. 
 
The Pros and Cons of a Top-Down Approach to  
New Therapy Development 
A Roadmap to Novel Therapeutic Targets 
As it relates to the work in this dissertation, the top-down approach sought to 
provide an anatomical and physiological roadmap for novel treatments based on existing 
treatments already shown to be effective at ameliorating disease symptoms. The rationale 
is that a better understanding of existing treatments will allow us to “fine-tune” their 
effects, and potentially highlight new therapeutic targets. Attempts to reverse-engineer 
existing treatments holds promise as a research approach that is perhaps best exemplified 
by the historical study of antipsychotics and antidepressants.  
Following the cloning of monoaminergic receptors, attempts to reverse-engineer 
antipsychotics and tricyclic antidepressants using high throughput receptor screening 
assays revealed that antipsychotic and tricyclic antidepressant drugs had high affinity for 
a variety of monoaminergic receptors. Chemical libraries were soon screened for ligands 
selective for individual receptor subtypes. One target that emerged from these efforts is 
the serotonin 5-HT6 receptor subtype (Roth et al., 1994). In the following years, 5-HT6 
receptor selective ligands were developed and tested in behavioral assays revealing 
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remarkable results – particularly the antagonists, which have been shown to improve 
cognition on a number of hippocampal, striatal, and prefrontal cortex-dependent tasks 
(Fone, 2008). Moreover, 5-HT6 receptor antagonists also exhibit antidepressant and 
anxiolytic properties, and are now implicated for their potential use in the treatment of 
schizophrenia, anxiety disorders, seizures, and the latest – obesity (Hirst et al., 2006; Heal 
et al., 2008; Schechter et al., 2008; Yun and Rhim, 2011). On the strength of the 
preclinical data, 5-HT6 receptor antagonists advanced to clinical trials in patients with 
AD, showing modest but beneficial effects on cognitive function with relatively few 
adverse events (Maher-Edwards et al., 2010; Maher-Edwards et al., 2011; Wilkinson et 
al., 2014). As a result of their widely reported nootropic effects, researchers are now 
trying to reverse-engineer 5-HT6 receptor physiology and function.  
Results in this dissertation, and a previously published body of literature, suggest 
that 5-HT6 receptor antagonists exert their procognitive effects by attenuating inhibition 
and facilitating information flow through excitatory networks – a neural phenomenon 
known as disinhibition (Dawson et al., 2001; Woolley et al., 2004; Fone, 2008; Schechter 
et al., 2008; Codony et al., 2011; Ramirez, 2013). Moreover, results obtained in Chapter 
2 are, to my knowledge, the first to suggest that 5-HT6 receptors bidirectionally modulate 
inhibition in the DG, and may do so via their direct effects on mossy cells. Thus, attempts 
to reverse-engineer antipsychotics and antidepressants led researchers to the remarkable 
effects of 5-HT6 receptor ligands on cognition that are now being tested in clinical trials, 
and attempts to reverse-engineer 5-HT6 receptor effects on cognition are now 
highlighting potential cell types that may be targeted for the treatment of cognitive 
dysfunction, thereby illustrating that the top-down approach may be useful for the 
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development of novel therapies. 
 
The Top-Down Approach Relies on the Bottom-Up 
Our understanding of brain function in health and disease has undoubtedly made 
great progress but is far from complete. One limitation to reverse-engineering 5-HT6 
receptor antagonists’ nootropic effects, or therapeutic targets, is that it is reliant on the 
integration of these results into an existing framework of CNS function. For instance, 
hypothesizing that 5-HT6 receptor antagonists may produce their nootropic effects by 
disinhibiting DGCs via their direct effects on mossy cells is only possible by interpreting 
our results within the context of an existing body of literature showing that mossy cells 
drive inhibition onto DGCs that gate information flow into the hippocampus (Scharfman, 
1995; Hsu, 2007; Jinde et al., 2012). Furthermore, reverse-engineering complex therapies 
such as atypical antipsychotics or antidepressants was fruitful, in part, because the 5-HT6 
receptor had been sequenced and cloned the year before. These examples illustrate why a 
top-down guided approach is inextricably linked to, facilitated by, and can even blur 
distinction with, bottom-up mechanistically-driven studies elucidating basic CNS 
function. Thus, research aimed at novel therapy development needs to tackle this 
formidable endeavor via both approaches, letting the top-down approach “show us the 
way” and allowing the bottom-up approach lay the groundwork with which to understand 






Targeting Disinhibition To Treat Memory Deficits 
A Validated and Pharmacologically Targetable  
Phenomenon for Memory Enhancement 
Chapter 2 in this dissertation tested the effects of 5-HT6 receptor ligands on 
inhibitory synaptic transmission in the DG. Results from these and other studies suggest 
that 5-HT6 receptor antagonists exert their procognitive effects, in part, via a reduction in 
inhibition – a phenomenon also known as disinhibition. Defined as a transient and 
selective break in inhibition that alters the excitation-inhibition balance to promote 
excitability in postsynaptic targets, disinhibition was first explored for its role in basal 
ganglia function, particularly motor output and action selection (Goldberg et al., 2013). 
However, disinhibition is perhaps now best known for its role in learning and memory 
(Froemke, 2015; Letzkus et al., 2015). Because disinhibition is a fundamental gating 
mechanism hardwired into synapses, neurons, and circuits, there may be innumerable 
molecular, cellular, and network targets to implement disinhibition for therapeutic 
benefit.  
There is a vast body of literature describing the complex molecular, cellular, 
network mechanisms orchestrating disinhibition in learning and memory (Froemke, 2015; 
Letzkus et al., 2015). As it may relate to 5-HT6 receptors and other neuromodulatory 
systems, disinhibition is a reduction in inhibitory synaptic transmission that increases the 
probability that incoming excitatory synaptic events will sufficiently depolarize the 
postsynaptic neuron. This depolarization strengthens existing active inputs by relieving 
the magnesium block on NMDARs, and / or increasing the probability an input will 
achieve action potential threshold, and thus promote long-term synaptic plasticity. This 
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simplified example of disinhibition illustrates how a temporary lapse in inhibition can 
facilitate the survival, strengthening, and / or creation of new synapses, and thus, promote 
learning and memory.  
Validation for disinhibition as a therapeutic target comes from studies 
pharmacologically attenuating inhibition for memory enhancement. For instance, 
administration of GABAA receptor antagonists targeting GABA receptors containing the 
alpha-5 subunit, which are found primarily in the hippocampus, have been shown to 
improve acquisition and recall during the hippocampal-dependent water maze task in 
healthy rodents (Collinson et al., 2002; Collinson et al., 2006). Moreover, blockade of 
GABAB receptors with selective antagonists has been shown to improve novel object and 
place recognition, as well as contextual fear learning in a transgenic model of Down’s 
syndrome (Kleschevnikov et al., 2012). Together, these studies begin to establish 
disinhibition as a pharmacologically targetable neural process for the treatment of 
memory deficits in disease. 
Although detailing the countless mechanisms and time-scales by which 
disinhibition occurs throughout the nervous system is beyond the scope of this 
discussion, neurotransmitters such as acetylcholine, dopamine, norepinephrine, oxytocin, 
and serotonin, have all been shown to regulate inhibition and are implicated in producing 
their effects, in part, via disinhibition (Froemke, 2015). These neurotransmitter systems 
influence behavior via a plethora of receptor subtypes and downstream signaling 
cascades that can be pharmacologically targeted by receptor subtype-specific ligands to 
disinhibit neural circuits and potentially treat cognitive dysfunction in disease. Together, 
this body of literature suggests disinhibition is a validated and pharmacologically 
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targetable mechanism for improving learning and memory and may be a general target 
for treating cognitive dysfunction in disease. However, there are several limitations to 
disinhibiting neural circuits for memory enhancement. 
 
The Drawbacks and Dangers of Disinhibition 
One limitation of targeting disinhibition to alleviate cognitive deficits in disease is 
disinhibition will likely be a symptomatic treatment that is unlikely to slow, halt, or 
prevent disease progression. Nevertheless, symptomatic treatments for memory deficits 
could ease suffering for millions of patients who currently have few or no treatments 
options available, delay admission into nursing homes, and vastly improve patients’ 
quality of life (Gold and Budson, 2008; Raina et al., 2008; Gaugler et al., 2009). 
Therefore, the discovery of symptomatic treatments for cognitive dysfunction that act via 
disinhibition, or any mechanism, could dampen the looming financial and emotional 
burden of neurological disease and should be pursued alongside all other approaches to 
treating disease. 
Another hurdle faced by treatments that attempt to implement disinhibition for the 
amelioration of memory deficits in disease is that disinhibition can disrupt the excitation-
inhibition balance and possibly facilitate seizure activity (Staley, 2015). Particularly 
concerning is that many neurological disorders presenting with cognitive dysfunction also 
exhibit aberrant neuronal hyperexcitability and seizures. For instance, seizures are the 
primary symptom in epilepsy, and surveys indicate that epilepsy patients rate fear of 
another seizure and memory impairment amongst their greatest concerns (Thompson and 
Corcoran, 1992; Fisher et al., 2000). Thus, treating memory deficits in epilepsy patients 
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with treatments that facilitate excitatory network activity could exacerbate seizures, as 
well as aberrant epileptiform activity thought to disrupt memory function (Kleen et al., 
2013). This risk also applies to patients with AD: Depending on the study, 1.5–64% of 
AD patients have had at least 1 unprovoked seizure (Friedman et al., 2012). Alarmingly, 
another study reported that half of all patients with AD and epilepsy have been shown to 
exhibit nonconvulsive “silent” seizures that may pass as amnestic spells or brief “blips” 
in consciousness (Vossel et al., 2013). Moreover, a longitudinal study in AD patients 
with no prior history of seizures reported that 42% of patients had epileptiform activity 
(compared to 10.5% of age-matched controls) (Vossel et al., 2016). Importantly, there 
were no differences in cognitive function between AD patients with and without 
epileptiform activity at the initial time of EEG testing. However, 3 years later, patients 
with epileptiform activity performed significantly worse on the Mini-Mental Status 
Exam, suggesting aberrant hyperexcitability is a risk factor for accelerated cognitive 
decline. Thus disinhibiting neural circuits to rescue memory impairment could worsen 
aberrant hyperexcitability and seizures in a manner that is difficult to recognize, and have 
long-term deleterious and counterproductive effects on cognition.  
 
Disinhibiting Neural Circuits for Memory Enhancement:  
Precision Is Key 
Assuming pharmacological treatments implementing disinhibition can be 
effective in patients without exacerbating the risk of seizures, there is yet another closely 
related formidable barrier: Globally increasing excitatory activity or attenuating 
inhibitory synaptic transmission is not sufficient. For example, attenuating inhibitory 
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synaptic transmission via optogenetics or overexpression of the gamma-aminobutyric 
acid transporter GAT1 can have deleterious effects on spatial memory formation (Hu et 
al., 2004; Andrews-Zwilling et al., 2012), suggesting that not all reductions in inhibition 
improve memory. Additionally, increasing inhibition onto DGCs via the addition of 
newly born neurons that drive inhibition in the DG has been shown to be necessary for 
normal cognitive function (Park et al., 2015). Thus, targeting disinhibition as a potential 
therapy requires spatially and temporally precise implementation that does not cause 
seizures (or other adverse effects such as motor impairment), and facilitates, rather than 
impairs memory formation. Towards this end, reverse-engineering treatments shown to 
exhibit procognitive and anticonvulsant effects such as 5-HT6 receptor antagonists, which 
are thought to work via disinhibition, can provide a blueprint for how to properly and 
precisely implement disinhibition to maximize therapeutic benefits. 
 
Cell Death and Destruction Diminish the Possibility of  
Therapeutic Benefit 
Pharmacological treatments targeting disinhibition, or any treatment intended to 
ameliorate cognitive dysfunction, faces yet another barrier in neurological disease: 
Extensive brain damage increases the odds a patient will exhibit pharmacoresistance. For 
instance, by the time AD patients experience symptoms that substantially interfere with 
work and daily living, their brain is likely inundated with amyloid plaques and fibrillary 
tangles, and is undergoing temporal lobe and cortical atrophy (Frisoni et al., 2010). 
Unfortunately, AD patients with high levels of medial temporal lobe atrophy are less 
likely to respond to donepezil, the most commonly prescribed treatment for AD, 
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compared to patients with less damage (Connelly et al., 2005). Moreover, TLE patients 
exhibiting widespread neuron loss and hippocampal sclerosis (Thom, 2009; Thom et al., 
2009) are more likely to be pharmacoresistant and cognitively impaired than those 
without noticeable damage (Helmstaedter, 2002). Together these studies highlight the 
idea that disinhibition, or any therapeutic target, may be difficult to implement in patients 
with overt cell loss. Moreover, promoting excitability via disinhibition of neural circuits 
may exacerbate cell loss via Ca2+-dependent apoptotic mechanisms. However, not all 
hope is lost: Some neurons are quite resilient to cell death in disease. For instance, DGCs 
are fairly resistant to cell death in epilepsy, and not all hilar inhibitory interneurons and 
mossy cells die off (Wittner et al., 2001; Kobayashi and Buckmaster, 2003; Sun et al., 
2007). Moreover, not all epilepsy patients demonstrating memory impairment have 
severe hippocampal damage (Aikia et al., 1995; Lah et al., 2014), and hippocampal cell 
loss is not always associated with memory impairment (Castro et al., 2013; Schmidt et 
al., 2015). Lastly, associations between hippocampal volume loss and performance on 
memory tests are highly variable in patients with epilepsy (Aikia et al., 2001). Together, 
these studies suggest that in some patients more subtle changes in hippocampal 
physiology may underlie memory dysfunction, and patients with overt cell death may still 
have essential neural circuitry in place that may be available for therapeutic benefit. 
Thus, targeting disinhibition may be useful in alleviating cognitive dysfunction, but will 
likely depend upon the degree of cell loss, brain damage, and remodeling.  
In summary, as it relates to the work in this dissertation, a top-down guided 
approach attempts to elucidate an anatomical and physiological roadmap for treating 
diseases by reverse-engineering existing treatments that are not well understood but have 
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already been shown to alleviate symptoms in disease. Results from the present studies 
support a much larger body of work suggesting that disinhibition is a viable and 
pharmacologically targetable phenomenon for the symptomatic treatment of memory 
deficits. However, disinhibition must be precisely targeted, so as to not exacerbate the 
risk of seizures or cell death, while achieving efficacy in the presence of overt cell loss 
and remodeling that accompanies disease. Despite these formidable barriers, 5-HT6 
receptors (and other targets discussed below) offer proof of concept that procognitive and 
anticonvulsant therapies exist, and reverse-engineering their anatomical and 
physiological properties may provide a roadmap towards achieving procognitive and 
anticonvulsant therapies in patients with memory deficits and seizures.   
 
Understanding Disease from the Bottom-Up:  
The Pros and Cons 
New Therapies and New Tools from Old Ways 
 Understanding the pathological basis of disease is a cornerstone of health science 
and is perhaps one of the greatest challenges researchers face. The enormity of this 
endeavor stems from the number of diseases, the innumerable dynamic and synergistic 
molecular, cellular, and network mechanisms that define their pathophysiology, and the 
complex heterogeneity underlying each disease. Despite these tremendous challenges, 
basic research into health and disease must continue, as it has led to, and will likely 
continue to yield new therapies.  
For example, seminal studies identifying major neurotransmitter systems and their 
anatomical origins elucidated the underlying pathophysiology of many neurological 
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diseases. This pioneering work gave rise to our first approved treatments for AD and 
Parkinson’s disease (PD) that are still is use today (Hornykiewicz, 2010; Contestabile, 
2011). Identification and ablation of brainstem nuclei producing acetylcholine and 
dopamine revealed their role in higher cognitive function, and in movement and reward, 
respectively, prompting researchers to examine these brainstem nuclei in postmortem 
tissue from AD and PD patients. These foundational studies led to the development of 
treatments aimed at preventing the breakdown of acetylcholine, or facilitating the 
production of dopamine, giving rise to the first approved treatments for AD and PD that 
are still in use today – acetylcholinesterase inhibitors and L-Dopa. AD and PD are just 2 
examples of how an understanding of the underlying etiology has contributed to the 
development of effective treatments for devastating neurological disorders. Patients with 
multiple sclerosis, schizophrenia, addiction, epilepsy, and countless other diseases 
outside the nervous system have also benefited from basic insights into biological 
function in health and disease.  
In addition to providing insights into mechanisms driving disease, basic research 
bestows new technologies that catapult our understanding of biology. Undoubtedly, one 
of the latest advancements in neuroscience made possible by basic research has been 
optogenetics. Named “Breakthrough of the Decade” by Science in 2010 (News, 2010), 
incorporation of light-activation algal proteins into the mammalian genome has given 
researchers unprecedented spatial and temporal control over individual cell types, 
particularly the motley of inhibitory interneuron subtypes found throughout the brain, 
allowing scientists to probe their individual contribution to neurophysiology, and 
ultimately their effects on behavior. Currently underway, this revolution in neuroscience 
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would not be possible without a basic understanding of light-sensitive microbial opsins, 
as well as the genetics required to obtain their stable expression in the mammalian 
genome. Together, these examples provides insight into how basic research into 
neuroanatomy and neurotransmitter systems, as well as microorganism function, brought 
about our first treatments for AD and PD, and provides tools that revolutionize our 
understanding of the CNS. 
 
Sorting Through the Complexity  
from the Bottom-Up 
Advances in neurological science have reaped invaluable benefits from bottom-up 
mechanistic-driven studies into the fundamentals of nervous system function. However, 
the bottom-up approach faces perhaps the greatest challenge in all of biological science: 
Obtaining an understanding of the pathogenic mechanisms underlying disease. Insight 
into the mechanistic basis of disease continues to reveal increasing complexity perhaps 
best exemplified by AD. There are currently 5.3 millions Americans and 35 million 
people worldwide suffering from AD, with estimates projecting 100 million people will 
have AD by 2050 (Brookmeyer et al., 2007; Alzheimer's, 2015). And yet, the cause of 
sporadic AD, which makes up approximately 99% of cases, remain unknown. Numerous 
pathogenic mechanisms have been implicated in the etiology of AD including Aβ, 
accumulation of tau neurofibrillary tangles, autophagy dysfunction related to 
apolipoprotein E (APOE), hyperexcitability and seizures, oxidative stress and metabolic 
dysfunction, inflammation, neurovascular defects, and others, all of which have all been 
suspected to individually or synergistically contribute to the progressive loss of cognitive 
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function in AD (Huang and Mucke, 2012). Unfortunately, complex pathological 
heterogeneity is not unique to AD: Epilepsy is defined as a family of neurological 
disorders made up of varying pathophysiology that produce unprovoked spontaneous 
recurrent seizures. The causes of epilepsy have been attributed to single or multiple gene 
mutations, as well as environmental factors such as traumatic brain injury, brain tumors, 
stroke, infection, stress, and fevers. All of these events can trigger varying cellular, 
molecular, and network level cascades that contribute to seizures and associated 
comorbidities (Mody, 1998; Pitkanen and Lukasiuk, 2009, 2011; Goldberg and Coulter, 
2013). The need to understand the underlying pathophysiology in AD and epilepsy is 
highlighted by the number of patients without treatment options. For example, 20–30% of 
patients with epilepsy do not have their seizures adequately controlled, despite the 
availability of over 20 FDA-approved ASDs (Sillanpaa and Schmidt, 2006; Brodie et al., 
2012).  Moreover, current treatments for cognitive dysfunction in AD are few in number, 
mechanistically homogenous, only marginally effective (Nygaard, 2013). However, the 
need to study the basic pathophysiology of disease is perhaps best highlighted by results 
from the latest clinical trials in AD, suggesting that targeting Aβ, commonly believed to 
be the primary pathophysiology thought to contribute to cognitive dysfunction in AD, has 
repeatedly failed (although targeting Aβ early in disease progression has shown some 
promise at delaying disease onset) (Loeffler, 2013; Nygaard, 2013). Together, these 
studies suggests that the etiology of AD is much more complex than was originally 
suspected, and the development of urgently needed treatments could be greatly facilitated 
by a mechanistic understanding of the complex pathophysiology in AD and epilepsy.  
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Hyperexcitability as a Therapeutic Target for  
Cognitive Dysfunction 
Our studies into the mechanistic basis of memory deficits in corneal kindled mice 
revealed pathological hyperexcitability in DGCs and synaptic plasticity deficits at 
perforant-path DGC synapses in the absence of overt cell loss. These results fit into a 
much larger body of work reporting neuronal hyperexcitability, synaptic plasticity 
abnormalities, and cognitive impairment in other animal models of epilepsy thought to 
closely parallel findings in humans (Cossart et al., 2001; Hannesson et al., 2001; Sloviter 
et al., 2003; Harvey and Sloviter, 2005; Leung and Shen, 2006; Sloviter et al., 2006; Sun 
et al., 2007; Chauviere et al., 2009; Jinde et al., 2012). Our results differ from these 
models in that they were observed in a noninvasive readily producible model of corneal 
kindling that is not constrained by a laborious electrode implantation surgery and thus 
may have greater amenability for drug discovery and development. Although the causes 
of hyperexcitability and synaptic plasticity deficits in the DG of corneal kindled mice 
remain unknown, it is suspected that the observed attenuation in LTP in the DG may be a 
compensatory response to the over-activation of excitatory networks during kindling, 
which could have saturated the capability for further synaptic potentiation at the 
perforant-DGC synapse via metaplastic changes, as suggested by others (Huang et al., 
1992; McIntyre et al., 2002; Meador, 2007). Regardless of the cause, studies suggest that 
treating seizures and pathological hyperexcitability with antiseizure drugs may not only 
reduce seizures, but may also alleviate cognitive dysfunction. This is not surprising, since 
hyperexcitability, as well as the seizures themselves, can impair cognition (Kleen et al., 
2013; Holmes, 2015, 2016).   
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Treating hyperexcitability to alleviate seizures and cognitive dysfunction in 
epilepsy is perhaps best illustrated by the blockbuster ASD levetiracetam (LEV). LEV 
not only exhibits remarkable efficacy at reducing seizures, but also has a relatively 
benign side effect profile, particularly with respect to its effects on cognition. 
Remarkably, in a clinical trial, LEV not only reduced seizures in patients with AD, but 
patients also exhibited improved scores during tasks measuring attention and oral fluency 
(Cumbo and Ligori, 2010). Moreover, a neuroimaging study conducted in patients with 
mild cognitive impairment reported that LEV treatment attenuated pathological 
hyperexcitability in the hippocampus and improved patients’ performance during a 
spatial memory test (Bakker et al., 2012). Thus, attenuating the underlying 
hyperexcitability in epilepsy or AD may restore proper cognitive function. Moreover, 
corneal kindled mice may be a novel model to explore the underlying causes of 
hyperexcitability in the absence of overt cell death, and a behavioral model for testing 
whether novel treatments that alleviate hyperexcitability rescue their cognitive 
impairments. However, targeting hyperexcitability to ease cognitive dysfunction is not 
without limitation.   
One drawback to attenuating hyperexcitability for the treatment of seizures and 
cognitive dysfunction mirrors one of the difficulties with implementing disinhibition to 
treat cognitive dysfunction: Dampening neuronal excitability must be done precisely, or it 
can cause cognitive dysfunction, whereas disinhibiting neuronal circuits to improve 
memory must be done precisely to avoid cognitive dysfunction or seizures. These 2 are 
inextricably linked because they both affect the precise excitation-inhibition balance 
governing proper neural function. One example of treatments that imprecisely affect the 
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excitation-inhibition balance and cause cognitive dysfunction comes from ASDs: 
Carbamazepine, phenobarbital, phenytoin, topiramate, and valproate are all highly 
effective treatments for alleviating seizures, but have also been shown to impair memory 
and other aspects of cognitive function in healthy individuals, patients with epilepsy, and 
AD patients. (Meador et al., 1993; Meador et al., 1995; Lee et al., 2003; Meador et al., 
2005; Salinsky et al., 2005; Cumbo and Ligori, 2010). Their beneficial effects on seizures 
and unwanted effects on cognition likely result from dampening excitatory network 
activity as evidenced by mild electroencephalogram (EEG) slowing (Meador et al., 
1993). The reason for LEV’s more benign effects on cognition are not well understood, 
however, LEV is thought to temper presynaptic vesicle release at excitatory synapses 
only during pathologically hyperexcitable conditions with excessive vesicle release, thus 
leaving vesicle release during normal levels of excitatory synaptic transmission 
unperturbed (Meehan et al., 2011). Nevertheless, these studies illustrate that treating 
hyperexcitability is an established pharmacologically targetable treatment option for 
seizures and cognitive dysfunction but must be done with precision to avoid unwanted 
side effects such as cognitive dysfunction itself. Moreover, it also reinforces the idea that 
reverse-engineering the effects of a drug such as LEV may be instructive in guiding 
future therapy development. Finally, these studies highlight the idea that treatments for 
cognitive dysfunction and seizures need not only improve memory or attenuate seizures; 




The Future of Treating Cognitive Dysfunction in Disease:  
All Hope Is Not Lost 
So far, I have highlighted the pros and cons of top-down and bottom-up guided 
approaches to new therapy development. Reverse-engineering existing treatments could 
pave the way to new therapeutic targets and perhaps highlight new network-level 
treatment strategies such as disinhibition to alleviate cognitive dysfunction in disease. On 
the other hand, bottom-up mechanistically driven studies have lead to disease-specific 
treatments in AD, PD, and other devastating neurological disorders and holds great 
promise for the development of disease-modifying therapies. Not only is each of these 
approaches invaluable, but they inform each other, such that a basic understanding of 
CNS function provides a framework for which to understand treatments already shown to 
alleviate disease symptoms, and that framework can be expanded and directed by 
mechanistic insight into existing treatments. In fact, the lines between these 2 strategies 
blur as they approach a final common goal: The development of new and improved 
therapies to treat disease.  
 
Procognitive and Anticonvulsant Targets:  
A Double-Edged Sword 
The results obtained in this dissertation and their overall implications on the 
treatment of cognitive dysfunction in disease present a double-edge sword. Investigation 
of 5-HT6 receptors and other cognition enhancing manipulations of the CNS show that 
disinhibition may yield a rich source of therapeutic targets to treat cognitive dysfunction 
in disease. However, decades of literature suggest that hyperexcitability can cause 
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seizures and cognitive dysfunction, and dampening hyperexcitability may worsen 
cognitive function. These phenomena – disinhibition and hyperexcitability – intersect and 
give rise to the idea that treatments for cognitive dysfunction in disease should be both 
procognitive and anticonvulsant. Remarkably, several procognitive and anticonvulsant 
targets have emerged over the last 2 decades, providing encouragement that treatments 
with these seemingly paradoxical properties exist, and hope that mechanistic insights into 
procognitive and anticonvulsant targets may yield insights into appropriate ways to 
modulate neuronal function for therapeutic benefits in diseases presenting with cognitive 
dysfunction and seizures. 
Given the increasing urgency for therapies that alleviate cognitive dysfunction in 
diseases comorbid with pathological hyperexcitability and seizures, procognitive and 
anticonvulsant targets hold tremendous therapeutic value. Research in Chapters 2 and 3 
of this dissertation focused on 5-HT6 receptor antagonists, which have been shown to 
improve cognitive function in rodents on a variety of tasks, and exhibit anticonvulsant 
effects during acute seizure testing and following pilocarpine treatment in rats. 5-HT6 
receptor antagonists are thought to achieve their procognitive effects via an attenuation of 
inhibitory synaptic transmission, and in accordance with their effects on synaptic 
transmission, results in our study suggest that they may exacerbate seizures depending on 
the species, strain, or type of seizure being tested. Although these results are preliminary 
and need to be confirmed, they are alarming because 5-HT6 receptor antagonists are 
currently being tested in patients with AD and thus may be worsening nonconvulsive 
“silent” seizures or epileptiform activity that easily goes unnoticed. However, results in 
J20 mice suggest that 5-HT6 receptor antagonists do not exacerbate seizures during the 
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minimal clonic seizure test in a model of AD. Nevertheless, further preclinical testing is 
needed to better understand how 5-HT6 receptor antagonists affect different types of 
seizures. Clinical awareness of 5-HT6 receptor antagonist effects on seizures and 
hyperexcitability in patients with AD is needed, as they may be having beneficial, 
negligible, or possibly deleterious effects on seizures.  
Another promising procognitive and anticonvulsant target is the glycine 
transporter (GlyT1). GlyT1 inhibitors have been reported to increase seizure threshold in 
the maximal electroshock test, and suppress seizures following intrahippocampal kainate-
induced epilepsy (Shen et al., 2015). Moreover, GlyT1 inhibitors have been shown to 
improve working memory and rescue performance deficits during the radial arm maze in 
an animal model of schizophrenia (Manahan-Vaughan et al., 2008; Singer et al., 2009). 
Interestingly, GlyT1 inhibitors are thought to have complex effects on synaptic 
transmission, having both excitatory and inhibitory effects via NMDA and glycine 
receptors, respectively. On the strength of the preclinical data, GlyT1 inhibitors have 
been evaluated for their effects on treating extrapyramidal symptoms in patients with 
schizophrenia. Although these studies had mixed results (Umbricht et al., 2014; Singer et 
al., 2015), to my knowledge, the effects of GlyT1 inhibitors on seizures and cognition in 
patients with epilepsy and AD have not been evaluated. In light of the preclinical 
demonstration of their procognitive and anticonvulsant effects, future studies should 
comprehensively test GlyT1 inhibitors for their procognitive and anticonvulsant effects in 
rodents, and attempt to reverse-engineer GlyT1 inhibitors’ effects on CNS function to 
better understand their effects on seizures and cognition. 
The histamine H3 receptor (H3R) is another target with procognitive and 
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anticonvulsant potential. Histamine is an endogenous anticonvulsant produced in the 
brain, and the H3R receptor subtype is an autoreceptor that limits histamine release 
(Yokoyama et al., 1992; Brown et al., 2001). Despite the idea that histamine has 
endogenously inhibitory effects on neural circuits, blocking its release via H3R receptor 
antagonists exhibits anticonvulsant activity in rats during the maximal electroshock test 
(Sadek et al., 2016). Moreover, the H3R antagonist Pitolisant exhibited anticonvulsant 
activity in an early Phase II study in humans with photosensitive epilepsy by attenuating 
photoparoxysmal response monitored via EEG (Kasteleijn-Nolst Trenite et al., 2013). 
These results warrant larger Phase II clinical studies evaluating the effects of H3R 
antagonists on seizures. In addition to their preclinical and clinical anticonvulsant effects, 
treatment with an H3R antagonist or inverse agonist have been shown to improve 
memory consolidation, retrieval, and retention during a 1-trial inhibitory avoidance task 
in healthy and scopolamine-treated rodents (Charlier et al., 2013; Sadek et al., 2016). 
Interestingly, H3R antagonists are thought to increase levels of acetylcholine, just like 5-
HT6 receptor antagonists, but differ in that they have been shown to increase the release 
of GABA, whereas 5-HT6 receptors antagonists are thought to decrease the release of 
GABA (Yamamoto et al., 1997; Haas et al., 2008). Thus, future studies that disentangle 
the complex effects of histamine and H3R blockade on brain function could provide novel 
insights into regulating neural circuits for procognitive and anticonvulsant effects that 
differ from 5-HT6 receptors. 
Together, these 3 targets, 5-HT6, GlyT1, and H3R validate that procognitive and 
anticonvulsant treatment targets exist, are pharmacologically targetable, and may achieve 
similar therapeutic endpoints via differing effects on synaptic transmission. Moreover, 
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reverse-engineering their effects on brain function may elucidate the mechanisms by 
which these targets achieve their procognitive and anticonvulsant effects, and potentially 
highlight new therapeutic approaches or targets to effectively and simultaneously treat 
cognitive function and seizures in disease. 
 
A Polytherapeutic Approach to Treating  
Cognitive Dysfunction in Disease 
Given the complex underlying etiology of cognitive dysfunction in AD, it is 
unlikely that any one drug therapy or “magic bullet” is going to prevent and / or rescue 
cognitive dysfunction in AD. Rather, it is likely that a polytherapeutic approach will need 
to be employed. Classically defined by the accumulation of Aβ plaques, AD is now 
thought to arise from a much more complex and diverse set of pathophysiological 
mechanisms that is not well understood (Huang and Mucke, 2012; Nygaard, 2013). The 
multifactorial pathophysiology underlying AD is further highlighted by mixed, but 
mostly failed, results of clinical trials targeting Aβ (Yang and Xiao, 2015; Sevigny et al., 
2016), as well as studies showing that cognitive dysfunction can be rescued in animal 
models and patients with AD by treating hyperexcitability without reducing the 
pathological accumulation of Aβ (Cumbo and Ligori, 2010; Bakker et al., 2012; Sanchez 
et al., 2012). Although treatments targeting Aβ may still be effective and necessary to 
halt disease progression, successful treatment of AD will likely require early 
identification of individuals who will develop AD long before symptoms have arisen, a 
polytherapeutic approach to prevent one or several of the underlying pathologies from 
progressing, and symptomatic treatment with cognition enhancing drugs.  
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Putting Neurons Back: Are Stem Cells the Future of  
Treating Cognitive Dysfunction in  
Neurodegenerative Disorders? 
Until treatments preventing cell loss and destruction in AD become available, the 
latest hope on the horizon for neurodegenerative disorders is stem-cell therapy. Although 
still in its infancy, major breakthroughs in the last decade have established the possibility 
of stem-cell therapy for replacing cells lost in disease. For instance, bilateral implantation 
of GABAergic progenitor cells in the hippocampi of mice with pilocarpine-induced 
epilepsy produced complete remediation of spontaneous seizures and memory 
dysfunction during Morris water maze and novel object recognition tasks (Hunt et al., 
2013). Moreover, stem cell therapy has been shown to rescue cognitive function during 
working memory and novel place recognition tasks in 2 rodent models of AD (Wang et 
al., 2006; Yamasaki et al., 2007). Additionally, the possibility of treating patients with 
stem cell therapy recently overcame a major hurdle, as reprograming of patient-derived 
somatic stem cells may circumvent immune rejection (Tincer et al., 2016). Moreover, 
these advances may facilitate personalized medicine by using patient-derived cells for 
preclinical drug screening, and also guide patient selection for clinical trials targeting a 
particular AD-related pathophysiology (Israel et al., 2012). Although the translation of 
stem cells into patient therapies is still greatly hampered by the threat of tumor 
generation, stem cell therapy holds great promise for the treatment of intractable 
neurological disorders, particularly those accompanied by overt cell loss (Dantuma et al., 
2010). Additionally, the possibility of stem cell therapy and personalized medicine 
provide an excellent example of how basic research – in this case, programming and 
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reprogramming progenitors cells – can lead to the development of new therapies and 
potentially revolutionize how we treat disease.  
 
Cognitive Enhancement in Healthy Individuals:  
Social and Ethical Implications 
There is clearly a need to develop therapies to alleviate memory deficits in 
disease. However, the development of procognitive therapies such as amphetamine and 
methylphenidate has already led to their availability and use in healthy individuals as 
cognitive enhancers. Their use outside of disease would be expected to increase with the 
development of new cognition enhancing drugs, which has a number of implications and 
limitations. For instance, improving cognitive function in healthy individuals could have 
numerous societal benefits: Scientists, clinicians, engineers, mathematicians, military and 
other safety personnel, as well as construction and transportation workers, could all 
potentially achieve greater productivity and safety aided by cognitive enhancement. 
However, these benefits are not without constraint. Ethical considerations need to be 
taken, as limited availability of cognitive enhancement to those who can and cannot 
afford them may create a socioeconomic divide (Mehlman, 2004). Moreover, the long-
term effects of cognitive enhancement need to be evaluated before individuals begin their 
long-term use, as these compounds could have deleterious health effects. Nevertheless, 
researchers are in hot pursuit of cognition enhancing compounds and it is likely that new 




Future Directions and Closing Remarks  
 Future studies attempting to better understand how 5-HT6 receptors affect brain 
function could conduct a similar set of experiments performed in Chapter 2 in brain slices 
prepared from animals expressing genetically encoded calcium indicators. This would 
allow changes in neuronal excitability to be visualized and quantified in several mossy 
cells simultaneously without having to directly and individually record from them. 
Additionally, ongoing experiments are testing the hypothesis that mossy cells mediate the 
observed effects of 5-HT6 receptor ligands on inhibitory synaptic transmission by 
repeating experiments performed in Chapter 2 in the presence of drugs that block 
glutamatergic synaptic transmission. As a follow up to Chapters 3 and 4, the effects of 5-
HT6 receptor antagonists on cognitive function and seizures should be comprehensively 
tested in multiple models of epilepsy, such as kainate- or pilocarpine-induced epilepsy, or 
perhaps in corneal kindled C57BL/6 mice. It would also be interesting to test the effects 
of 5-HT6 receptor antagonists on cognitive function in combination with other ASDs 
shown to have more favorable effects on cognition such as LEV. Beneficial effects 
observed during combinatorial drug studies with LEV would facilitate the advancement 
of 5-HT6 receptor antagonists into clinical trials for treating cognitive dysfunction in 
epilepsy and encourage future efforts to better understand how 5-HT6 receptors affect 
brain function. Lastly, future studies should further evaluate the procognitive and 
anticonvulsant properties of GlyT1 inhibitors and H3R inverse agonists in models of 
epilepsy and AD, either alone, or in combination with other ASDs. 
In summary, studies attempting to reverse-engineer existing treatments or 
elucidate the mechanistic basis of disease have advanced our understanding and treatment 
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of cognitive dysfunction in disease. Neither of these approaches should be neglected nor 
favored; rather, both should be implemented simultaneously to maximize benefit. Results 
from the present studies suggest targeting disinhibition and hyperexcitability for the 
treatment of memory deficits. However, these broad therapeutic targets overlap and 
highlight the idea that treatments for cognitive dysfunction in disease need to be both 
procognitive and anticonvulsant. A number of receptor targets including 5-HT6 receptors, 
H3R, and GlyT1 suggest pharmacologically targetable procognitive and anticonvulsant 
treatments exist, and future studies untangling their complex effects on brain function 
could provide insights that facilitate the development of additional procognitive and 
anticonvulsant therapies. Lastly, symptomatic treatments for memory impairments will 
likely be part of a larger polytherapeutic armamentarium that also targets the underlying 
pathophysiology to slow or halt disease progression, and possibly reverse disease 
symptoms via stem-cell therapy. Together, both top-down and bottom-up guided 
approaches hold great promise in directing new therapy development for the treatment of 
memory deficits in disease. 
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DETECTING THE EFFECTS OF INHIBITORY SYNAPTIC  
TRANSMISSION ON LONG-TERM POTENTIATION  
IN THE DENTATE GYRUS IN VITRO 
 
Abstract 
The goal of this study was to test the effects of a 5-HT6 receptor antagonist on 
theta-burst stimulation- (TBS) induced long-term potentiation (LTP) in the dentate gyrus 
(DG) in brain slices prepared from a transgenic mouse model of Alzheimer’s disease 
(AD). Inducing robust LTP in the DG in vitro using theta-burst stimulation (TBS) 
requires bath application of drugs that block inhibitory synaptic transmission but 
precludes experimentation with the effects of inhibition on LTP. This was particularly 
problematic since 5-HT6 receptors were shown to bidirectionally modulate inhibition in 
the DG in Chapter 2, and J20 mice, a transgenic model of AD, exhibit pathologically 
increased inhibition in the DG. To circumvent complete blockade of inhibition, we 
established a reliable TBS LTP induction paradigm in the presence of 50 µM picrotoxin 
(PTX) (2 trains of 4 pulses at 100 Hz separated by 200 ms, repeated 5 times with a 20 s 
interval). Next, a concentration-response study with PTX revealed an EC50 of 4 µM. We 
then found that the GABAA receptor agonist diazepam (50 µM) attenuated LTP in 4 µM 
PTX, suggesting these conditions are sensitive to increased inhibition. Next, we tested the 
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5-HT6 receptor antagonist SB-399885 (1 µM) in slices prepared from J20 mice and their 
nontransgenic (NTG) littermates: LTP in J20 and NTG littermates did not differ, and SB-
399885 had no effect on LTP in either genotype. At this time, the 4-channel Slicemaster 
was updated to an 8-channel Slicemaster, and our TBS LTP induction paradigm was no 
longer attenuated by 50 µM DZP. We tested several LTP induction paradigms, none of 
which were sensitive to DZP. Lastly, we retested our initial TBS LTP induction paradigm 
in the presence of 4 and 50 µM PTX in J20 mice: LTP in J20 mice was not altered in 
either condition, although results in 50 µM PTX may have been underpowered. 
Nevertheless, establishing an in vitro TBS LTP induction paradigm in the DG that is 
sensitive to increased inhibition is possible and may be useful for detecting the effects of 
drugs that regulate LTP in the DG via inhibitory synaptic transmission. 
 
Introduction 
The first goal of this study was to establish an in vitro theta-burst stimulation 
(TBS) long-term potentiation (LTP) induction paradigm that reliably produced LTP in 
the dentate gyrus (DG). We also wanted a reliable a TBS LTP induction paradigm that is 
sensitive to changes in GABAergic synaptic transmission. These objectives stem from 
our ultimate goal of this research, which was to test the effects of a 5-HT6 receptor 
antagonist on LTP in a transgenic model of Alzheimer’s disease (AD) that exhibits  
GABAergic remodeling in the DG. These data were intended to support other studies 
conducted in this dissertation, particularly our evaluation of 5-HT6 receptor antagonists in 
J20 mice during a DG-associated spatial pattern processing paradigm, the metric task, in 
Chapter 3.  
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Prior to the experiments in this Appendix, we published a study testing the effects 
of the anticonvulsant drugs on LTP in the DG (West et al., 2014). Using a TBS paradigm 
that is routinely used by our lab to induce LTP in hippocampal area CA1, we found that 
the anticonvulsant valproic acid (VPA) attenuated LTP in the DG. However, the CA1 
TBS LTP induction paradigm did not reliably produce LTP when adopted for use in the 
DG and thus, required testing in many brain slices to complete the experiment for 
publication. Therefore, we wanted to establish a TBS-LTP induction paradigm that more 
reliably produced LTP at perforant-path DG granule cell (DGC) synapses.  
Besides reliability, we also wanted a DG TBS LTP induction paradigm sensitive 
to alterations in GABAergic synaptic transmission, which presents an experimental 
conundrum. LTP at perforant path-DGC synapses can be produced in vitro using high-
frequency stimulation (HFS) or TBS. However, HFS-induced LTP at perforant path DG 
synapses lacks sensitivity to inhibitory synaptic transmission (Chapman et al., 1998; 
Arima-Yoshida et al., 2011), and is considered a nonphysiological LTP induction 
paradigm (Albensi et al., 2007). On the other hand, TBS is considered a physiologically 
relevant induction paradigm because it mimics hippocampal theta rhythm thought to be 
necessary for memory formation (Winson, 1978; Gupta et al., 2012). However, inducing 
LTP at the perforant-path DGC synapse in vitro using TBS requires bath application of 
drugs that block GABAA receptors (GABAAR)(Arima-Yoshida et al., 2011). Therefore, 
most in vitro studies conducting TBS LTP in the DG bath perfuse brain slices with 
saturating concentrations of GABAAR antagonists picrotoxin (PTX) or bicuculline which 
limits experimentation with the effects of inhibitory synaptic transmission on LTP 
(Arima-Yoshida et al., 2011). Therefore, we wanted to develop a TBS LTP induction 
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paradigm that produced robust LTP at perforant-path DGC synapses but also allows 
experimentation with the effects of inhibitory synaptic transmission on LTP and detection 
of pathological alterations in LTP that may be due to changes in inhibition. 
Detecting the effects of GABAergic synaptic transmission on TBS-induced LTP 
is particularly relevant to our investigation of serotonin (5-HT) 5-HT6 receptor 
antagonists and a transgenic mouse model of AD. 5-HT6 receptor antagonists are a class 
of nootropic drugs thought to exert their procognitive effects primarily via a reduction to 
inhibitory synaptic transmission that indirectly facilities excitatory synaptic transmission 
(Woolley et al., 2004). In addition to testing the effects of 5-HT6 receptor ligands in the 
DG physiology and function (Chapters 2 and 3 of this dissertation, respectively), we also 
wanted to test their effects on LTP in a transgenic animal model of AD known. J20 mice 
express human amyloid precursor protein (hAPP) harboring Swedish and Indiana 
mutations (Mucke et al., 2000) and at 3- to 5-months-of-age develop memory deficits, 
spontaneous seizures, and enhanced GABAergic synaptic transmission onto DGCs (Palop 
et al., 2007). Additionally, J20 mice also exhibit attenuated LTP at perforant path-DGC 
synapses compared to their (NTG littermates when tested with TBS in the presence of 
saturating concentration of GABAAR antagonists, precluding an understanding of the 
effects of GABAergic remodeling on LTP in the DG of J20 mice. Thus, our assay needed 
to be sensitive to increased GABA to determine whether J20 mice exhibited LTP 
impairments and whether 5-HT6 receptor antagonists affected this process.  
To circumvent the use of saturating concentrations of a GABAAR antagonist 
during TBS LTP in the DG, we established a reliable TBS stimulation paradigm at 
perforant-path DGC synapses in saturating concentrations of PTX in acute hippocampal 
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brain slices. Next, we determined the EC50 for PTX’s effects on LTP in the DG, and 
hypothesized that bath application of PTX at the EC50 would block enough GABAARs to 
facilitate TBS-induced LTP in the DG, but leave enough GABAARs available to detect 
the additional effects of increased GABAergic synaptic transmission on LTP. Upon 
confirmation that our TBS LTP induction paradigm was sensitive to diazepam (DZP), a 
GABAAR allosteric agonist, we subsequently tested the effects of a 5-HT6 receptor 
antagonist on LTP in acute hippocampal brain slices prepared from J20 mice and their 




Five- to six-week-old male C57BL/6 mice (15–20 g, Charles River, Raleigh, NC, 
U.S.A.) were used for in vitro LTP. We also used 4- to 6-month-old (20–25 g) male 
heterozygous transgenic hAPPJ20 mice expressing human amyloid precursor protein 
(hAPP) with the Swedish and Indiana FAD mutations, and their nontransgenic (NTG) 
wild-type littermates (Jackson Laboratory, Mutant Mouse Regional Research Center) 
(Mucke et al., 2000). All mice were group housed in a light- and temperature-controlled 
(12 h on / 12 h off) environment and permitted access to food and water ad libitum 
throughout the study. All experiments were conducted in accordance with the National 
Institute of Health Guide for the Care and Use of Laboratory Animals and approved by 
the University of Utah Institutional Animal Care and Use Committee. All efforts were 




Hippocampal Brain Slice Preparation 
Acute hippocampal brain slices were prepared daily as described previously 
(West et al., 2014). Briefly, mice (20–25 g) were anesthetized with sodium pentobarbital 
(60 mg/kg, i.p.), and brains were rapidly removed and submerged in ice-cold (4°C) 
oxygenated sucrose-based artificial cerebral spinal fluid (ACSF) bubbled with 95% 
O2/5% CO2. Sucrose-based ACSF contained the following (in mM): Sucrose (200.0), 
KCl (3.0), Na2PO4 (1.4), MgSO4 (3.0), NaHCO3 (26.0), glucose (10.0), and CaCl2 
(0.5). The pH and osmolarity of the sucrose-based ACSF were adjusted to 7.30–7.35 and 
290–300 mOsm, respectively, before each experiment. Next, coronal brain slices 
(350µm) containing dorsal hippocampus were cut using a vibrating microtome 
(VT1000S, Leica Microsystems Inc.). Slices were then transferred to oxygenated 
standard ACSF and incubated for 2 h at room temperature prior to recording. Standard 
ACSF was made from the same recipe as sucrose-based ACSF, only sucrose was 
replaced with NaCl (126.0 mM), the MgSO4 concentration lowered to 1.0 mM, and the 
CaCl2 concentration raised to 2.5 mM. In experiments with J20 and NTG mice, 1 mM 
ascorbic acid was added to the recipe for standard ACSF to prevent breakdown of 5-HT. 
 
Long-Term Potentiation of Excitatory Synaptic Transmission 
These experiments were conducted over the course of several years and the 
electrophysiology rig used in this study was updated midway through. The first set of 
experiments were conducted on a 4-channel Scientifica Slicemaster (Scientifica, Ukfield, 
East Sussex, U.K.), a high throughput semiautomatic brain slice recording system that 
conducts separate simultaneous recordings (Stopps et al., 2004). The 4-channel 
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Slicemaster was then upgraded to an 8-channel Scientifica Slicemaster. The major 
differences between the 2 recording setups, aside from simultaneously recording from 4 
or 8 brain slices, are that the 4-channel Slicemaster acquired data using a pClamp 10 
interfaced to a Digidata 1440A data acquisition board (Molecular Devices, Sunnyvale, 
CA, U.S.A.) whereas the 8-channel Slicemaster was interfaced to a Digidata 1550A data 
acquisition board. Additionally, the 4-channel used concentric bipolar stimulating 
electrodes (MCE-100; Rhodes Medical Instrument, Summerland, CA, U.S.A.), whereas 
the 8-channel Slicemaster used a Twisted Nichrome-Formvar stimulating electrodes. 
Additionally, because all stimulation strengths needed to be manually dialed-in on the 8-
channel Slicemaster, adjustments of stimulation strength during TBS to strengths other 
than 50% on the I/O curve were substituted by increasing the pulse duration from 100 µs 
to 200 µs. Table A.1 indicates all TBS paradigms tested in this manuscript according to 
the 4- or 8-channel Slicemaster. Otherwise, all experiments were conducted as detailed 
below. 
Extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded by 
transferring coronal brain slices containing dorsal hippocampus from either hemisphere 
into the integrated brain slice chambers (IBSCs) of the Scientifica Slicemaster. All slices 
were perfused with regular ACSF (2 mL/min) at 30°C. In most LTP experiments, ACSF 
contained PTX for the duration of the entire experiments, the concentrations of which are 
indicated in the text and figure captions. In experiments testing the effects of 5-HT6 
receptor antagonists, ACSF contained serotonin (5-HT HCl) and the selective serotonin 
reuptake inhibitor (SSRI) fluoxetine HCl for the duration of the experiment to promote 
availability of 5-HT during studies testing the effects of 5-HT6 receptor antagonists. The 
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presence and concentrations of all drugs are indicated in the text and figure captions. 
Stimulating electrodes were placed in the middle-third of the molecular layer in the upper 
blade of the DG to stimulate the medial perforant path; recording electrodes were placed 
in the middle-third of the molecular layer approximately 400–600 µm away from the 
stimulating electrode. Input/output (I/O) relationships were measured by incrementally 
stimulating for 100 µs in 0.5 V steps until a population spike was observed or 20 V 
maximum stimulus intensity was reached. Data were acquired using pClamp 10 
interfaced to a Digidata 1440A or 1550A data acquisition board (4-channel and 8-
channel, respectively) (Molecular Devices, Sunnyvale, CA, U.S.A.) at a sampling rate of 
10 kHz, low-pass filtered at 1 kHz, and high-pass filtered at 3 Hz. The magnitude of the 
fEPSP was determined by measuring the 20–80% slope of the rising phase. 
After obtaining fEPSPs and conducting I/O curves, baseline stimulation strength 
was set to 50% and slices received 1 stimulation pulse every 30 s for 30 min. Drugs were 
applied via bath exchange for 20 min prior to the LTP induction stimulus. LTP was 
induced via TBS or HFS. The LTP induction parameters varied and are indicated in 
Table A.1 as well as the figure captions using the following nomenclature: number of 
pulses X number of trains X number of bursts. Pulse duration was either 100 or 200 µs; 
intra-train frequency was always 100 Hz; intertrain frequency was 5 Hz for all TBS 
stimulations paradigms; interburst interval for TBS was always 20 s, and 10 or 60 s for 
HFS. All fEPSPs were normalized to the average slope of the last 4 fEPSPs prior to TBS 
and are represented as the mean ± standard error of the mean (SEM). fEPSP amplitudes 




Chemicals and Drugs 
 Unless indicated otherwise, all chemicals and drugs were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Stock solutions of SB-399885 (Tocris Bioscience, 
Minneapolis, MN, U.S.A.) DZP, 5-HT, fluoxetine were dissolved in ddH2O. PTX was 
dissolved in DMSO. All drugs were made into stock solutions ≥ 1000-fold their final 
concentrations and stored at -20°C. On the day of the experiment, individual aliquots 
were defrosted and dissolved in ACSF to the concentration indicated in each figure.  
 
Statistics 
Statistical comparisons were made by comparing the mean normalized slope of 
each condition over the last 30 min of recording using a two-way analysis of variance 
(ANOVA) with repeated measures. When drawing comparisons across 4 groups, ACSF- 
and SB-399885-treated slices from J20 and NTG mice, a two-way ANOVA with 
Bonferroni’s multiple comparisons was used to compare that mean normalized slope of 
the last 5 fEPSPs. Post-tetanic potentiation (PTP) time constants (tau) were also 
measured; these were represented as best-fit values (95% confidence interval [CI]) from 
one-phase exponential decay regression functions. The EC50 for PTX’s effects on LTP 
were determined by fitting a nonlinear regression to the PTX concentration-response 
LTP, composed of the mean normalized slope of the last 5 fEPSPs for each PTX 
concentration tested. All N values are presented as the number of slices tested / from the 
number of animals slices were prepared from. *, **, or *** indicate a p-value of < 0.05, 





4x2x5 at 70% in 50 µM PTX Is a Reliable  
TBS LTP Induction Paradigm 
First, we wanted to determine a reliable TBS LTP induction stimulus at perforant 
path-DGC synapses in the presence of 50 µM PTX. We attempted a variety of 
stimulation parameters that varied by train and burst number, all of which are detailed in 
Table A.1. One of the first TBS paradigms that produced reliable LTP was 4x2x5 
adjusted to 70% of the stimulation strength needed to produce a population spike, as 
determined from I/O relationships. We also tested the dependency of our paradigm on 
adjusting the stimulation strength by comparing slices stimulated at 70% (n = 10 / 2) it 
with LTP produced from 4x2x5 at 50% (n = 6 / 1) (Figure A.1). Two-way repeated 
measures ANOVA comparing the last 30 min revealed a significant effect of stimulation 
strength (F(1, 826) = 6.15; p < 0.05) and interaction between stimulation strength and time 
(F(59, 826) = 1.85; p < 0.001). Stimulation strength also significantly affected the PTP 
decay constant (Stimulation Strength: 70% tau: 23.0 (95% CI 14.6–54.5); 50% tau: 7.2 
(95% CI 4.8–14.3), p < 0.05, nonlinear regression). These results suggest that our 
stimulation paradigm, 4x2x5, produces robust LTP when the stimulation strength is set to 
70% on the I/O curve. All experiments conducted on the 4-channel Slicemaster 







The EC50 for PTX’s Effects on the TBS LTP Induction  
Paradigm 4x2x5 at 70% Is 4 µM 
Next, we conducted a concentration-response for the effects of PTX on LTP using 
our TBS-LTP induction stimulus 4x2x5 at 70%. Time course LTP and the concentration-
response curve for the effects of 0, 1, 3, 10, 30, and 100 µM PTX on TBS-LTP are 
plotted in Figure A.2. Nonlinear regression of PTX’s concentration-response on LTP 
revealed an EC50 of 3.8 µM PTX. Future studies rounded the EC50 for PTX up to 4 µM. 
 
The TBS LTP Induction Paradigm 4x2x5 at 70% in  
4 µM PTX Is Sensitive to DZP 
Next, we tested whether the TBS LTP induction paradigm 4x2x5 at 70% in the 
presence of 4 µM PTX was sensitive to increased GABAergic synaptic transmission by 
bath perfusing 50 µM DZP for 20 min before prior to TBS (Figure A.3). Two-way 
ANOVA with repeated measures revealed DZP-treated slices (n = 12 / 3) exhibited 
significantly attenuated LTP compared to ACSF-treated slices (n = 10 / 3) with 
significant effects for drug, time, and interaction (Drug: F(1, 1200) = 4.75, p < 0.05; Time: 
F(60, 1200) = 12.70; p < 0.001; Interaction: F(60, 1200) = 2.76; p < 0.001). Moreover, nonlinear 
regression showed that DZP significantly reduced the PTP decay constant (Control tau: 
22.6 (95% CI 9.9–15.8) and DZP tau: 12.1 (95% CI 16.2–37.3), p < 0.05). Together, 
these results suggest that the TBS LTP induction paradigm 4x2x5 at 70% stimulation 
strength in the presence of 4 µM PTX is sensitive to pharmacologically increased 




LTP in J20 and NTG Mice Did Not Differ and Was  
Unaffected by SB-399885 
Once we established a TBS LTP induction paradigm sensitive to 
pharmacologically increased inhibitory synaptic transmission, we tested the effects of the 
5-HT6 receptor antagonist SB-399885 (1 µM) on LTP at perforant-path DGC synapses in 
acute hippocampal brain slices prepared from a transgenic animal model of AD, J20 
mice, and their NTG littermates (Figure A.4). To increase extracellular concentrations of 
5-HT, these experiments were conducted in the presence of 4 µM PTX, as well as 1 µM 
5-HT and 10 µM fluoxetine. Two-way ANOVA with repeated measures revealed no 
significant effects in J20 or NTG mice (Figure A.4A) Additionally, two-way ANOVA 
comparing the mean normalized slope of the last 5 fEPSPs across the 4 treatment groups 
revealed no significant effects. Thus, J20 and NTG mice did not exhibit significant 
differences in LTP, and SB-399885 had no effect on LTP in either group. 
 
4x2x5 at 70% Is No Longer Sensitive to DZP on the 
8-Channel Slicemaster 
At this time, the 4-channel Scientifica Slicemaster was updated to the 8-channel 
Slicemaster and we wanted to test whether the TBS LTP induction paradigm 4x2x5 at 
200 µs stimulation duration produced LTP that is sensitive to pharmacologically 
increased GABAAR receptor-mediated inhibition (Figure A.5). Two-way repeated 
measures ANOVA revealed that LTP on the 8-channel Slicemaster was no longer 
sensitive to the effects of 50 µM DZP when tested in the presence of 1, 4, or 10 µM PTX 
(Figure A.5A–C). We did observe a significant decrease in the PTP decay constant in 
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DZP-treated slices at 10 µM PTX (Figure A.5C; Control tau: 15.5 (95% CI 12.4–20.5) 
and DZP tau: 44.0 (95% CI 16.9–∞), p < 0.05, nonlinear regression).  
Since our TBS LTP paradigm was no longer sensitive to pharmacologically 
increased GABAAR-mediated inhibitory synaptic transmission, the effects of DZP on 
LTP were tested in a variety of TBS and HFS stimulation paradigms; see Table A.1 for 
details. Two-way repeated measures ANOVA revealed none of these paradigms 
produced LTP that was significantly attenuated by DZP. Thus, we were unable to 
establish a TBS or HFS LTP stimulation paradigm on the 8-channel Slicemaster that was 
sensitive to pharmacologically increased GABAergic synaptic transmission. 
 
LTP in J20 and NTG Mice Did Not Differ When Tested  
in the Presence of 4 or 50 µM PTX  
Despite the inability to implement an LTP stimulation paradigm on the updated 8-
channel Slicemaster that was sensitive to increased GABAergic synaptic transmission, 
we tested the TBS LTP paradigm 4x2x5 at 200 µs LTP in the presence of 4 and 50 µM 
PTX in slices from J20 and NTG mice (Figure A.6). Two-way ANOVA with repeated 
measures revealed no significant effects at either 4 or 50 µM PTX. PTP comparison using 
nonlinear regression revealed no significant differences in the decay constants, and an 
unpaired Student’s t test comparing the mean normalized slope in the first 2 min 
following TBS showed no PTP differences between NTG and J20 mice in 4 or 50 µM 
PTX. These results suggest that J20 mice do not have significant LTP deficits at 
perforant-path DGC synapses in the absence of GABAergic synaptic transmission, or 




 This study tested a variety of TBS and HFS LTP induction paradigms at perforant 
path-DGC synapses in acute hippocampal brain slices on 2 separate electrophysiology 
rigs. On the 4-channel Slicemaster, the TBS LTP induction paradigm 4x2x5 at 70% 
stimulation strength produced reliable LTP at perforant path-DGC synapses in the 
presence of 50 µM PTX. Next, we determined that the EC50 for PTX’s effect on LTP 
using our TBS paradigm was 4 µM, and that these conditions were sensitive to increased 
GABAAR receptor-mediated inhibition via 50 µM DZP. Experiments in slices from J20 
and NTG mice suggested they do not have differences in LTP in the presence of 4 µM 
PTX, and the 5-HT6 receptor antagonist SB-399885 had no effect on LTP in either 
genotype. On our 8-channel Slicemaster, none of the TBS or HFS LTP induction 
paradigms tested were attenuated by DZP. We did, however, retest the effects of our 
initial TBS LTP induction paradigm 4x2x5 at 200 µs stimulation duration in slices from 
J20 and NTG mice. Again, we observed no significant differences in LTP between J20 
and NTG mice in either 4 or 50 µM PTX. Together, these results suggest it is possible to 
reliably produce TBS-induced LTP at perforant-path DGC synapses that is sensitive to 
increased GABAAR-mediated inhibitory synaptic transmission. Furthermore, this assay 
may be useful for determining the effects of drugs or disease states that affect LTP via 
GABAergic mechanisms. 
 Rationale for these experiments is rooted in the idea that changes in LTP 
associated with a drug or disease state may be predictive of their effects on learning and 
memory. For instance, a number of drugs or genetic manipulations that improve memory 
also increase or restore pathologically attenuated LTP (Lee and Silva, 2009; Lynch and 
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Gall, 2013; Lynch et al., 2014). Moreover, ASDs such as carbamazepine, phenobarbital, 
phenytoin, and valproate have all been shown to impair memory, as well as attenuate 
hippocampal LTP in vitro (Meador et al., 1993; Meador et al., 1995; Lee et al., 2003; 
Meador et al., 2005; Salinsky et al., 2005; West et al., 2014). Interestingly, the 
anticonvulsant LEV, which has a more benign cognitive profile, did not impair 
hippocampal LTP (West et al., 2014). Lastly, many neurological disorders that present 
with memory deficits also exhibit abnormalities in LTP, in tissue from both patients and 
animals models of disease (Beck et al., 2000; Palop et al., 2007; Kleschevnikov et al., 
2012). Although not without exception, these studies support the idea that drug- or 
disease state-induced alterations in LTP can be predictive of their beneficial or 
deleterious effects on learning and memory.  
The present study developed a screening assay to test the effects of drugs and 
disease states that affect LTP at perforant-path DGC synapses via GABAergic 
mechanisms, which was successful in the presence of DZP. Inhibitory synaptic 
transmission plays a critical role in the fine-tuning of synaptic transmission required for 
synaptic plasticity and memory formation (Letzkus et al., 2015), and drugs and disease 
states, as well as genetic and optogenetic manipulations that impact GABAergic synaptic 
transmission can also affect learning and memory (Palop et al., 2007; Cui et al., 2008; 
Braudeau et al., 2011; Andrews-Zwilling et al., 2012; Kleschevnikov et al., 2012; Verret 
et al., 2012). Thus, developing a physiologically relevant TBS LTP paradigm sensitive to 
changes in inhibition may be useful in the discovery of nootropic drugs that improve 
learning and memory via their effects on inhibitory synaptic transmission, as well as 
drugs that may adversely impact cognition. However, detecting the effects of inhibitory 
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synaptic transmission on LTP in vitro, and thus its use in drug development, is hampered 
in the DG when using a physiologically relevant LTP induction paradigm such as TBS. 
Our study circumvented this limitation by testing our TBS paradigm at PTX’s EC50 and 
revealing its sensitivity to increased GABAergic synaptic transmission with the positive-
allosteric GABAAR modulator DZP. 
Despite the use of a TBS LTP induction paradigm sensitive to DZP, we did not 
detect any differences in LTP between J20 mice and their NTG littermates when 
GABAergic synaptic transmission is presumably only partially blocked by 4 µM PTX. 
Interestingly, these results conflict with results reported by Palop et al. (2007), illustrating 
that J20 mice exhibit attenuated TBS-induced LTP at perforant path-DGC synapses when 
GABAergic synaptic transmission was completely blocked. We hypothesized that slices 
from J20 mice would exhibit attenuated LTP in the presence of 4 µM PTX since J20 mice 
exhibit increased inhibitory synaptic transmission onto DGCs (Palop et al., 2007), and 
increases in inhibitory synaptic transmission are thought to attenuate LTP. One 
interpretation of our results is that enhanced GABAergic synaptic transmission in J20 
mice may correct LTP deficits reported in the absence of inhibitory synaptic 
transmission. Although our study did not detect a significant difference in LTP in J20 
mice when inhibitory synaptic transmission was completely blocked (Figure A.6B), we 
may have been able to replicate the finding by Palop et al. (2007) had we tested a greater 
number of slices. However, our experiments were limited by the availability of J20 mice. 
Together, these results, combined with Palop et al’s. (2009) findings, suggest that J20 
mice have LTP deficits at perforant-path DGC synapses independent of GABAergic 
synaptic transmission. Thus, testing LTP in J20 mice with a paradigm sensitive to 
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increased GABAergic synaptic transmission may have been useful in obtaining a better 
understanding of the mechanisms underlying LTP deficits in J20 mice. 
In addition to testing our TBS LTP induction paradigm in a mouse model of AD, 
we also tested the effects of the 5-HT6 receptor antagonist SB-399885 on LTP in brain 
slices prepared from J20 mice and their NTG littermates. We hypothesized that SB-
399885 would increase LTP in the DG because of its widely reported nootropic effects in 
naïve, aged, and amnestic rodents in a variety of cognitive tests (Fone, 2008). 
Additionally, drugs that attenuate inhibitory synaptic transmission typically increase LTP 
(Arima-Yoshida et al., 2011), and results from Chapter 2 of this dissertation suggest that 
5-HT6 receptor antagonists dampen inhibitory synaptic transmission in the DG. Lastly, 
West et al. (2009) reported that 5-HT6 receptor activation attenuated LTP at CA3-CA1 
synapses. However, our results showed that SB-399885 had no effect on LTP in slices 
from NTG or J20 mice. One possible explanation for these results could be that 5-HT6 
receptor antagonist effects on LTP in the DG are subtle, and our test was not sensitive 
enough to detect 5-HT6 receptor-mediated changes to LTP in the DG. Another possibility 
is that the EC50 for PTX’s effects in NTG and J20 mice may be left-shifted compared to 
the EC50 in naïve C57BL/6 mice (which the PTX concentration-response was initially 
conducted in) such that 4 µM PTX blocked more than 50% of GABAARs in the DG, 
leaving less GABAARs available to mediate the effects of SB-399885. Although 
additional studies are needed, it is also possible that SB-3998855 does not affect LTP in 
the DG. Future experiments could test whether SB-399885 affects LTP in the DG in 




In regards to the validity of LTP as an assay used to predict performance on 
learning and memory tasks, it is encouraging that our results were trending on detecting 
an attenuation in LTP in the DG of J20 mice when tested in the presence of 50 µM PTX, 
as these results would replicate findings published by Palop et al. (2009). However, it is 
discouraging that we did not observe an effect of SB-399885 on LTP in J20 or NTG 
mice. Results in Chapter 3 of this dissertation show that SB-399885 significantly 
improved the performance of NTG during the metric task, a spatial pattern processing 
paradigm thought to rely on DG function; and yet, we did not detect any effects of SB-
399885 on LTP. Although other factors, including SB-399885’s potential sedative 
effects, may have influenced the performance of NTG mice during the metric task, the 
memory enhancing effects of SB-399885 and other 5-HT6 receptor antagonists are well-
established. Thus, results in the present study were not predictive of the cognitive 
enhancing effects of SB-399885, at least in the DG, and suggest that the conditions of our 
assay may need to be modified to better predict the procognitive effects of drugs.  
Another caveat to the present study is that sensitivity of our LTP induction 
paradigm to DZP was no longer detected on the 8-channel Slicemaster. This could have 
been due to a number of reasons pertaining to the stimulator and stimulating electrodes 
that changed when the 4-channel Slicemaster was updated to the 8-channel Slicemaster. 
However, it is unlikely that the 8-channel Slicemaster is incapable of producing LTP that 
is sensitive to changes in inhibition. Future studies should test a variety of TBS LTP 
induction paradigms and test their sensitivity to changes in GABAergic synaptic 
transmission using DZP, and perhaps additional compounds that affect GABAergic 
synaptic transmission, such as the ASDs gabapentin or tiagabine. Moreover, an important 
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control experiment in the present study would be to test the effects of DZP or other 
GABA-enhancing drugs on LTP in saturating concentrations of PTX to rule out 
nonspecific effects. Additionally, the number of slices and animals tested in the some of 
these paradigms was limited. Future studies should test each TBS paradigm more 
comprehensively using at least 12 slices from 4 animals per condition.  
In conclusion, results in this study suggest it is possible to develop a TBS 
paradigm that produces reliable LTP at perforant path-DGC synapses sensitive to 
pharmacologically increased inhibitory synaptic transmission. Although we were unable 
to reproduce these results on the 8-channel Slicemaster, and we did not observe any LTP 
differences in slices prepared from J20 and NTG mice, as well as 5-HT6 receptor 
antagonist-treated slices, we did validate our TBS LTP paradigm, showing sensitivity to 
the positive allosteric GABAAR agonist DZP. Given the predictive validity of LTP and 
its effects on memory, and the critical role inhibitory synaptic transmission plays in 
memory formation, alterations in LTP resulting from a drug or disease state that exerts its 
effects via inhibitory synaptic transmission may be a predictive biomarker for their 
enhancing or deleterious effects on learning and memory. Coupled with an 8-channel 
recording system such as the Slicemaster, in vitro LTP is suitable to high-throughput drug 
screening that may be a valuable tool in the discovery of novel therapeutics for the 







Figure A.1.  The TBS-LTP induction paradigm 4x2x5 requires the stimulation strength to 
be set at 70% on the I/O curve to achieve LTP. fEPSP slope as a function of time.  fEPSP 
slopes are normalized to the average of the last 4 fEPSP slopes before TBS. Brain slices 
were stimulated at 0 min using the TBS-LTP induction paradigm 4x2x5 with the 
stimulation strength set to either 70% (red, n = 10 slices from 2 animals) or 50% (black, n  
= 6 slices from 1 animal) in the presence of 50 μM PTX. TBS at 70% stimulation 
strength produced LTP that was significantly greater slices that received TBS at 50% 







Figure A.2.  PTX concentration-response reveals an EC50 of 4 µM for its effects on LTP 
in the DG.  A) fEPSP slope as a function of time. Brain slices in the presence of either 0, 
1, 3, 10, 30, or 100 μM PTX were stimulated at 0 min using the TBS-LTP induction 
paradigm 4x2x5 at either 70% (n = number of slices / number of animals). fEPSP slopes 
are normalized to the average of the last 4 fEPSPs before TBS. B) the average normalized 
slope of the last 5 fEPSPs for each concentration of PTX presented as a bar graph. C) 
Concentration-response curve for the last 5 fEPSPs. Nonlinear regression revealed an 





Figure A.3.  LTP induced using the TBS paradigm 4x2x5 at 70% in 4 μM PTX is 
attenuated by DZP. fEPSP slopes are normalized to the average of the last 4 fEPSPs 
before TBS. Brain slices in the presence of 4 μM PTX were stimulated at 0 min using the 
TBS-LTP induction paradigm 4x2x5 at either 70% were exposed to 50 μM DZP (red, n = 
12 slices from 3 animals) or regular ACSF (black, n  = 10 slices from 3 animals) for 20 
min before TBS (blue bar). Slices exposed to 50 μM DZP exhibited significantly 
attenuated LTP compared to slices exposed to regular ACSF (* p < 0.05, two-way 
repeated measures ANOVA of last 30 min). Additionally, DZP significantly reduced the 
PTP decay constant (Control tau: 22.6 (95% CI 16.2–37.3) and DZP tau: 12.1 (95% CI 






Figure A.4.  J20 and NTG mice exhibit similar LTP in the DG that is unaffected by SB-
399885. A) fEPSP slope as a function of time. Brain slices from NTG mice were 
stimulated at 0 min using the TBS-LTP induction paradigm 4x2x5 at 70% in the presence 
of 4 µM PTX, 1 µM 5-HT, and 10 µM fluoxetine.  For 20 min prior to TBS (black bar), 
slices were exposed to 1 µM SB-399885 (red, n = 13 slices from 4 animals) or regular 
ACSF (black, n  = 15 slices from 4 animals). fEPSP slopes are normalized to the average 
of the last 4 fEPSPs before TBS. Compared with ACSF-treated slices, 1 µM SB-399885 
had no effect on LTP in NTG mice (p > 0.05, two-way repeated measures ANOVA of 
last 30 min). B) Brain slices from J20 mice were stimulated at 0 min using the TBS-LTP 
induction paradigm 4x2x5 at 70% in the presence of 4 µM PTX, 1 µM 5-HT, and 10 µM 
fluoxetine. For 20 min before TBS (black bar), slices were exposed to 1 µM SB-399885 
(red, n = 11 slices from 4 animals) or regular ACSF (black, n  = 9 slices from 4 animals). 
Compared with ACSF-treated slices, 1 µM SB-399885 had no effect on LTP in J20 mice 
(p > 0.05, two-way repeated measures ANOVA of last 30 min). C) Bar graph illustrating 
the means of the normalized fEPSP slope by treatment group. No significant effects were 





Figure A.5.  The TBS-LTP induction stimulus 4x2x5 with a 200 µs pulse duration was 
unaffected by DZP on the upgraded 8-channel Slicemaster. A) fEPSP slope as a function 
of time. Brain slices prepared from C57BL/6 mice in the presence of 1 μM were 
stimulated at 0 min using the TBS-LTP induction paradigm 4x2x5 with a 200 µs pulse 
duration. For 20 min before TBS (blue bar), slices were exposed to 50 μM DZP (red, n = 
15 slices from 5 animals) or regular ACSF (black, n  = 16 slices from 5 animals). Slices 
exposed to 50 μM DZP did not exhibit significantly different LTP compared to ACSF-
treated slices (p > 0.05, two-way repeated measures ANOVA of last 30 min). B) In the 
presence of 4 μM PTX, slices exposed to 50 μM DZP (red, n = 3 slices from 1 animal) 
did not exhibit significantly different LTP compared to slices exposed to ACSF (black, n 
= 4 slices from 1 animal) (p > 0.05, two-way repeated measures ANOVA of last 30 min). 
C) In the presence of 10 μM PTX, slices exposed to 50 μM DZP (red, n = 3 slices from 1 
animal) did not exhibit significantly different LTP compared to ACSF-treated slices 
(black, n = 4 slices from 1 animal) (p > 0.05, two-way repeated measures ANOVA of last 
30 min). Additionally, in 10 μM PTXDZP significantly reduced the PTP decay constant 
(Control tau: 15.5 (95% CI 12.4–20.5); DZP tau: 44.0 (95% CI 16.9–infinity), p < 0.05, 





Figure A.6.  J20 and NTG mice exhibit similar LTP in the DG under partial and complete 
blockade of GABAA receptors. A) fEPSP slope as a function of time. Brain slices from 
NTG (black, n = 11 slices from 3 animals) and J20 mice (red, n = 15 slices from 3 
animals) were stimulated at 0 min using the TBS-LTP induction paradigm 4x2x5 with a 
200 µs pulse duration in the presence of 4 μM PTX. fEPSP slopes are normalized to the 
average of the last 4 fEPSPs before TBS. No group difference in LTP were detected (p > 
0.05, two-way repeated measures ANOVA of last 30 min). B) Brain slices from NTG 
(black, n = 11 slices from 3 animals) and J20 mice (red, n = 5 slices from 2 animals) were 
stimulated at 0 min using the TBS-LTP induction paradigm 4x2x5 with a 200 µs pulse 
duration in the presence of 50 µM PTX. No difference in LTP was detected (p > 0.05, 





Summary of TBS and HFS LTP induction paradigms tested in the DG. 
 
All experiments were conducted in acute hippocampal brain slices prepared from 
C57BL/6 mice. Abbreviations: 4 Ch = 4-channel Slicemaster; 8 Ch = 8-channel 
Slicemaster; C = control (always standard ACSF); D = drug (always 50 µM Diazepam); 
HFS = high-frequency stimulation; I/O = input-output curve; ISI = interstimulus interval; 
LTD = long-term depression; LTP = long-term potentiation; N = number of slices in 
control condition, number of slices in drug condition / from the number of animals tested; 
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